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The research work incorporated in the thesis entitled “STUDIES ON 
SOME HETEROCYCLIC COMPOUNDS OF MEDICINAL INTEREST” has been 
described as under. 
 The aim of research is to develop new bioactive entities, especially with 
antimicrobial activities bearing a heterocyclic ring system. Numerous 
heterocyclic compounds like aryl amide, sulphonamides, chalcones, isoxazoles, 
Pyrazolines, pyrimidines have been prepared. Above heterocyclic compounds 
possess wide anti-inflammatory, antimicrobial, antimalarial, anticonvulsant, 
antipyretic, antitumor activity. 
 Some newly synthesized heterocycles, which have been described as 
under. 
PART – I: STUDIES ON ARYLAMIDE. 
  Aryl amide derivatives showed different biological activity such as 
antipyretic, analgesic, antiseptic, antiamoebic etc. Some new aryl amide 
derivatives have been synthesized, which have been described as under. 
SECTION-I:  Synthesis and biological screening of 1-Aroylamino-4-[(4'- 
chlorophenyl) (phenyl) methyl] piperazines. 
      
 
  
 
    
    
    
    
    
    
    
    
    
  
Cl
N N NH
O
R
 
Type-I                                  R= Aryl 
Aryl amide of Type-(I) have been synthesized by the condensation of     1-
amino -4-[(4'-chlorophenyl) (phenyl) methyl] piperazine with aryl chloride. 
SECTION-II: Synthesis and biological screening of N-[(4'-Chlorophenyl) 
(phenyl)   methyl] aryl amides. 
    
    
    
 
 
      
      
      
      
   
      
      
      
 Aryl amide of Type-(II) have been synthesized by the condensation of 1-amino 
[(4'-chlorophenyl) (phenyl)] methane with aryl chloride.  
                  Cl
NH
O
R
 
 Type-II                                  R= Aryl 
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PART – II: STUDIES ON SULPHONAMIDES.     
 Sulphonamide derivatives have been found to be associated with various 
pharmacological activities such as antibacterial, antimalarial, antiviral, 
anticonvulsant etc. These finding observation us to synthesized some new 
sulphonamide derivatives as under.  
 
SECTION-I: Synthesis and biological screening of 1-
Arylsulphonamido-4-[(4'-chlorophenyl) (phenyl) methyl] 
piperazines.       
 
 
 
  
    
    
    
    
    
    
 Sulphonamide of Type-(III) have been synthesized by the 
condensation of 1- amino [(4'-chlorophenyl) (phenyl) methyl] piperazine 
with arylsulphonyl chloride. 
Cl
N N NH
S
O
R
O
 
Type-III                                  R= Aryl 
 
SECTION-II: Synthesis and biological screening of N-[(4'-
Chlorophenyl) (phenyl) methyl]-arylsulphonamides. 
            
 
 
    
    
    
  
 Sulphonamide of Type-(IV) have been synthesized by the condensation of         
1-amino [(4'-chlorophenyl) (phenyl)] methane with arylsulphonyl chloride. 
Cl
NH
S
O
R
O
 
 Type-IV                                  R= Aryl 
 
SPART – III: STUDIES ON 5 – OXO – IMIDAZOLINES.  
5–Oxo–imidazoline derivatives have been reported to be active as 
anticonvulsant, potent CNS depressant, anti-inflammatory, anticancer, hypnotics 
and as monoamino oxidase (MAO) inhibitor. These valid observations prompted 
us to synthesis some new 5-oxo-imidazoline derivatives, which have been 
described as under. 
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SECTION-I: Synthesis and biological screening of N-{4-[(4'-
Chlorophenyl) (phenyl) methyl] piperazine-1-yl}-4''-
arylidene-2''-(4'''-methoxy phenyl)-5-oxo-imidazolines. 
 
    
    
    
    
  
Cl
N N N
N
O R
O
CH3  
Type-V                                  R= Aryl 
 
 
 
 
 
 
 
 
5-Oxo-imidazoline of Type-(V) have been synthesized by the 
condensation of   1-amino [(4'- chlorophenyl) (phenyl) methyl] piperazine with 
different oxazolones. 
 
SECTION-II: Synthesis and biological screening of N-[(4'-Chlorophenyl)     
(phenyl) methyl]-4''-arylidene-2''-(4'''-methoxy phenyl)-5'-
oxo-imidazolines. 
 
 
   
 
 
 
 
    
    
    
    
    
  
Cl
N
N
O
R
O
CH3  
Type-VI                                  R= Aryl 
 
 
 
 
 5-Oxo-imidazoline of Type-(VI) have been synthesized by the 
condensation of 1-amino [(4'- Chlorophenyl) (phenyl)]-methane with different 
oxazolones. 
PART – IV: STUDIES ON CHALCONES. 
 Chalcones are phenyl styrylketones containing reactive keto- ethylenic 
group. Literature survey reveals that chalcone derivatives possess antibacterial, 
antiviral, antispasmodic activities. Hence it was thought worth while to synthesis 
chalcone derivatives, which have been described as under. 
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SECTION-I: Synthesis and biological screening of N-{4'-[(4'''-
Chlorophenyl) (phenyl) methyl amino] phenyl-1'-yl}-3-
aryl-2-propene-1-ones. 
 
 
    
  
    
    
    
    
Cl
NH
O
R
 
Type-VII                                  R= Aryl 
  
 
 
 
 The Chalcones of Type-(VII) have been synthesized by the condensation 
of 4'-[(4'''-chlorophenyl) (phenyl) methylamino phenyl-1-yl] ethanone with 
different aromatic aldehyde in the presence of aqueous NaOH. 
 
PART-V: STUDIES ON PYRAZOLINES. 
  
Pyrazoline derivatives showed different therapeutic activity such as 
antibacterial, analgesic, anthelminitic, anti-inflammatory, antitubercular etc. This 
valid observation led us to synthesised some new pyrazoline derivatives, which 
have been described as under. 
 
SECTION-I: Synthesis and biological screening of 1-(H)-3-N-{4'-[(4'''-
Chlorophenyl) (phenyl) methyl amino] phenyl}-5-aryl-pyrazolines. 
  
 
   
    
    
    
    
    
 Pyrazoline derivatives of Type-(VIII) have been synthesized by the 
condensation of chalcones of Type-(VII) with hydrazine hydrate.  
Cl
NH
N NH
R
Type-VIII                                  R= Aryl 
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SECTION-II: Synthesis and biological screening of 1-Acetyl-3-N-               
{4'-[(4'''-chlorophenyl) (phenyl) methyl amino] phenyl}-5-
aryl pyrazolines.       
 
 
 
 
 
 
 
  
Cl
NH
N N
R
O
CH3
 
Type-IX                                  R= Aryl 
  
  
 
 
 
 
 
 
Acetyl pyrazoline derivatives of Type-(IX) have been synthesized by the 
reaction of chalcones of Type-(VII) with hydrazine hydrate and glacial acetic 
acid.  
 
SECTION-III: Synthesis and biological screening of 1-Phenyl-3-{4'-[(4'''-
chlorophenyl) (phenyl) methyl amino] - phenyl}-5-aryl 
pyrazolines. 
 
    
    
    
    
    
    
    
     
    
   
Cl
NH
N N
R
 
        Type-X                                  R= Aryl  
 
  Phenyl pyrazoline derivatives of Type-(X) have been synthesized by the 
condensation of chalcones of Type-(VII) with phenyl hydrazine. 
 
PART - VI: STUDIES ON CYANOPYRANS. 
   
Cyanopyran derivatives represents one of the modest classes of the compounds 
possessing wide range of therapeutic activities such as antibacterial, antifungal, 
antiviral and anticonvulsant agents. Prompted by above facts, we synthesised 
some new cyanopyrans, which have been described as under. 
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SECTION-I: Synthesis and biological screening of 2-Amino-6-{4'-[(4'''-
chlorophenyl) (phenyl) methyl amino]-phenyl}-4-aryl-4H-pyran 
-3-carbonitriles. 
    
    
    
    
    
    
    
    
    
 Cyanopyran derivatives of Type-(XI) have been synthesized by the 
condensation of the chalcones of Type-(VII) with malononitrile in pyridine.  
Cl
NH
O
NH2
N
R
Type-XI                                R= Aryl 
 
PART-VII: STUDIES ON CYANOPYRIDINES. 
  
Cyanopyridines derivatives showed wide range of applications in the field 
of pharmaceutical. Cyanopyridine derivatives have been reported to be active as 
antifungal, antidiabetic, anticholestemic, tuberculosis and antihypertensive etc. 
These valid observations led us to synthesize some new cyanopyridines 
derivatives, which have been described as under. 
 
SECTION-I: Synthesis and biological screening of 2-Methoxy-6-{4'-[(4'''-
chlorophenyl) (phenyl) methyl amino] phenyl} -4-aryl 
nicotinonitriles. 
  
 
 
    
    
    
    
    
    
 Cyanopyridine derivatives of Type-(XII) have been synthesized by the 
Cl
NH
N
O
N
R
CH3
Type-XII                                R= Aryl 
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condensation of the chalcones of Type-(VII) with malononitrile and sodium 
methoxide. 
 
SECTION-II: Synthesis and biological screening of 2-Amino-6-{4'-[(4'''-
chlorophenyl) (phenyl) methylamino] phenyl}-4-aryl 
nicotinonitriles. 
 
    
    
    
    
    
    
    
    
   Cl
NH
N
NH2
N
R
Type-XIII                                R= Aryl 
 Cyanopyridine derivatives of Type-(XIII) have been synthesized by the 
condensation of the chalcones of Type-(VII) with malononitrile and ammonium 
acetate. 
 
PART-VIII: STUDIES ON PYRIMIDINES.     
   
  Pyrimidine nucleus possesses remarkable pharmaceutical importance 
and biological activities, some of their derivatives occur as natural products, like 
nucleic acids and vitamin B. Many pyrimidine derivatives have displayed diverse 
pharmacological activities like antitumor, diuretic, antitubercular, 
antihypertensive etc. These valid observations led us to synthesise some new 
pyrimidines having better potency, which have been described as under. 
 
SECTION-I: Synthesis and biological screening of 2-Amino-{4'-[(4'''-
chlorophenyl) (phenyl) methyl amino] - phenyl}-6-aryl 
pyrimidines.        
  
      
     
Cl
NH
N N
NH2
R
Type-XIV                               R= Aryl 
 
 
 
 
 
 
 
  
 
 
  Aminopyrimidine derivatives of Type-(XIV) have been synthesized by the 
Condensation of the chalcones of Type-(VII) with guanidine hydrochloride. 
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SECTION-II: Synthesis and biological screening of 6-{4'-[(4'''-
Chlorophenyl) (phenyl) methyl amino] - phenyl}-4-aryl 
pyrimidin-2(1H)-ones. 
      
   
      
      
      
      
      
      
      
  
Cl
NH
NH N
O
R
 
Type-XV                               R= Aryl 
  
 
 
  Pyrimidinone derivatives of Type-(XV) have been synthesized by the 
cyclization of chalcones of Type-(VII) with urea in presence of basic catalyst like 
KOH. 
SECTION-III: Synthesis and biological screening of 6-{4'-[(4'''-
Chlorophenyl) (phenyl) methyl amino]-phenyl}-4-aryl 
pyrimidin-2(1H)-thiones. 
      
    
      
      
      
      
      
      
      
  
Cl
NH
NH N
S
R
 
Type-XVI                               R= Aryl 
   
 
 
  Thiopyrimidine derivatives of Type-(XVI) have been synthesized by the 
cyclocondensation of chalcones of Type-(VII) with thiourea in presence of basic 
catalyst like KOH. 
 
PART-IX: STUDIES ON ISOXAZOLES.      
  
Isoxazole derivatives possess remarkable pharmaceutical importance and 
biological activities such as antidepressants, skeleton muscle relaxant, 
antidiabetic, anti-inflammatory, analgesic etc. These valid observations led us to 
synthesize some new isoxazole derivatives described as under. 
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SECTION-I: Synthesis and biological screening of 3-{4'-[(4'''-Chlorophenyl) 
(phenyl) methyl amino] - phenyl} -5-aryl isoxazoles. 
  
    
    
    
    
    
   
 
      
      
   
Cl
NH
N
R
O
 
Type-XVII                               R= Aryl   
 
  Isoxazole derivatives of Type-(XVII) have been synthesized by the 
condensation of chalcones of Type-(VII) with hydroxylamine hydrochloride in the 
presence of sodium acetate in acetic acid.  
 
PART-X: STUDIES ON BENZODIAZEPINES. 
   
  Benzodiazepines derivatives have been found to possess wide range of 
therapeutic activities, like anthelminitic, anticonvulsant, antimicrobial etc. 
Prompted by these facts, new benzodiazepines have been synthesized, which 
are described as under. 
 
SECTION-I: Synthesis and biological screening of 2-Aryl-4-yl-[4'-(4'''-
chlorophenyl) (phenyl)- methyl amino phenyl]-1H-1,5-
benzodiazepines. 
 
      
      
      
      
      
      
      
      
      
      
      
    Cl
NH
N N
R
H
 
 
Type-XVIII                               R= Aryl 
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  Benzodiazepines derivatives of Type-(XVIII) have been synthesized by 
the condensation of chalcones of Type-(VII) with o-phenylene diamine in the 
presence of acidic medium.        
 Characterizations:        
   
The constitution of the synthesized products have been characterized using 
elemental analysis, IR, 1H NMR spectroscopy and further supported by mass 
spectrometry. Purity of the compounds has been checked by thin layer 
chromatography.          
 
Studies on biological activities.       
   
  All the compounds have been also evaluated for their antibacterial activity 
towards Gram positive and Gram negative bacterial strains and antifungal 
activity towards Aspergillus niger at a concentration of 50 µg/ml. The biological 
activities of the synthesized compounds have been compared with known 
standard drugs. 
 
 
 
 
 
  
 
10 
 
 
 
STUDIES ON SOME HETEROCYCLIC COMPOUNDS OF MEDICINAL 
INTEREST 
INTRODUCTION: 
Research programs for the discovery of new drugs and for improving the 
evolution criteria are under way in many laboratories. In addition knowledge of 
specific constituents of the mycobacterium cell and their biochemical roles has 
advanced considerably in the recent years and may permit a more rational 
approach to the design of new drug action on specific targets. Also, recent 
improvements in the knowledge of the mechanism of action of available drugs 
and the biochemical mechanism of resistance to them may be used as a basis 
for design new and better weapons to fight the mycobacterial diseases. 
The last few decades have witnessed massive advances in biochemistry, 
physiology, pharmacology and genetics. This has to a better understanding of 
working the body at the molecular level. This in turn has resulted a much better 
understanding of the structure and function of important drug targets e.g. 
enzymes and receptors and that how drugs can be designed for these targets. 
Advances in organic chemistry have made possible the synthesis of 
complexes molecules. Enantiometry is an important process in medicinal 
chemistry since life is inherently chiral and the drug targets within the body are 
chiral. As such, they can distinguish between the enantiomers of a chiral drug, 
so the use of recemic drug is inherently wasteful, since only one enantiomer is 
ideally designed to interact with its target. Moreover, the existences of the 
“wrong” enantiomer could create problems if it interacted wtih a different 
receptor, resulting inside effects. 
A prerequisite for the design of safe drugs is knowledge about the various 
metabolic reactions that xenobiotics and endogenous compounds undergo in the 
organism. Because pharmacological activity depends on molecular structure, the 
medicinal chemist is restricted in the choice of functional groups for the design of 
new drugs. Often he finds or she encounters a situation where a structure has 
adequate pharmacologic activity but has an inadequate pharmacokinetic profile 
(i.e., absorption, distribution, metabolism and excretion). This is because 
pharmacology and pharmacokinetic departments in the pharmaceutical industry 
often do not collaborate at the early stage of drug development. It is only later, 
when the new compound is tested in animals or in humans, that pharmacokinetic 
12 
 
 
 
disadvantages become obvious.       
 Modern drug discovery starts with the identification of a pharmacologic 
target that is hypothetically the primary cause of disease. Potential targets 
include host cell genes, receptors, signaling systems, organelles and 
biochemicals such as enzymes. Additionally, an element of a disease modifying 
process, such as anti-inflammatory mediator, may be a target. Biological 
processes required for propagation of infectious agents have also proven to be 
therapeutically useful targets; examples include protease and reverse 
transcriptase of the human immuno deficiency virus (HIV). Common to all targets 
selected as therapeutic opportunities is the hypothesis that some type of 
pathogenetic linkage exists to the disease causing process, rather than to 
specific signs, symptoms, or effects. 
Heterocyclic compounds have great applicability in pharmaceutics 
because they have specific chemical reactivity and provide false synthons in 
biosynthetic process or block the normal functioning of biological receptors. The 
inhibition of amide resonance resulting into more susceptibility of β-lactam to 
nucleophile is considered at least in part responsible for antibacterial property, 
apparently by acetylating transpeptidase and thus inhibiting bacterial cell wall 
biosynthesis. 
Most of the alkaloids which are nitrogenous bases occurring in plants and 
many antibiotics including penicillin and streptomycin have also heterocyclic ring 
system. Many natural pigments such as indigo, haemoglobin and anthocyanin 
are heterocycles. Most of the sugars are their derivatives including Vitamin C for 
instance, exist largely in the form of five membered. Vitamin B6 (Pyridoxine) is a 
derivative of pyrimidine essential in amino acid metabolism. 
Important drugs, poisons and medicines (both natural and synthetic) such 
as sulphathiazole, pyrenthrin, rotenmone, alpidem, zolpidem, fluconazole, 
strychnine, reserpine, certain of the antihistamines, the ergot alkaloids caffeine, 
cocaine, barbiturates, etc. are heterocyclic compounds. 
The ultimate product of a successful drug design effort. Our goal for this is 
to begin to deconvolute this information in order to apply it to design of new 
drugs. Taking in view of the applicability of heterocyclic compounds, we have 
undertaken the preparation of heterocycles bearing imidazo[1,2-a]pyridine 
nucleus and difluoro benzene nucleus. The placement of a wide variety of 
13 
 
 
 
substituents of these nuclei has been designed in order to evaluate the 
synthesized products for their pharmacological profile against several strains of 
bacteria and fungi. 
AIM AND OBJECTIVES 
In the pharmaceutical field, these have always been and will continue to 
be a need for new and novel chemical inhibitors of biological function. Our efforts 
are focused on the introduction of chemical diversity in the molecular frame work 
in order to synthesizing pharmacologically interesting compounds of widely 
different composition. During the course of our research work, looking to the 
application of heterocyclic compounds, several entities have been designed, 
generated and characterized using spectral studies. The details are given as 
under. 
1. To synthesize therapeutically active compounds like pyrazolines, 
cyanopyridines, isoxazoles, oxopyrimidines, imidazolinones bearing 4-[(4-
chlorophenyl) (phenyl) methyl]piperazine-1-amine moiety and cyanopyrans, 
pyrimidines and cyanopyridones bearing 4-[(4-chlorophenyl)(phenyl)methyl 
amino]phenyl-ethanone nucleus. 
2. To characterize these products for structure elucidation using several 
spectroscopic techniques like IR, 1H NMR and Mass spectral studies. 
3. To assess the reaction and purity of the compounds were done by TLC. 
4. To evaluate these products for better drug potential against different strains of 
bacteria and fungi. 
PART-I: STUDIES ON ARYLAMIDE 
PART-II: STUDIES ON SULPHONAMIDES.  
PART-III: STUDIES ON 5 – OXO – IMIDAZOLINES.  
PART-IV: STUDIES ON CHALCONES. 
PART-V: STUDIES ON PYRAZOLINES. 
PART-VI: STUDIES ON CYANOPYRANS. 
PART-VII: STUDIES ON CYANOPYRIDINES. 
PART-VIII: STUDIES ON PYRIMIDINES. 
PART-IX: STUDIES ON ISOXAZOLES.   
PART-X: STUDIES ON BENZODIAZEPINES.     
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STUDIES ON ARYLAMIDES 
INTRODUCTION         
 The characteristic group present in the simple carboxylic amide is 
CONH2. They are the acyl substitution products of ammonia. Many natural 
products are amides, urea, and diamides derivatives of carboxylic acid. The 
peptides and proteins are linear structure of cyclic polyamides. The alkaloids 
of pepper, piperidine and chavicine are N-substituted amides of unsaturated 
acid. N-isobutyl amides of certain highly unsaturated aliphatic acids occur in 
plants, shows insecticidal activity1. Amides derived from polyacetylenic acid 
have been isolated from certain fungi2.    
SYNTHETIC ASPECT:        
 Various methods for the synthesis of aryl amides are described in 
literature3-9. Marayama Tatsuya, Suzuki Onda10 have synthesized arylamide 
(I) as under. 
NH2
NH
OH
Ph
Cl
N
N
Cl
O
N N
NH
Cl
O
NH
OH
Ph
+
Pyridine
( I )
 
MECHANISM 
R N+
H
H
O
R'
R1
Cl
O
R NH2
..
+
R N+
H
H
O-
R
Cl + Cl-
R N
H O
R'
-H+
+ B.HCl
 
         
THERAPEUTIC IMPORTANCE 
 Amides, aryl amides, heterocyclic aryl amides showed widely useful as 
pharmacologically activities. Some arsano organometallic compounds like 
tryparsamide and arsacetin having amide groups have proved to be 
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successful chemotherapeutic agents. The biological activities of aryl amide 
derivatives have been reported as under.   
1. Anticonvulsant11
2. Antiallergic11
3. Herbicidal12
4. Cardiotonic13          
5. Antimicrobial14, 15
6. Analgesic16
7. Antiulcer17
8. MAO inhibitor18
9. Anticancer19, 20
10. Antiinflammatory21
11. Anti-HIV22
12. Sodium channel blockers23, 24       
 A. K. Mallams25 has reported arylamide derivatives as antitumor agent. 
More over S. J. Laulloo et al26 and J. Hazarika27 have prepared some novel 
biologically active arylamide derivatives and reported them as antimicrobial 
agents. Dhanak Dushyant et al.28 have synthesised arylamide (II) useful as 
urotensin-II antagonist. 
Cl
Cl
O NH
N
S
O
O
O
N
H
( II )
Cl
Cl
NH O
NH NH
( III )
    
E. J. Sanderson Philip et al29 (III) have synthesized aryl amides and studied 
their biological activity. M. B. Anthony et al.30 have reported aryl amide 
derivatives as antiulcer agents. J. E. Foster et al.31 have synthesised some 
new amide derivatives as potent anticonvulsant. A. R. Mulik et al.32 have 
studied some aryl amides shows antibiotic activity. G. Bridge et al33. have 
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screened arylamides as anti-HIV agent. L. Bettineti and co-workers34 have 
prepared arylamides as antibacterial agents. D. W. Hobbs et al.35 have 
designed some amides (III) and reported them as MCH-receptor antagonist.
 S. Tabuchi et al.36 have screened arylamide derivatives as novel potent 
antagonist of human neuropeptide YY5 receptor. J. H. Chan37 have recorded 
substituted benzophenone arylamide derivatives as inhibitor reverse 
transcriptase. L. Pieters et al.38 have synthesized novel diazene 
carboxamides (IV) as anticancer. N. J. Anthony and co-workers39 have 
investigated amides as anti-HIV. G. Chen et al.40 have reported aryl amides 
(V) as antitumor agents. 
NH
N
O
N
F F
F
FF
N
NH
O
CF3
N
CH3
CH3
NH
F
( IV )
( V )
          
CONTRIBUTION FROM OUR LABORATORY 
 Some new acetamide derivatives bearing benzimidazol (VI) moiety 
were assessed by H. H. Parekh et al.41 for antimicrobial activity. A. R. Parikh 
et al.42-45 have synthesised novel acetamide derivatives of type (VII), (VIII) and 
reported them as antimicrobial agents. 
 
N
N
H O
NH NH
R
O
N
N
S
N
NH R
NH2O
N
N
R
O
NH2
OH( VI )
( VII )
( VIII )
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 V. H. Shah et al.46 (IX) have synthesized some new aryl amides and 
evaluated its antimicrobial activity. V. N. Patoliya et al.47-50 (X-XI) have 
synthesized and evaluated its antimicrobial activity.   
N
N
OH
O
R
O
N
N
Cl
O
R
O
N
N
NH
O
R
O
NH2
N
N
O
O NH R
O
CH3
CH3
N
N
O
O
R
O
OH O
N
S
COR
CH3
COOH N
N CH3
CH3
O
NH
RO
Cl
N
N NH R
OO
OH
NN
R
O
F
F
(IX)
(X)
(XI)
(XII)
 D. M. Purohit et al.51have reported new aryl amides in Piperazine 
molecules as a antimicrobialagent (XII).      
 In the past years, considerable evidence has been accumulated to 
demonstrate the pharmacodynamic and chemotherapeutic activities of amide 
derivatives. To further assess the potential of such type of compounds, the 
synthesis have been carried out which have been described as under. 
SECTION-I: Synthesis and biological Screening of 1-Arylamino-4-[(4'- 
Chlorophenyl)(phenyl) methyl] Piperazines. 
SECTION-II: Synthesis and biological Screening of N-[(4'-chlorophenyl) 
(phenyl)   methyl] arylamides. 
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SECTION-I: 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ARYLAMINO-4-[(4'-
CHLOROPHENYL) (PHENYL) METHYL] PIPERAZINES.   
 Aryl amide represents one of the important classes of compounds, with 
an intension of preparing the compounds possessing better therapeutic 
activity, arylamides of Type (I) have been synthesised by the condensation of 
1-amino -4-[(4'-chlorophenyl) (phenyl) methyl] piperazine with aryl chloride. 
Cl
N N NH
O
R
Type-I R=Aryl  
 The constitutions of the synthesized products have been characterized 
using elemental analyses, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by mass spectrometry.    
All the compounds have been screened for their antibacterial activity towards 
Gram positive and Gram negative bacterial strains and antifungal activity 
towards Aspergillus niger at a concentration of 50 µg/ml. The biological 
activities of the synthesised compounds have been compared with standard 
drugs. Some compounds have been found to have moderate activity as 
compared to known standard drugs, recorded on Graphical Chart No.1.  
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IR SPECTRAL STUDY OF N-{4-[(4'-CHLOROPHENYL)(PHENYL)METHYL] 
PIPERAZINE-1-YL}-4"' -METHOXYBENZAMIDE. 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Halide 
Arylamide 
 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.) 
C-H str. 
C=C str. 
C-Cl str. 
C-N str. 
C=O str. 
N-H str. 
2958 
2874 
1456 
1388 
3072 
1513 
695 
1101 
1706 
3396 
2975-2950 
2880-2860 
1470-1435 
1390-1370 
3090-3030 
1540-1480 
800-600 
1220-1020 
1710-1650 
3500-3100 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF N-{4-[(4'- CHLOROPHENYL) (PHENYL) 
METHYL] PIPERAZINE-1-YL}-4"-METHOXYBENZAMIDE. 
 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (300 MHz)  
Signal 
No.  
Signal 
Position  
(δppm) 
Relative No. 
of protons  
 
Multiplicity Inference 
1  2.25-2.44 2H triplet  N-H(f) 
2 2.51-2.71 2H Triplet N-H(g)  
3 3.48-3.49 2H Triplet N-H(e) 
4  4.25-4.35  2H Triplet N-H(h) 
5 4.22 1H Singlet C-H(i) 
6  3.88  3H singlet  Ar-OCH3(a) 
7 7.20-7.33 5H multiplet  Ar-H(l) 
8 8.130-8.133 2H Doublet Ar-H(bb’) 
9 8.23-8.28 4H Doublet Ar-H(jj’,kk’) 
10 8.20 1H Singlet N-H(d) 
11 8.28-8.31 2H Doublet Ar-H(cc’) 
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MASS SPECTRAL STUDY OF N-{4-[(4'-CHLOROPHENYL)(PHENYL)METHYL] PIPERAZINE-1-YL}-4"-
METHOXYBENZAMIDE. 
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BIOLOGICAL SCREENING 
 
Method   :  Cup-Plate515
 
Gram positive bacteria :  Staphylococcus aureus 
      Bacillus Megatarium  
Gram negative bacteria :  Escherichia coli   
      Salmonella typhy 
Fungi    :  Aspergillus niger   
          
Concentration  :  50µg/ml 
 
Solvent   :  Dimethyl formamide 
Standard drugs  :  Ampicillin, Chloromphenicol, 
      Norfloxacin 
       Greseofulvin. 
           
 The biological screening was compared with standard drug viz 
Ampicillin, Chloromphenicol, Norfloxacin, and antifungal activity was 
compared with viz Greseofulvin. The inhibition zones measured in mm. 
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Cl
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Cl
N N NO
LiAlH4
Cl
N N NH2
O
R
Cl
Cl
N N NH
O
R
Type-I R = Aryl
REACTION SCHEME
0-5 0C
+ HCl
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EXPERIMENTAL    
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-AROYL AMINO-4-[(4'-
CHLOROPHENYL) (PHENYL) METHYL] PIPERAZINE 
(A) Synthesis of 4-[(4'-chlorophenyl) (phenyl)methyl] piperazine 
 A mixture of 4-[(4'- chlorophenyl) (phenyl)methyl]chloride [2.37 gm, 0.01 
M] in toluene and piperazine (3.28 gm, 0.04 M) was refluxed for 8 hrs. The 
reaction mixture was filtered off to remove unreacted piperazine and toluene 
layer extracted by 10 ml distilled water. Add 10 ml distilled water and 8 ml HCl 
(30%) stir well for 30 min. Separate out layer, in aqueous layer adjust pH 
=11.5 to12.0 with NaOH and Stir well for 4 hrs. Cool between 10 oC to15 oC 
and filtered solid material and wash with water. Yield 83 %, m.p.72 oC.  
(B) Synthesis of 4-[(4'-Chlorophenyl)(phenyl) methyl]-1-
nitrosopiperazine 
 A mixture of 4-[(4'-Chlorophenyl) (Phenyl) methyl] piperazine (8.4 gm, 
0.03 M) in 50 ml of ice cold water containing 24 ml of diluted HCl is nitrosated 
with (2.1 gm, 0.03 M) NaNO2 in 10 ml water. The reaction mixture is made 
alkaline by the addition of NaOH Solution and an oily layer forms. The oily 
product is separated and crystallized from a mixture of 4.5 ml ethyl acetate 
and 70 ml n-heptane. The resultant solid is recrystallized from a mixture of 2-
propanol and hexane, to give 4-[(4'-chlorophenyl) (phenyl) methyl]-1-nitroso 
piperazine yield 82%, m.p.121-123oC. 
(C) Synthesis of 1-Amino-[(4'-chlorophenyl) (phenyl) methyl] piperazine
  A mixture of 4-[(4'-Chlorophenyl) (Phenyl) Methyl]-1-nitroso piperazine 
(9.27 gm, 0.03 M) in 140 ml of anhy. ether and 5 ml of benzene is added 
dropwise to a suspension of (1.9 gm, 0.03 M) of Lithium aluminum hydride in 
140 ml of ether. The reaction mixture is stirred for 1hr at room temperature 
and then refluxed and stirred for 2hrs.The reaction is cooled in an ice bath 
and excess lithium aluminum hydride is decomposed by the addition of ethyl 
acetate. The reaction mixture is hydrolyzed by dropwise addition of 2 ml of 
water and 2ml of 20 % NaOH solution. The inorganic salts are filtered of and 
washed with ether. The filtrate is dried over anhy. Sodium sulphate. The 
solvent is evaporated. The residue is dissolved in benzene and the solvent is 
evaporated once again to give 1-amino-4-[(4'-chlorophenyl) (phenyl) 
methyl]piperazine. Yield 55 %, m.p- 106-109 oC.  
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(D) Synthesis of N-{4'-[(4'-Chlorophenyl)(phenyl)methyl] piperazine 1-
yl}-4″-methoxy benzamide.  
 A mixture of 1-Amino-4-[(4'-chlorophenyl) (phenyl) methyl] piperazine.  
(2.87 g, 0.01 M) and 4-methoxy benzoyl chloride (1.70g, 0.01 M) in dry 
pyridine (20 ml) was refluxed for 8 hrs. The resulting mixture was poured onto 
crushed ice and neutralized with HCl. The product was filtered, washed with 
cold water and crystallized from ethanol. Yield: 60%, m.p. 134oC. 
(C25H26ClN3O2: required: C 68.88; H, 5.97; N, 9.64; found: C: 68.85; H, 5.95; 
N, 9.61 %).         
 Similarly other aryl amides were synthesized. The physical data are 
recorded in Table No. 1. 
(E) Biological screening 1-Aroylamino-4-[(4'-chlorophenyl) (phenyl) 
methyl] piperazine 
All the compounds have been evaluated for biological screening described as 
under. 
(a) Biological screening 
It was carried out by cup-plate diffusion method515 which has been described 
as under. 
(I)Antibacterial screening515       
 The purified products were screened for their antibacterial activity.The 
nutrient agar, both prepared by the usual method was inoculated aseptically 
with 0.5 ml of 24 hr. old subcultures of B. megaterium, S. aureus, E.coli and 
sallamonala typhy in separate conical flasks at 40-50°C and mixed well by 
gentle shaking. About25 ml content of the flask were poured and evenly 
spreaded in a petridish. (13 cm diameter) and allowed to set for 2 hr. The 
cups (10 mm diameter) were formed by the help of borer in agar medium and 
filled with 0.01ml (1µg/l) solution of sample in DMF. The plates were 
incubated at 37°C for 24 hr. and the control was also maintained with 0.01ml 
of DMF in a similar manner and the zone of inhibition of the bacterial growth 
were measured in millimeter and recorded in Graphical Chart No. 1   
(II) Antifungal screening515      
Aspergillus niger was employed for testing antifungal activity using cup-plate 
method. The culture was maintained on sabouraud's agar slants. Sterilized 35 
sabourauds agar medium was inoculated with 72 hrs. Old  0.5ml suspension 
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of fungal spores in a separate flask. About 25 ml of the inoculated medium 
was evenly spreaded in a petridish and allowed to set for 2 hr. The plates 
were incubated at 30°C for 48 hr. After the completion of incubation period, 
the zone of inhibition of growth in the form of diameter in mm was measure. 
Along the test solution in each petridish one cup was filled up with solvent, 
which acts as control. The zones of inhibition are recorded in Graphical Chart 
No. 1.           
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TABLE NO. 1: PHYSICAL CONSTANT OF 1-AROYLAMINO-4-[(4'- CHLOROPHENYL) (PHENYL) METHYL] 
PIPERAZINES. 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield 
% 
 Calcd.  Found.
JG-1        C6H5 - C24H24ClN3O 405.5 172 72 10.35 10.28
JG-2        2-CH3-C6H4- C25H26ClN3O 419.5 184 70 10.01 9.95
JG-3        3-CH3-C6H4- C25H26ClN3O 419.5 157 71 10.01 9.65
JG-4        4-CH3-C6H4- C25H26ClN3O 419.5 118 69 10.01 9.79
JG-5       2-OCH3-C6H4- C25H26ClN3O2 435.5 208 70 9.64 9.61
JG-6       3-OCH3-C6H4- C25H26ClN3O2 435.5 210 67 9.64 9.60
JG-7       4-OCH3-C6H4- C25H26ClN3 O2 435.5 134 60 9.64 9.61
JG-8        4-NH2-C6H4- C24H25ClN4O 420.5 149 65 13.31 13.25
JG-9  C       3-4-(CH3)2-C6H3- 26H28ClN3O 433.5 110 71 9.68 9.63
JG-10       2-OH-C6H4- C24H24ClN3O2 421.5 132 70 9.96 9.89
JG-11       4-NO2-C6H4- C24H23ClN4O3 450.5 243 64 12.43 12.41
JG-12        C4H3 N2-(pyrazine) C22H22ClN5O 407.5 228 69 17.17 17.14
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GRAPHICAL CHART NO.1: BIOLOGICAL SCREENING OF 1-AROYLAMINO-4-[(4'-CHLOROPHENYL) (PHENYL) 
METHYL] PIPERAZINES. 
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-I 
 
Section – I: Biological screening of 1-Aroylamino-4-[(4'- chlorophenyl) (phenyl) methyl] piperazines 
 
 
                                                                   Antibacterial activity                                             Antifungal activity 
                                                                                Zone of inhibition in m. m.                                   Zone of inhibition in m. m.   
                                                                   
                                   B. mega           S. aureus             E-coli            S. typhi           A. niger 
                                                                                                                                                                                        
                                         JG-1(17)                 JG-2(16)                 JG-8(17)               JG-1(14)                JG-7(17)                               
                                         JG-3(19)                 JG-4(16)                 JG-10(17)              JG-8(13)               JG-9(19)                               
                                         JG-12(18)               JG-7(16)                 JG-12(17)             JG-10(14)              JG-10(20)                             
                                                                                                                                                                               
Ampicillin     (50 µg)            23                           22                            21                          15                           -- 
Chloromphenicol  (50 µg)   22                           23                            21                          18                           -- 
Norfloxacin   (50 µg)           24                            17                            23                          17                           --    
Greseofulvin (50 µg)           --                              --                              --                            --                           25 
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 SECTION-II 
SYNTHESIS AND BIOLOGICAL SCREENING OF N-[(4'-CHLOROPHENYL) 
(PHENYL)   METHYL] ARYL AMIDES. 
 Aryl amides represent one of the important classes of the compounds, 
with an intension of preparing the compounds possessing better therapeutic 
activity, aryl amides of Type (II) have been synthesized by the condensation 
of 4-[(4'-chlorophenyl) (phenyl) methyl] amine with aryl chloride. 
Cl
NH
O
R
TYPE (II)            R=  Aryl
 
 The constitution of the synthesized products have been characterized 
using elemental analyses, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by mass spectrometry.    
All the compounds have been screened for their antibacterial activity towards 
Gram positive and Gram negative bacterial strains and antifungal activity 
towards Aspergillus niger at a concentration of 50 µg/ml. The biological 
activities of the synthesised compounds have been compared with standard 
drugs. Some compounds have been found to have moderate activity as 
compared to known standard drugs recorded on Graphical Chart No. 2. 
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IR SPECTRAL STUDY OF N-[(4'-CHLOROPHENYL)(PHENYL)METHYL]-4" 
METHYL BENZAMIDE. 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
 
 
 
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Halide 
 
Arylamide 
 
C-H str. (asym.) 
C-H  str. (sym.) 
C-H def. (asym.)
C-H  def. (sym.) 
C-H str. 
C=C str. 
C-Cl str. 
C-N str. 
C=O str. 
N-H str. 
2957 
2873 
1435 
1380 
3060 
1492 
754 
1198 
1710 
3107 
2975-2950 
2880-2860 
1470-1435 
1390-1370 
3090-3030 
1540-1480 
800-600 
1220-1020 
1710-1650 
3500-3100 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF N-[(4'-CHLOROPHENYL)(PHENYL) METHYL] 
-4"- METHYL BENZAMIDE. 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (400 MHz) 
 
Signal No.  
Signal 
Position  
(δppm) 
Relative No. 
of protons  
 
Multiplicity Inference 
1 
2 
3 
4 
5 
6 
7 
2.43 
6.08 
6.89-6.89 
7.08-7.21 
7.37-7.44 
7.62-7.64 
8.01 
3H 
1H 
2H 
5H 
4H 
2H 
1H 
Singlet 
Singlet 
doublet 
Multiplet 
doublet 
doublet 
singlet 
C-H(a) 
C-H(e) 
Ar-H(ff’) 
Ar-H(h) 
Ar-H(bb’,gg’) 
Ar-H(cc’) 
N-H(d) 
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MASS SPECTRAL STUDY OF N-[(4'-CHLOROPHENYL)(PHENYL) METHYL]-4"-METHYLBENZAMIDE. 
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REACTION SCHEME
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF N-[(4'-CHLOROPHENYL) 
 (PHENYL) METHYL] ARYL AMIDES. 
(A) Synthesis of 4-[(4'- chlorophenyl) (phenyl) methyl] amine  
 A mixture of 4-[(4'-chlorophenyl) (phenyl) methyl] chloride (2.37 gm, 
0.01 M) in toluene ammonia gas (0.85 gm, 0.05 M) is purged for 8 hrs at 70-
80oC and then toluene was distilled out. Yield: 54 %, m.p- 70-72oC.  
      
(B)Synthesis of N-4-[4'-chlorophenyl)(phenyl)methyl]-4"-methoxy 
benzamide: 
 A mixture of 4-[(4'-chlorophenyl) (phenyl) methyl]amine (2.18 gm, 0.01 
M) and 4-methyl benzoyl chloride (1.70 gm, 0.01 M) in dry pyridine (20 ml) 
was refluxed for 8 hrs. The resulting mixture was poured onto crushed ice and 
neutralized with HCl. The product was filtered, washed with cold water and 
crystallized from ethanol. Yield 62%, m. p. 173o C. (C21H18ClNO2: required: C 
71.69; H, 5.12; N, 3.98; found: C, 71.67; H, 5.10; N, 3.90 %).   
 Similarly other aryl amides were synthesized. The physical data are 
recorded in Table No. 2. 
(C)Biological Screening of N-[(4'-chlorophenyl)(phenyl)methyl]aryl 
amides. 
Biological screening was carried out as described in Section-I (E). The 
zone of inhibition of test solutions is recorded in Graphical Chart No. 2. 
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    TABLE NO. 2: PHYSICAL CONSTANT OF N-[(4'-CHLOROPHENYL)(PHENYL) METHYL] ARYL AMIDES. 
40 
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41 
 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield %
 
Calcd.  Found.
JG-13        C6H5 - C20H16ClNO 321.5 206 65 4.35 4.31
JG-14       2-CH3-C6H4- C21H18ClNO 335.5 212 62 4.17 4.12
JG-15        3-CH3-C6H4- C21H18ClNO 335.5 239 68 4.17 4.11
JG-16        4-CH3-C6H4- C21H18ClNO 335.5 154 69 4.17 4.14
JG-17       2-OCH3-C6H4- C21H18ClNO2 351.5 159 63 3.98 3.96
JG-18       3-OCH3-C6H4- C21H18ClNO2 351.5 145 62 3.98 3.97
JG-19       4-OCH3-C6H4- C21H18ClNO2 351.5 173 62 3.98 3.90
JG-20        4-NH2-C6H4- C20H17ClN2O 336.5 226 64 8.32 8.30
JG-21  C       3-4-(CH3)2-C6H3- 22H20ClNO 349.5 163 60 4.00 7.65
JG-22  C      2-OH-C6H4- 20H16ClNO2 337.5 235 66 4.15 4.10
JG-23       4-NO2-C6H4- C20H15ClN2O3 366.5 146 63 7.64 7.60
JG-24        C4H3 N2-(pyrazine) C18H14ClN3O 323.5 239 70 12.98 12.95
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GRAPHICAL CHART NO.2: BIOLOGICAL SCREENING OF N-[(4'-CHLOROPHENYL)(PHENYL) METHYL] ARYL        
                                    AMIDES. 
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-I 
 
Section – II: Biological screening of N-[(4'-Chlorophenyl) (phenyl) methyl] aryl amides 
 
                                                               Antibacterial activity                                                 Antifungal activity 
                                                                            Zone of inhibition in m. m.                                      Zone of inhibition in m. m.    
                                                                   
                                   B. mega            S. aureus               E-coli              S. typhi           A. niger 
                                                                                                                                                                                        
                                          JG-15(19)               JG-15(16)                    JG-8(17)                JG-1(14)              JG-7(17)                          
                                          JG-18(18)               JG-17(15)                    JG-10(17)              JG-8(13)              JG-9(19)                          
                                          JG-20(20)               JG-24(15)                    JG-12(17)              JG-10(14)            JG-10(20)                        
                                                                                                                                                                               
Ampicillin             (50 µg)      23                           22                               21                           15                          -- 
Chloromphenicol (50 µg)     22                           23                               21                            18                          -- 
Norfloxacin          (50 µg)      24                           17                               23                            17                          -- 
Greseofulvin        (50 µg)      --                             --                                 --                              --                          25 
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44 
STUDIES ON SULPHONAMIDES 
INTORDUCTION         
 The discovery of sulphonamides as drugs is considered to be the 
beginning of chemotherapeutic era by making possible a direct attack on 
microbial infection.       
 Sulphonamide was first prepared by Glemo in 1908. Gerhald Domagk 
in 1935 tested prontosil towards infection by hemolytic streptococci and found 
it very effective antibacterial which lead to the synthesis of newer molecules 
by incorporating different nucleus. Sulphonamides have the general structure 
R-SO2- N-R′, R″, where R=organic radical, R′,R″=hydrogen or organic radical. 
They are classified as aliphatic, aromatic and heterocyclic which is depending 
upon the nature of R. Aromatic and heterocyclic sulphonamides have 
achieved greater commercial significance. Their application on chemotherapy 
is so well known that the name, ‘sulpha drug’ is widely used as a general 
name for sulphonamide derivatives as therapeutic agent.   
     
THERAPEUTIC IMPORTANCE AND SYNTHETIC ASPECT   
 It has been now well established that sulphonamides possess valuable 
biological properties including, 
1. Hypoglycemic52 
2. Antimalarial53
3. Antiinflammatory54
4. Herbicidal55
5. Anticoagulant56
6. Anti-HIV57
7. Antitumer58
8. Antihypertension and antiglaucoma59
9. Antimicrobial60
10. Antidiabetic61
11. Anticancer and antibacterial62
12. Herbicidal and Crop tolerance63
13. Potassium channel inhibitor64
14. Antibacterial65
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 Sulphonamides showed good biological activities. Due to these many 
sulphonamide derivatives are recently in clinical use some of them are shown 
below.           
 
N
NCH3
SO2
NH2
NH
O
CH3
Methazolamide
CA inhibitor
N
S
SO2
NH2
O
H5C2
Ethoxzolamide 
CA inhibitor
O
NH SO2 CH3
NO2
O
NH SO2 CH3
O
F
F
NS-398NS-398
COX-inhibitor
Flosulide
COX-inhibitor
SO2-NH2
SO2-NH2
Cl
Chlorphenaide
diuretic
NH2
SO2-NH2
Sulphanilamide
antibacterial
NH2
SO2-C6H4-NH2
Dapsone
antileprotic
N
NH3CO
H3CO
NH SO2 NH2
Sulphodoxine
antimalarial
Cl
SO2 NH CO NH
N
CH3 CH3
Glyparamide 
antidiabetic
 
 Sulphonamides continue to be used as antibacterial as they are 
effective, inexpensive and free of super infection of problems caused by 
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antibiotics. Extensive research has been carried out to enhance the activity 
and reduced toxicity of sulpha drugs. 
 Recently two isoenzymes of cyclooxy genase have been identified: 
COX-1 and COX-2 selective inhibition of COX-2 or dual inhibition of COX-1 
and COX-2 is under discussion as a promising principle in the treatment of 
inflammatory diseases. For several reasons, including increased 
cardiovascular risk, the important role of COX-2 produced prostaglandins in 
the response of the mucosa to irritants and in healing and other critical 
aspects the accuracy of selective COX-2 inhibition as the principle tent is 
under debate. 
A number of substituted sulphonamides are known as antiinflammatory 
agent. The substances were diflumidone and nimesulide which was lead NS-
348 and flosulide. 
Diarylmethanoes such as ketoprofen, tiaprofenic acid, tolmetine and 
ketorolac are used in the therapy of inflammation. 
The objective of this study was to correlate the structural parameters 
with the inhibitory potency and the enzyme selectivity i.e. to evaluate the 
significance of sulphonamides as latest biologically active compounds.
 Moreover G. Dannhardt et.al66 have described the synthesis and COX-
1/COX-2 inhibitory activity of some sulphonamides.  
COX-1 and COX-2 inhibitors
O
CH3
NH
SO2
CH3
NH
SO2
CH3
 
 C. T. Supuran et. al67 have documented some CA inhibitors .CA is 
concerning to von-Hippel-Lindau tumors. Progressive polycystic kidney 
disease, carcinomas of the pancreas of Autoimmune/idiopathic chronic 
pancreatities, it appeared of great interest to further explore the connections 
between CAs and tumors. 
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SO2 NH OCH3
X
F
F
F F
Carbonic Anhydrase (CA) isozyme inhibitors
 
 P. P. Stein et.al68 have reported arylsulphonaidopiperidones and also 
tested biological activity such as inhibitors of Factor Xa.   
 D. Dushyant et.al69 synthesized some sulphonamides as antagonist of 
urotensin II. 
SO2 NHH3CO
H3CO
Cl
O
N
CH3
O CH3
Antagonist of urotensin-II
 
CONTRIBUTION FROM OUR LABORATORY  
Parikh and Co-workers70 have evaluated several sulphonamide 
derivatives having the general formula R-SO2-NH-R′, where R= phenyl, 
substituted phenyl, α and β-napthyl and R′= 2, 4-distributed s-triazine 71,  
V. H. Shah and Coworkers72-77 have synthesized new sulphonamide 
derivatives and evaluated its antimicrobial screening. 
 D. M. Purohit et al. 78 have synthesized new piperazine sulphonamide 
derivatives and evaluated its antimicrobial activity. 
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N
N
N
CH3
SO2-PhNH
R
N
N
N
CH3
SO2-PhSO2
Ph
R = Phenyl,Substituted phenyl etc
O2N
NO2
NO2
NHSO2R
N
N
O
R'
SO2R
Cl
Cl
OCH2COOH
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N
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CH3
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NH
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N
CH2CH2NHNHSO2R
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NO2
NO2
NN
R
Ph
O
SO2
OCH2COOH
Cl
Cl
R' = -OH, -Cl, -NHNH2, -OCH2COOH
NN
F
F
SO2R
  
 John et.al.79 has prepared some sulphonamide derivatives as potent 
antidiabetic agent. More recently Mishra et. Al80 and O.A. Fathalla81 have 
reported some novel sulphonamides as antifungal, pesticidal and anticancer 
agent. 
Keeping in view of these valid observations prompted us to synthesis 
sulphonamides. 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF 1- 
ARYLSULPHONAMIDO-4-[(4'-CHLOROPHENYL) 
(PHENYL) METHYL] PIPERAZINES.  
SECTION-II: SYNTHESIS AND BIOLOGICAL SCREENING OF N-[(4'-
CHLOROPHENYL)(PHENYL)METHYL]-ARYL 
SULPHONAMIDES. 
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SECTION –I 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1- 
ARYLSULPHONAMIDO-4-[(4'-CHLOROPHENYL)(PHENYL)METHYL] 
PIPERAZINES.         
 With an aim to getting better therapeutic agent and considering 
the association of various biological activity with 4-[(4'-chlorophenyl) 
(phenyl)methyl] nuclei, the preparation of aryl sulphonamide of Type 
(III) have been undertaken by the condensation of 1-amino-4-[(4'-
chlorophenyl)(phenyl)methyl]piperazine with substituted sulphonyl chloride in 
presence of pyridine. 
Cl
N N NH S
O
O
R
Type -III R= aryl
 
The structures elucidation of synthesized compounds has been done 
on the basis of elemental analysis, IR, 1H nuclear magnetic resonance 
spectroscopy and further supported by Mass spectrometry. 
All the compounds have been evaluated for their in vitro biological 
assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards Aspergillus niger at a 
concentration of 50 µg/ml. The biological activities of synthesized compounds 
were compared with standard drugs. Some compounds have been found to 
have moderate activity as compared to known standard drugs recorded on 
Graphical Chart No. 3. 
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IR SPECTRAL STUDY OF 1-N-[(2''-METHYL-5''-CARBOXYBENZENE) 
SULPHONAMIDO]-4-[(4'-CHLOROPHENYL)(PHENYL)METHYL]- 
PIPERAZINE. 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-
00 cm4
 
-1(KBr disc). 
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Moiety 
Halide 
Sulphonamide 
 
 
 
 
C-H   str. (asym.) 
C-H   str. (sym.) 
C-H   def. (asym.) 
C-H   def. (sym.) 
C-H   str. 
C=C   str. 
C-Cl  str. 
C-N   str. 
S=O str.(asym.) 
S=O str.(sym.) 
C-S str. 
C=O str. 
C-OH str. 
N-H str. 
2979 
2881 
1441 
1375 
3098 
1515 
790 
1101 
1375 
1101 
700 
1701 
3215 
3375 
2975-2950 
2880-2860 
1470-1435 
1390-1370 
3090-3030 
1540-1480 
800-600 
1220-1020 
1300-1380 
1180-1140 
700-600 
1725-1700 
3250-2800 
3500-3100 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF 1-N-[(2"-METHYL-5"-CARBOXY BENZENE) 
SULPHONAMIDO]-4-[4'-CHLOROPHENYL)(PHENYL)-METHY]PIPERAZINE. 
Internal 
Standard: TMS; Solvent: CDCl3; Instrument Bruker Spectometer (300 MHz) 
Signal 
No.  
Signal 
Position  
(δppm) 
Relative No. 
of protons  
 
Multiplicity Inference 
1  1.65 3H singlet  Ar-CH3(a) 
2 2.30-2.39 2H triplet N-H(h)  
3 2.59-2.65 2H triplet N-H(i) 
4  3.85-3.84 2H triplet N-H(f) 
5 4.25-4.26 2H triplet C-H(g) 
6  4.14 1H singlet  N-H(e) 
7 4.26 1H singlet C-H(j) 
8 7.20-7.69 12H multiplet Ar-H (b,b’,c,k,l,l’,m,m’) 
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9 8.64 1H singlet O-H(d) 
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MASS SPECTRAL STUDY OF 1-N-[(2"-METHYL-5"-CARBOXY BENZENE)SULPHONAMIDO]-4-[(4"-CHLOROPHENYL) 
(PHENYL)METHYL]-PIPERAZINE. 
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Cl
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S OO
R
Cl
Cl
N N NH S
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Type-III R = Aryl
REACTION SCHEME
0-5 0C
+ HCl
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ARYLSULPHONA 
MIDO-4-[(4'-CHLOROPHENYL) (PHENYL) METHYL] PIPERAZINES. 
[A] Synthesis of 4-[(4'- Chlorophenyl) (phenyl) methyl] piperazine 
 For preparation see page no:27 
[B] Synthesis of 4-[(4'-Chlorophenyl) (phenyl) methyl]-1-
nitrosopiperazine 
 For preparation see page no:27 
[C] Synthesis of 1-Amino-[(4'-chlorophenyl) (phenyl) methyl] piperazine 
 For preparation see page no:27 
[D] Synthesis of 1-N-[(2''-Methyl-4''-carboxybenzene)    
sulphonamido-4-[(4'-chlorophenyl)(phenyl)methyl] piperazines. 
 A mixture of 1-amino-4-[(4'-chlorophenyl)(phenyl)methyl] piperazine- 
(2.87gm, 0.01 M) and 2-methyl-4-carboxybenzene sulphonyl chloride 
(2.34gm, 0.01 M) in the presence of 5ml pyridine was refluxed. The reaction 
mixture was poured in to crushed ice and filtered, washed with water and 
crystallized from ethanol. Yield 52%; m. p 180 0C (C25H26ClN3O4S: required: 
C;60.06;H,5.20;N,.8.40; Found:C;60.01;H,5.20;N,.8.35%).  
Similarly other sulphonamides were synthesized. The physical data are 
recorded in Table-3.  
[E] Biological Screening of 1-Arylsulphonamido-4-[(4'-
chlorophenyl)(phenyl) methyl]piperazines.     
Biological screening was carried out as described in Part-I, 
Section-I (E). The zones of inhibition of test solutions are recorded in 
Graphical chart no. 3.        
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TABLE NO. 3: PHYSICAL CONSTANT OF 1-ARYLSULPHONAMIDO-4-[(4'-CHLOROPHENYL) (PHENYL) 
METHYL] PIPERAZINES. 
 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield %
 
Calcd
. 
Found
. 
JG-25 3-COOH- C6H4-      C24H24ClN3O4S 485.5 118 62 8.65 8.61
JG-26 4-OCH3-3-COOH-C6H3-       C25H26ClN3O5S 515.5 180 55 8.14 8.10
JG-27 5-OCH3-3-COOH-C6H3-      C25H26ClN3O5S 515.5 192 58 8.14 8.12
JG-28 4-OH-3-COOH-C6H3-      C24H24ClN3O5S 501.5 196 61 8.37 8.32
JG-29 2-OH-5-COOH-C6H3-       C24H24ClN3O5S 501.5 111 52 8.37 8.30
JG-30 4-Cl-3-COOH-C6H3-       C24H23Cl2N3O4S 520.0 215 57 8.07 8.01
JG-31 2-Cl-5-COOH-C6H3-       C24H23Cl2N3O4S 520.0 138 64 8.07 8.04
JG-32 4-CH3-3-COOH-C6H3-      C25H26ClN3O4S 499.5 181 66 8.40 8.31
JG-33 5-CH3-3-COOH-C6H3-      C25H26ClN3O4S 499.5 180 52 8.40 8.35
JG-34 2-CH3-5-COOH-C6H3-      C25H26ClN3O4S 499.5 216 58 8.40 8.33
JG-35 
2-COOH-C4H2 N 2-
(pyrazine) 
C22H22ClN5O4S     487.5 110 65 14.35 14.33
JG-36 4-NHCOCH3-C6H4- C      25H27ClN4O3S 498.5 136 63 11.23 11.20
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GRAPHICAL CHART NO.3: BIOLOGICAL SCREENING OF 1-ARYLSULPHONAMIDO-4-[(4'-CHLOROPHENYL) 
                             (PHENYL)METHYL] PIPERAZINES. 
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-II 
 
Section – I: Biological screening of 1-Arylsulphonamido-4-[(4'-chlorophenyl) (phenyl) methyl] piperazines 
 
                                                                           Antibacterial activity                                                    Antifungal activity 
                                                                           Zone of inhibition in m. m.                                         Zone of inhibition in m. m.   
                                                                   
                                      B. mega             S. aureus             E-coli             S. typhi           A. niger 
                                                                                                                                                                                        
                                             JG-27(19)                 JG-25(15)                JG-27(17)             JG-30(15)              JG-27(19)                      
                                             JG-31(20)                 JG-31(15)                JG-29(17)             JG-31(17)              JG-34(19)                      
                                             JG-34(20)                 JG-36(14)                JG-36(18)             JG-34(17)              JG-36(18)                      
                                                                                                                                                                               
Ampicillin             (50 µg)         23                            22                            21                          15                            -- 
Chloromphenicol (50 µg)         22                            23                            21                          18                            -- 
Norfloxacin          (50 µg)          24                            17                            23                          17                            -- 
Greseofulvin        (50 µg)          --                             --                               --                            --                            25 
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SECTION –II 
SYNTHESIS AND BIOLOGICAL SCREENING OF N-[(4'-CHLOROPHENYL) 
(PHENYL) METHYL] ARYLSULPHOAMIDES 
With an aim to getting better therapeutic agent and considering the 
association of various biological activity with 4-[(4'-chlorophenyl) 
(phenyl)methyl] nuclei, the preparation of aryl sulphonamide of Type (IV) 
have been undertaken by the condensation of 4-[(4'-chlorophenyl) (phenyl) 
methyl]amine with substituted sulphonylchloride in presence of pyridine. 
Type-IV R= aryl
Cl
NH
S
O
O
R
 
The structures elucidation of synthesized compounds have been done on the 
basis of elemental analysis, IR and 1H nuclear magnetic resonance spectroscopy 
and further supported by Mass spectrometry. 
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains 
and antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. 
The biological activities of synthesized compounds were compared with standard 
drugs. Some compounds have been found to have moderate activity as compared to 
known standard drugs recorded on Graphical Chart No. 4.    
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IR SPECTRAL STUDY OF N-[(4'-CHLOROPHENYL) (PHENYL) METHYL]-2"-
METHYL-5"-CARBOXY BENZENE SULPHONAMIDE. 
  Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000- 
 
 
 400 cm-1(KBr disc). 
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Moiety 
Halide 
Sulphonamide 
 
 
 
 
Sec. amine 
C-H   str. (asym.) 
C-H   str. (sym.) 
C-H   def. (asym.) 
C-H   def. (sym.) 
C-H   str. 
C=C   str. 
C-Cl  str. 
C-N   str. 
S=O str.(asym.) 
S=O str.(sym.) 
C-S str. 
C=O str. 
C-OH str. 
N-H str. 
2949 
2864 
1442 
1346 
3061 
1487 
705 
1093 
1346 
1184 
705 
1717 
3161 
3350 
2975-2950 
2880-2860 
1470-1435 
1390-1370 
3090-3030 
1540-1480 
800-600 
1220-1020 
1380-1300 
1180-1140 
700-600 
1725-1700 
3250-2800 
3500-3100 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
" 
" 
" 
" 
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  NMR SPECTRAL STUDY OF N-[(4'-CHLOROPHENYL) (PHENYL) METHYL]- 
  2"-METHYL-5"-CARBOXY BENZENE SULPHONAMIDE 
 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (300 MHz) 
Signal 
No.  
Signal 
Position  
(δppm) 
Relative No. 
of protons  
Multiplicity 
Inference 
1  2.50 3H singlet  Ar-CH3(a) 
2 2.92 1H singlet N-H(e)  
3 6.64 1H singlet C-H(f) 
4  7.57-8.31 12H multiplet Ar--H(bb',c,i,gg',hh') 
5 9.99 1H singlet O-H(d) 
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MASS SPECTRAL STUDY OF N-[(4'-CHLOROPHENYL) (PHENYL) METHYL]-2"-METHYL-5"-CARBOXY 
BENZENE SULPHONAMIDE. 
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF N-[(4'-CHLOROPHENYL) 
(PHENYL)METHYL]ARYLSULPHOAMIDES. 
 
(A) Synthesis of 4-[(4'- Chlorophenyl) (phenyl) methyl] amine. 
 For preparation see page no:39 
(B)Synthesis of N-[(4'-Chlorophenyl) (phenyl) methyl]-2"-methyl 
     4"-carboxy benzene sulphonamide. 
A compound of 4-[(4'-chlorophenyl) (phenyl) methyl] amine (2.18gm, 
0.01 M) and 2-methyl-4-carboxybenzene sulphonyl chloride (2.34gm, 0.01 M) 
in presence of 5ml pyridine was refluxed. The reaction mixture was poured in 
to crushed ice and filtered, washed with water and crystallized from ethanol. 
Yield; 55%, m.p1430C, (C21H18ClNO4S: required: C;60.65;H,4.36;N,3.37%; 
Found: C;60.61;H,4.33;N,.3.35.%). 
Similarly other Sulphonamides were synthesized. The physical data 
are recorded in Table-4.   
(C)Biological Screening of N-[(4'-Chlorophenyl)(phenyl) methyl] 
arylsulphoamides. 
Biological screening was carried out as described in Part-I, 
Section-I (E). 
The actual zone of inhibition are recorded in Graphical chart 
No.4.  
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TABLE NO. 4: PHYSICAL CONSTANT OF N-[(4'-CHLOROPHENYL) (PHENYL) METHYL]-ARYLSUL 
  PHONAMIDES. 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield % 
 
Calcd. Found.
JG-37        3-COOH- C6H4- C20H16ClNO4S 401.5 181 60 3.49 3.47
JG-38        4-OCH3-3-COOH-C6H3- C21H18ClNO5S 431.5 134 54 3.24 3.22
JG-39        5-OCH3-3-COOH-C6H3- C21H18ClNO5S 431.5 193 68 3.24 3.21
JG-40        4-OH-3-COOH-C6H3- C20H16ClNO5S 417.5 166 60 3.35 3.32
JG-41        2-OH-5-COOH-C6H3- C20H16ClNO5S 417.5 153 60 3.35 3.31
JG-42        4-Cl-3-COOH-C6H3- C20H15Cl2NO4S 436.0 195 60 3.21 3.18
JG-43        2-Cl-5-COOH-C6H3- C20H15Cl2NO4S 436.0 137 57 3.21 3.20
JG-44        4-CH3-3-COOH-C6H3- C21H18ClNO4S 415.5 138 61 3.37 3.34
JG-45        5-CH3-3-COOH-C6H3- C21H18ClNO4S 415.5 143 55 3.37 3.35
JG-46        2-CH3-3-COOH-C6H4- C21H18ClNO4S 415.5 123 51 3.37 3.35
JG-47       2-COOH-C4H2N2-
(pyrazine) 
C18H14ClN3O4S 403.5 158 59 10.41 10.38
JG-48  C       4-NHCOCH3-C6H4- 21H19ClN2O3S 414.5 178 60 6.75 6.72
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GRAPHICAL CHART NO.4: BIOLOGICAL SCREENING OF N-[(4'-CHLOROPHENYL) (PHENYL) METHYL]- 
                             ARYLSULPHONAMIDES. 
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
 
PART-II 
 
Section – II: Biological screening of N-[(4'-chlorophenyl) (phenyl) methyl]-arylsulphonamides. 
 
                                                                                   Antibacterial activity                                           Antifungal activity 
                                                                                   Zone of inhibition in m. m.                                 Zone of inhibition in m. m.  
                                                                   
                                      B. mega            S. aureus             E-coli              S. typhi          A. niger 
                                                                                                                                                                                        
                                             JG-40(19)               JG-40(15)                 JG-40(16)             JG-39(17)             JG-37(18)                        
                                             JG-42(20)               JG-43(16)                 JG-43(18)             JG-43(14)             JG-42(19)                        
                                             JG-45(19)               JG-48(15)                 JG-44(17)             JG-46(16)             JG-48(20)                        
                                                                                                                                                                               
Ampicillin             (50 µg)         23                           22                             21                          15                           -- 
Chloromphenicol (50 µg)         22                           23                             21                          18                           -- 
Norfloxacin          (50 µg)          24                           17                             23                          17                           -- 
Greseofulvin        (50 µg)          --                             --                               --                           --                            25                        
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STUDIES ON 5-OXO-IMIDAZOLINES 
INTRODUCTION         
 The five membered heterocyclic ring system 5-oxo-imidazolines have 
two nitrogen atom at 1- and 3-positions and a carbonyl group at 5-position. 
 
 
NH
N
O
 (I)          
 
 
 
 
The discovery of the 2-substituted-5-imidazolines dates back to the 
year 1888, when A. W. Hoffman82 for the first time discovered 5-oxo-
imidazoline by heating N'-diacetylethylene diamine in a stream of dry 
hydrogen chloride.  
Moreover, some compounds were prepared by A. Ladenburg83 by the 
fusion of two equivalents of sodium acetate with one equivalent of ethylene 
diamine dihydrochloride.  
SYNTHETIC ASPECT        
 Various methods have been reported for the synthesis of 
imidazolinones in literature84. Aminolysis of oxazolone with amine leads to 
the formation of imidazolinones which has been reported in literature85.  
1. A. Saxena et. al.86 have synthesised new imidazolinones(II).  
N
O
N Ar
-
O
Cl
O
NH
NH2
Ar-
N
N
O
NH
O
Cl
(II)
 
2. H. A. Allimony et. al87 have synthesised (II) new imidazolinone derivatives 
by conventional method. 
3. Feng-Jun-Cai et. al88 have synthesised 5-imidazolinone derivatives by 
microwaves irradiation.         
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MECHANISM        
 Azalactone reacts with variety of compounds such as water, alcohols, 
amines and hydrogen halides. Amides of α-acylamino acryclic acids obtained 
from the condensation of azalactone and primary amine can be converted to 
imidazolinones as shown in equation (III).   
 
N
O
R
O
X
NH
O
X
R
O
NH R1
N
N
R
R1X
O
R1 NH2 POCl3
(a) (b) (c)
R' -NH2 ,Dry C5H5N / Abs.C2H5OH,K2CO3
( III ) 
 The ring closer can be affected under a variety of conditions. 
Substituted anilides have been converted to imidazolinone derivatives by the 
action of POCl3. 
THERAPEUTIC IMPORTANCE       
 Naphazoline hydrochloride, xylometazoline hydrochloride etc. are 
various imidazolinone derivatives which have been used as adrenergic 
stimulants and tolazoline and phenotolamine as adrenergic blocking agents. 
Various imidazolinones are known to exhibit a broad spectrum of biological 
activities such as,   
1. Antitubercular89
2. Potent CNS depressant90, 91
3. Insecticidal92
4. Antiviral93
5. Hypertensive94
6. Antiinflammatory95-97
7. Glucagon antagonists98
8. Antimicrobial99
9. Thrombin inhibitor100
10. Anticonvulsant101, 102
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11. Sedative and hypnotics103
12. Bactericidal104, 105
13. Fungicidal106, 107
14. Antiparkinsonian108, 109
15. Anthelmintic110
16. Antihistaminic111
17. Anticancer112, 113
18. Antidiabatic114         
 K. K. Awasthi et. al.115 (IV) have synthesised some new imidazolinone 
derivatives and reported their antimicrobial activity. 
N N
R O
NH
NH
S
CH3
CH3
( IV )
 
 F. C. Geoffrey et. al 116 and B. L. Pilkington et. al117 have synthesised 
and studied antifungal activity of imidazolinones. L. J. Peter and Co-worker118 
have prepared substituted imidazolinones which inhibited the abnormal cell 
growth in human body. S. Lauter and Co-worker119 have isolated imidazoline 
from different methods and tested for the treatment of cytokine release. 
Imidazoline derivatives have been prepared by Erick and co-worker120 
showing anti-HIV activity. Ding Ming-Wu et. al121 have prepared novel 
imidazolines and reported their antifungal activity. 
K. Vishnu et. al.122 has reported anti-AIDS, antibacterial and fungicidal 
activity of 5-oxo-imidazolines. B. R. Shah and co-worker123 have prepared 
some new imidazolines and reported anticancer and anti HIV activity. 
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N
O
N
N
H
NH
CH3
CH3
O CH3
CH3
N
N
O
R1
NH
N
N
N
R3
R2( VI )( V )
 
V. Akyoshi et. al.124 have prepared some new imidazolinone 
derivatives (V) and reported their herbicidal activity. Agrochemical activity of 
imidazolinones has been reported by J. P. Bascou and co-workers125.  
 R. Sharma and co-workers126 have reported antimicrobial activity of 5-
oxo-imidazolines (VI).        
  
CONTRIBUTION FROM OUR LABORATORY 
A. R. Parikh et. al127 have synthesised imidazolinones bearing thiazole 
as moderately active bactericidal and fungicidal. H. H. Parekh et. al128 have 
elaborated better activity for some imidazolinones with activated benzylidene 
group at 5-position. 
D. M. Purohit et al129 synthesized 5-oxo-imidazoline (VII) derivatives in 
“Fluchloralin” moiety. D. M. Purohit et al130, 131 have synthesized 5-oxo-
imidazolines (VIII) in “dichlorine” nucleus. D. M. Purohit et al 132 have 
synthesized 5-oxo-imidazolines (IX) in 2, 4-D derivatives.  
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F3C
NO2
NO2 CH3
NH N
O
N
R
O2N
Cl
Cl
N
O
N
R
N N
R
O
S
O
O
Cl
Cl
OCH2COOH
O2N
Cl
Cl
NH S N
N
O
O
O
CH3
N
O
N
R
( VII )
( VIII )
( IX ) ( X )
 
V. N. Patoliya et al 133, 134 have synthesized 5-oxo-imidazolines (XI, 
XII) evaluated its antimicrobial activity. 
N
N
O
N
O
N
R
Cl
CH3
CH3
N
N
O
N
O
N
R
( XI ) ( XII )
 
A. R. Parikh et. al. have synthesized imidazolinones bearing 
phthalazine135, 2-base of chloramphenicol136 moiety at one position which 
were evaluated for their antimicrobial activity. A. R. Parikh et. al. 137 have 
reported 4-(4'-Arylidine-2'- phenyl-5'-oxo-imidazolin-1-yl) benzophenones 
which were screened for their antimicrobial activity. Biplabde et. al. 138 have 
reported some new 5-oxoimidazoline as antimicrobial agents.Imidazolinones 
have been reported to possess antioxidant activity. 
Moreover, A. R. Parikh, H. H. Parekh and co-workers have synthesised 
the newer 5-oxo-imidazolines with different variety of activities described as 
under.   
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1) 1-p-(4'-Acetamidobenzenesulphonamido) phenyl-2-phenyl-4 -
substituted benzal-5-oxoimidazolines139. 
2) Synthesis of biologically active 5-oxo-imidazolines140-142 . 
3) Preparation and antimicrobial activity of 1-N-Aryl-2-methyl-4'-(8-
hydroxy quinolin-7'-yl)-methine-5-oxoimidazolines143. 
4) Synthesis of some 5-imidazolinones as novel bioactive compounds 
derived from benzimidazole144. 
5) Synthesis and biological screening of 2-Chloro-8-methylquinolin-3-yl-
N-(2'-phenyl-4'-arylidine-5'-oxo-imidazolin-1'-yl)-azomethines145. 
 Moreover Yoneda Naoto et. al146 have synthesised imidazolinones as 
antihypertensive agent. R. C. Dage et. al. 147 have synthesised cardiotonic 
imidazolones. Armando Rossello et. al. 148 have synthesised imidazolones as 
antifungal agent. A. B. Cooper and co-workers149 have found that 
imidazolones are inhibitors of farnesyl protein transferase. Machii Daisuke et. 
al.150 have synthesised new imidazolones as a telomerase inhibitors and 
antitumor agents M. R. Jean et. al. 151 have synthesised imidazolones and 
tested as antileishmanial agent. Chafiq Hamdouchi et. al. 152 have 
synthesised imidazolinones and screened for their potent and broad 
spectrum activity. M. L.  Irene et al.153 have synthesised imidazolinones and 
tested as antiretroviral activity (IX). Xu Zhi-Feng et. al. 154 have synthesised 
imidazolinones as biological agent. With a view to getting better therapeutic 
agent, it was contemplated to synthesized imidazolinones to enhance the 
overall activity of resulting compounds which have been described as under.
         
SECTION- I:  SYNTHESIS AND BIOLOGICAL SCREENING OF N-{4-
[(4'-CHLOROPHENYL)(PHENYL) METHYL] PIPERAZINE-
1-YL}-4''-ARYLIDENE-2''-(4'''-METHOXYPHENYL)-5''-
OXO-IMIDAZOLINES. 
 
SECTION- II: SYNTHESIS AND BIOLOGICAL SCREENING OF N-[(4'-
CHLOROPHENYL) (PHENYL) METHYL]-4''-ARYLIDENE-
2''-(4'''-METHOXYPHENYL)-5''-OXO-IMIDAZOLINES.  
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SECTION:-I 
SYNTHESIS AND BIOLOGICAL SCREENING OF N-{4-[(4'-
CHLOROPHENYL) (PHENYL) METHYL] PIPERAZINE-1-YL}-4''-
ARYLIDENE-2''-(4'''-METHOXYPHENYL)-5''-OXO-IMIDAZOLINES. 
Imidazolinones represent one of the most active classes of 
compounds having a wide spectrum of biological activities with an aim to 
getting better therapeutic agent. The preparations of 5-oxo-imidazolines of 
Type (V) have been undertaken by the condensation of 1-Amino [(4'-
Chlorophenyl) (phenyl) methyl] piperazine with different oxazolones. 
   
Cl
N N N
N
O R
O
CH3Type -V   R=  Aryl
 
 The constitution of the synthesized products have been characterized 
by using elemental analyses, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by mass spectrometry.  
All the compounds have been also evaluated for their antibacterial 
activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. 
The biological activities of the synthesised compounds have been compared 
with standard drugs. Some compounds have been found to have good and 
equivalent activity as compared to the known standard drugs recorded on 
Graphical Chart No. 5. 
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IR SPECTRAL STUDY OF N-{4-[(4'-CHLOROPHENYL)(PHENYL) 
METHYL]PIPERAZINE-1-YL}-4''-(4""-DIMETHYLAMINOBENZYLIDENE) -
2''-(4'''-METHOXYPHENYL)-5''-OXO-IMIDAZOLINES. 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc) 
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
Aromatic 
 
Imidazolone 
 
 
 
Halide 
Ether 
C-H Str.(asym.) 
C-H def.(asym.) 
C-H def.(asym.) 
C-H Str. 
C=C Ring skeletal 
C=O Str. 
CH=CH- Str.vinylic 
C=N Str. 
C-N Str. 
C-Cl Str 
C-O-C Str. 
2959 
1448 
1372 
3050 
1568 
1714 
1648 
1648 
1095 
758 
1130 
2975-2950 
1470-1435 
1385-1370 
3090-3030 
1600-1450 
1720-1700 
1655-1618 
1660-1630 
1100-1020 
800-600 
1200-1100 
516 
" 
" 
517 
" 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF N-{4-[(4'-CHLOROPHENYL)(PHENYL) 
METHYL]PIPERAZINE-1-YL}-4''-(4""-DIMETHYLAMINO 
BENZYLIDENE)-2''-(4'''-METHOXYPHENYL)-5''-OXO-IMIDAZOLINE. 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (300 MHz) 
Signal No. 
Signal 
Position 
(δppm) 
Relative 
No. of 
protons 
 
Multiplicity Inference 
1 2.27-2.29 2H triplet C-H(j) 
2 2.39 6H singlet C-H(a) 
3 2.58-2.69 2H triplet C-H(k) 
4 2.99-3.03 2H triplet C-H(h) 
5 3.73-3.81 2H triplet C-H(i) 
6 3.87 3H singlet Ar-OCH3(g) 
7 5.74-5.75 1H doublet C-H(l) 
8 6.99 1H singlet C-H(d) 
9 7.31-7.56 9H multilet Ar-H(bb',ff',m) 
10 7.65-7.69 2H doublet Ar-H(nn') 
11 7.69-7.71 2H doublet Ar-H(cc') 
12 7.71-7.93 2H singlet Ar-H(oo') 
13 7.95-7.95 2H doublet Ar-H(ee')  
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MASS SPECTRAL STUDY OF N-{4-[(4'-CHLOROPHENYL)(PHENYL) METHYL]PIPERAZINE-1-YL}-4''-(4""-
DIMETHYLAMINOBENZYLIDENE) -2''-(4'''-METHOXYPHENYL)-5''-OXO-IMIDAZOLINE. 
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF N-{4-[(4'-
CHLOROPHENYL) (PHENYL) METHYL] PIPERAZINE-1-YL}-4''-
ARYLIDENE-2''-(4'''-METHOXYPHENYL)-5''-OXO-IMIDAZOLINES. 
[A] Synthesis of 4-[(4'- Chlorophenyl) (phenyl) methyl] piperazine 
See part-I, section-I page no:27 
[B]  Synthesis of 4-[(4'-Chlorophenyl) (phenyl) methyl]-4-1-
nitrosopiperazine 
See part-I, section-I page no:27 
[C]  Synthesis of 4-[(4'-Chlorophenyl) (phenyl) methyl] piperazine-1-
amine 
See part-I, section-I page no:27 
[D]     Synthesis of 4-[4'-(Dimethylamino)benzylidine]-2-(4'' methoxy 
phenyl)-1,3-oxazol-5(4H)-one   
 A mixture of [(4-methoxybenzoyl)amino]acetic acid (6.0 gm,0.029 M), 
acetic anhydride (4.27gm,0.032 M),sodium acetate (2.62 gm,0.032M), 
4-(dimethylamino) benzaldehyde (4.16 gm,0.032 M) was heated on a water 
bath for 4 hrs. Resulting mass poured into ice cold water, filtered and 
crystallized from DMF. Yield, 64%, m.p.156 oC. 
[E]  Synthesis of N-{4-[(4'-chlorophenyl) (phenyl) methyl] 
piperazines-1-yl}-4''(4''''-dimethylamino benzylidene-2''-(4'''-
methoxyphenyl)-5''-oxo-imidazoline. 
 A mixture of 4-[(4'-Chlorophenyl) (phenyl) methyl] piperazine-1-amine 
(3.0 g, 0.01 M) and 4-[4'-(dimethylamino)benzylidine]-2-(4''-methoxyphenyl)-
1,3-oxazol-5(4H)-one(3.54 g, 0.01 M) in dry pyridine (20 ml) was refluxed for 
12 hrs. in oil bath. Resulting mass was poured into crushed ice and 
neutralised with HCl, filtered and crystallised from 1,4-dioxan. Yield; 65%, mp. 
120oC. (C36H36ClN5O2 ; Required : C, 71.33; H, 5.99; N, 11.56; found : C, 
71.33; H, 5.99; N, 11.52%). 
Similarly other 5-oxo-imidazolines have been prepared.  The physical 
constants are recorded in Table No-5.      
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[F]  Biological Screening of N-{4-[(4'-chlorophenyl) (phenyl) methyl] 
piperazine-1-yl}-4''-arylidene-2''-(4'''-methoxyphenyl)-5''-oxo-
imidazolines        
Biological screening was carried out as describe in Part-I, 
Section-I (E). The zone of inhibition of the test solution are 
recorded in graphical chart No 5. 
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TABLE NO. 5: PHYSICAL CONSTANT OF N-[(4'-CHLOROPHENYL) (PHENYL) METHYL]-PIPERAZINE-1-YL}-4''-  
ARYLIDENE-2''-(4'''-METHOXY PHENYL)-5”-OXO-IMIDAZOLINES. 
 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield %
 
Calcd
. 
Found. 
JG-49      C6H5- C34H31ClN4O2 562.5 191 66 9.95 9.91
JG-50      4-Cl-C6H4- C34H30Cl2N4O2 597.0 135 60 9.38 9.32
JG-51      4-F-C6H4- C34H30ClFN4O2 580.5 119 62 9.64 9.60
JG-52      4-Br-C6H4- C34H30BrClN4O2 641.5 140 58 8.73 8.71
JG-53      2-OH-C6H4- C34H31ClN4O3 578.5 168 57 9.68 9.63
JG-54      3- OH-C6H4- C34H31ClN4O3 578.5 105 59 9.68 9.66
JG-55      4-OH-C6H4- C34H31ClN4O3 578.5 101 52 9.68 9.65
JG-56      4-OCH3-C6H4- C35H33ClN4O3 592.5 125 63 9.45 9.41
JG-57      3-OCH3-4-OH-C6H3- C35H33ClN4O4 608.5 185 62 9.20 9.18
JG-58      4-N-(CH3)2-C6H3- C36H36ClN5O2 605.5 120 65 11.56 11.52
JG-59      4-NO2-C6H4- C34H30ClN5O4 607.5 177 68 11.52 11.50
JG-60     3-OCH3-4-OH-5- NO2-
C6H2 
C35H32ClN5O6 653.5 171 60 10.71 10.69
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GRAPHICAL CHART NO.5: BIOLOGICAL SCREENING OF N-[(4'-CHLOROPHENYL)(PHENYL)METHYL]- 
                                           PIPERAZINE-1-YL}-4''-ARYLIDENE-2''-(4'''-METHOXYPHENYL)-5-OXO-          
                                         IMIDAZOLINES. 
 
0
5
10
15
20
25
30
Z
O
N
E
 
O
F
 
I
N
H
I
B
I
T
I
O
N
 
I
N
 
m
m
B.mega 18 15 14 16 18 8 19 13 18 9 18 17 23 22 24 0
S.aureus 12 14 16 11 13 11 15 10 15 13 14 11 22 23 17 0
E.coli 16 8 14 12 14 13 15 17 14 11 9 16 21 21 23 0
S. typhi 10 12 13 14 15 12 11 10 15 12 13 11 15 18 17 0
A.niger 14 18 12 16 19 16 20 16 17 13 21 17 0 0 0 25
JG-49 JG-50 JG-51 JG-52 JG-53 JG-54 JG-55 JG-56 JG-57 JG-58 JG-59 JG-60
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cin
Greseof
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-III 
 
Section – I: Biological screening of N-[(4'-chlorophenyl) (phenyl) methyl]-piperazine-1-yl}-4''-  
        arylidene-2''-(4'''-methoxy phenyl)-5''-oxo-imidazolines 
 
                                                           Antibacterial activity                                                                   Antifungal activity 
                                                           Zone of inhibition in m. m.                                                        Zone of inhibition in m. m.   
                                                                   
                                      B. mega           S. aureus             E-coli               S. typhi             A. niger 
                                                                                                                                                                                        
                                              JG-53(18)              JG-51(16)                 JG-55(15)               JG-52(14)               JG-53(19)                    
                                              JG-55(19)              JG-55(15)                 JG-56(17)               JG-53(15)               JG-55(20)                    
                                              JG-59(18)              JG-57(15)                 JG-60(16)               JG-57(15)               JG-59(21)                   
                                                                                                                                                                               
Ampicillin             (50 µg)          23                         22                              21                           15                              -- 
Chloromphenicol (50 µg)          22                         23                              21                           18                              -- 
Norfloxacin          (50 µg)           24                         17                              23                           17                              -- 
Greseofulvin        (50 µg)           --                             --                             --                              --                              25 
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SECTION-II 
SYNTHESIS AND BIOLOGICAL SCREENING OF N-[(4'-
CHLOROPHENYL)     (PHENYL) METHYL]-4''-ARYLIDENE-2''-(4'''-
METHOXY PHENYL)-5''-OXO-IMIDAZOLINES.    
 Imidazolinones represent one of the most active classes of compounds 
having a wide spectrum of biological activities with an aim to getting better 
therapeutic agent. The preparation of 5-oxo-imidazolines of Type (VI) have 
been synthesized by the condensation of 1-Amino [(4'-chlorophenyl) 
(phenyl)]-methane with different oxazolones.  
Type -VI   R=  Aryl
Cl
N
N
O R
O
CH3
 
The constitution of the synthesized products have been characterized 
by using elemental analyses, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by mass spectrometry.  
All the compounds have been also evaluated for their antibacterial 
activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. 
The biological activities of the synthesised compounds have been compared 
with standard drugs. Some compounds have been found to have good activity 
as compared to the known standard drugs, recorded on graphical chart No. 6. 
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IR SPECTRAL STUDY OF N-[(4'-CHLOROPHENYL)(PHENYL) 
METHYL]-4''-(4''''-METHOXYBEZYLIDINE-2''-(4'''-METHOXY 
PHENYL)-5''-OXO-IMIDAZOLINE.   
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-
400 cm-1(KBr disc). 
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
Aromatic 
 
Imidazolone 
 
 
 
Halide 
Ether 
C-H Str.(asym.) 
C-H def.(asym.) 
C-H def.(asym.) 
C-H Str. 
C=C Ring skeletal
C=O 
C=C- Str. 
C-N Str. 
C=N Str. 
C-Cl Str  
C-O-C Str. 
2970 
1468 
1376 
3060 
1491 
1722 
1614 
1071 
1614 
696 
1071 
2975-2950 
1470-1435 
1385-1370 
3090-303  
1600-1450 
1720-1700 
1655-1618 
1100-1020 
1660-1630 
800-600 
1200-1100 
516 
" 
" 
517 
" 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF N-[(4'-CHLOROPHENYL) (PHENYL) 
METHYL]-4''-(4''''-METHOXYBEZYLIDINE-2''-(4'''-METHOXYPHENYL)-
5''-OXO-IMIDAZOLINE. 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (300 MHz) 
Signal No. 
Signal 
Position 
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 
2 
3 
4 
5 
6 
7 
8 
3.67 
6.30 
7.20 
7.36-7.39 
7.48-7.50 
7.55-7.57 
7.83-7.90 
8.50-8.52 
3 H 
1 H 
1 H 
2 H 
5 H 
5 H 
4 H 
2 H 
Singlet 
singlet 
singlet 
doublet 
multiplet 
multiplet 
doublet 
doublet 
O-CH3 (a)
C-H(f) 
C-H(d) 
Ar-H(bb') 
Ar-H(l) 
Ar-H(e) 
Ar-H(gg',hh') 
Ar-H(cc') 
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MASS   SPECTRAL STUDY OF N-[(4'-CHLOROPHENYL) (PHENYL) METHYL]-4''-(4''''-METHOXYBEZYLIDINE-2''-
(4'''-METHOXYPHENYL)-5''-OXO-IMIDAZOLINE. 
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF N-[(4'-
CHLOROPHENYL)     (PHENYL) METHYL]-4''-ARYLIDENE-2''-(4'''-
METHOXYPHENYL)-5''-OXO-IMIDAZOLINES.     
(A) Synthesis of 4-[(4'- Chlorophenyl) (phenyl) methyl] amine. 
See part-I, section-I page no:39 
(B) Synthesis of 4-[4'-(Methoxybenzylidine]-2-(4''-methoxyphenyl)-1,3-
oxazol-5(4H)-one.  
 A mixture of [(4-mehoxybenzoyl)amino]acetic acid (6.0 gm, 0.029 M), 
acetic anhydride (4.27 gm,0.032 M), sodium acetate (2.62 gm, 0.032 M), 4-
methoxy benzaldehyde (4.36 gm,0.032 M) was heated on a waterbath for 4 
hrs. Resulting mass poured into ice cold water, filtered and crystallized from 
DMF. Yield, 66%, m. p.,143oC. 
(C) Synthesis of N-{4-[(4'-chlorophenyl) (phenyl) methyl] piperazine- 
1-yl}-4''-(4''''-methoxybenzylidine-2''-(4'''-methoxyphenyl)-5''-oxo-
imidazoline. 
 A mixture of 1-(4-Chlorophenyl)-(phenyl) methanamine (3.0 g, 0.01 M) 
and 4-[4'-(methoxybenzylidine]-2-(4''-methoxyphenyl)-1,3-oxazol-5(4H)-one 
(4.26 g, 0.01 M) in dry pyridine (20 ml) was refluxed for 12 hrs. in oil bath. 
Resulting mass was poured into crushed ice and neutralised with HCl, filtered 
and crystallized from 1,4-dioxan. Yield 64%, mp. 186ºC. (C31H25ClN2O3 ; 
Required : C, 73.15; H, 4.95; N, 5.54%; found : C, 73.13; H, 4.90; N,5.47%).  
Similarly other 5-oxo-imidazolines have been prepared. The physical 
constants are recorded in Table No.6.       
(D) Biological Screening of N-[(4'-chlorophenyl) (phenyl)methyl]-4''-
arylidene-2''-(4'''-methoxyphenyl)-5''-oxo-imidazolines. 
Biological screening was carried out as describe in Part-I, Section-I 
(E). The zone of inhibition of the test solution is recorded in graphical 
chart No. 6. 
93 
 
"Studies on some heterocyclic compounds of medicinal interest" 
 
 
TABLE NO. 6: PHYSICAL CONSTANT OF N-[(4'-CHLOROPHENYL)(PHENYL) METHYL]-4''-ARYLIDENE-2''-(4''' 
METHOXYPHENYL)-5”-OXO-IMIDAZOLINES. 
 
% of Nitrogen 
 
Sr. No. R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield %
 
Calcd
. 
Found. 
JG-61      C6H5- C30H23ClN2O2 478.5 218 64 5.85 5.32
JG-62      4-Cl-C6H4- C30H22Cl2N2O2 513.0 166 58 5.45 5.40
JG-63      4-F-C6H4- C30H22ClFN2O2 496.5 135 60 5.63 5.61
JG-64      4-Br-C6H4- C30H22BrClN2O2 557.5 171 60 5.02 5.01
JG-65      2-OH-C6H4- C30H23ClN2O3 494.5 147 55 5.66 5.61
JG-66      3- OH-C6H4- C30H23ClN2O3 494.5 154 60 5.66 5.60
JG-67      4-OH-C6H4- C30H23ClN2O3 494.5 174 57 5.66 5.64
JG-68      4-OCH3-C6H4- C31H25ClN2O3 508.5 186 64 5.54 5.47
JG-69      3-OCH3-4-OH-C6H3- C31H25ClN2O4 524.5 194 60 5.33 5.31
JG-70      4-N-(CH3)2-C6H3- C32H28ClN3O2 521.5 161 62 8.05 8.02
JG-71      4-NO2-C6H4- C30H22ClN3O4 523.5 173 63 8.02 8.01
JG-72      C10H7 (napthyl) C34H25ClN2O2 528.5 211 64 5.29 5.25
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GRAPHICAL CHART NO.6: BIOLOGICAL SCREENING OF N-[(4'-CHLOROPHENYL)(PHENYL) METHYL] -4''- 
                                          ARYLIDENE-2''-(4'''-METHOXY PHENYL)-5'-OXO-IMIDAZOLINES. 
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-III 
 
Section – II: Biological screening of N-[(4'-chlorophenyl)(phenyl) methyl]-4''-arylidene-2''-(4'''-methoxy 
-phenyl)-5''-oxo-imidazolines 
 
                                                                          Antibacterial activity                                                Antifungal activity 
                                                                               Zone of inhibition in m. m.                                     Zone of inhibition in m. m.  
                                                                   
                                      B. mega           S. aureus              E-coli              S. typhi             A. niger 
                                                                                                                                                                                        
                                              JG-6319)               JG-61(14)                 JG-65(16)             JG-64(14)              JG-65(19)                       
                                              JG-65(17)              JG-68(15)                 JG-67(17)             JG-65(16)              JG-66(18)                       
                                              JG-69(19)              JG-71(15)                 JG-69(18)             JG-71(14)              JG-67(18)                       
                                                                                                                                                                               
Ampicillin             (50 µg)         23                            22                            21                          15                           -- 
Chloromphenicol (50 µg)         22                           23                             21                          18                           -- 
Norfloxacin           (50 µg)         24                           17                             23                          17                           -- 
Greseofulvin         (50 µg)         --                             --                              --                             --                           25 
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STUDIES ON CHALCONES 
INTRODUCTION 
The term “chalcone” was first coined by Kotanecki and Tambor155. The 
chemistry of chalcones has generated intensive scientific studies throughout 
the world, especially interesting for their biological and industrial applications. 
Chalcones are colored compounds because of the presence of the 
chromophore and auxochrome. They are known as benzalacetophenones or 
benzylidene acetophenones. Chalcones (I) are characterized by their 
possession of a structure in which two aromatic rings A and B are linked by an 
aliphatic three-carbon chain.  
(I)
O
A B
 
The alternative names given to chalcones are phenyl styryl ketones, 
beanzalacetophenone, β-phenyl acrylphenone, γ-oxo-α γdiphenyl-α-propylene 
and α- phenyl-β-benzoethylene. 
SYNTHETIC ASPECT        
 A variety of methods are available for the synthesis of chalcones. The 
most convenient method is one that involves the Claisen-Schmidt 
condensation of equimolar quantities of a aryl methyl ketones with aryl 
aldehyde in the presence of alcoholic alkali.156-157 Various condensing agent 
used for the synthesis of chalcones are alkali of different strength.158-159 
Hydrogen chloride160-161 Phosphorous oxychloride162, Piperidine163, 
Anhydrous Aluminium Chloride164, Boron trifluoride165, Borax166, 
Aminoacids167, Perchloric acid168 etc.     
MECHANISM         
 The following mechanisms have been suggested for the synthesis of 
chalcones.          
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 The intermediate aldol type products formed readily undergoes 
dehydration even under mild condition, particularly when R and R’ are aryl 
groups. 
REACTIVITY OF CHALCONE       
 The chalcones have been found to be useful for the synthesis of many 
heterocyclic compounds. 
1. Chalcones are intermediate compounds for the synthesis of some naturally 
occuring heterocyclic compounds like flavones, flavanones, flavanoid, 
dihydroflavanols, benzal coumarinones, anthocyanins, etc.   
    
2. Chalcone contain a Keto-ethylenic group and therefore reactive towards 
number of reagents yielding various heterocyclic compounds exhibiting 
significant biological activities viz. pyrazolines169, cyanopyridines170, 
cyanopyrans171, cyanopyridones172, pyrimidines173-174, isoxazoles175, 
indazole176 etc.      
3. They have been useful in providing structure of some natural products like 
cyanomulcurin177, eviodictoyl178, hemlocktanin179, narighenin180, plioretin181 
etc. 
4. Chalcones are also useful for the detection of Fe (II) 182 and Ca (II) 183 ions 
in presence of Ba and Sr as it reacts with number of metal ions. Trihydroxy 
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chalcones was used as an analytical reagent for amperometric estimation of 
cupper184 and for spectrophotomatric study of the germanium 185. 
5. Chalcone and their derivatives are also found to be applicable as light 
Chalcone and their derivatives are also found to be applicable as light 
stabilizing agent186, sweetening agent187, organic brightening agent, 
photosensitive material, polymerisation catalyst, scintillators as well as 
fluorescent whitening agent. 
6. The chalcones are natural biocides188-189 and are well-known key 
intermediate in the synthesis of heterocyclic compounds possessing 
biodynamic behaviour 190-191. 
THERAPEUTIC IMPORTANCE        
 Chalcones derivatives have been found to possess wide range of 
therapeutic activities as shown below 
1. Antiallergic192
2. Antiinflammatory193, 194
3. Antitumor195, 196
4. Antispasmodic197
5. Antiulcer198, 199
6. Anthelmintics200
7. Anticancer201, 202
8. Antiviral and Antitubercular203
9. Anti HIV204
10. Bactericidal205, 206
11. Cardiovascular207
12. Fungicidal208-210
13. Herbicidal211-212
14. Insecticidal213-216
Chalcones are potential biocides, because some naturally occurring 
antibiotics217 and aminochalcones218, 219 probably own their biological activity 
in the presence of the α, β-unsaturated carbonyl group. G. L. Nelson220 has 
synthesized the analogues of   prostaglandin (II).    
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O
R'
R
O
(II)
X OH
CH2
R
X = NCH3/S
R = H/OCH3
(III)
 
   
P.  P. Yadav and co-workers221 have synthesized nitrogen and sulfur 
containing furanoflavonoids and thiophenylflavonoids (III), Which have been 
screened for their antifungal and antibacterial activity. C. Q. Meng et al.222 
discovered some novel heteroaryl substituted chalcones (IV) as inhibitors of 
TNF-alpha-induced VCAM-1 expression.     
 Some dihydrochalcones are well known for their sweetening 
property223, 224 and appear to be non-nutritive sweeteners. A dihydrochalcone 
Uvaretin from Uvaria acuminata has shown antitumor activity225 in 
lymphocytic leukemia test.    
V.K. Ahluwalia et al.226 have noted that 5-cinnamoylchalcones (V) have 
shown good as antibacterial activity.    
 
OH
R'
R
O
OH
OH
O
R
R'
(V)
MeO
MeO
O OMe
OMe
S
(IV)
 
P. Boeck et al.227 have synthesized novel chalcone analougs (VI) with 
antileishmanial activity. Analougs containing nitro, fluorine or bromine group 
respectively displayed increased selectivity against the parasites as compared 
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with natural chalcone.        
  
R"
OH
H3CO OCH3
O
R
R'
R' =NO2,R" =H,R"' =H 
R=H,R" =F,R"' =H 
R' =NO2,R" =H,R"' =Br
(VI)  
Furthermore, M. J. Alcaraz et al.228 have described the role of nuclear 
factor-kappaB and heme oxygenase-1 in the mechanism of action of an anti-
inflammatory activity of chalcone derivative. O. Nerya et al.229 have prepared 
chalcones as potent tyrosinase inhibitors. O. Sabzevari et al.230 have 
constructed some new chalcone derivatives (VII) as molecular cytotoxic 
mechanisms for anticancer activity. 
CONTRIBUTION FROM OUR LABORATORY:    
 D. M. Purohit et al231 have been synthesized (VII) 2-(4'-Chlorophenyl)-
6-methyl-3-[1"-aryl-2"-propene-1"-one-3-yl]-imadazo [1,2-a] pyridine and 
evaluated its antimicrobial activity. 
(VII)
N
N
R
O
CH3
Cl
R = Aryl
 
Chalcones have been proved to be an important intermediate for the 
synthesis of many heterocyclic compounds in organic chemistry. These facts 
prompted us to synthesize some new chalcone derivatives.  
SECTION-I:  
SYNTHESIS AND BIOLOGICAL SCREENING OF N-{4-[(4'"-
CHLOROPHENYL) (PHENYL) METHYL AMINO] PHENYL-1'-YL}-3-ARYL-
2-PROPENE-1-ONES. 
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SECTION-I: 
SYNTHESIS AND BIOLOGICAL SCREENING OF N-{4-[(4'"-
CHLOROPHENYL) (PHENYL) METHYL AMINO] PHENYL-1'-YL}-3-ARYL-
2-PROPENE-1-ONES. 
Chalcone derivatives occupy a unique place in the field of medicinal 
chemistry due to wide range of biological activities exhibited by them, 
prompted by these facts, the preparation of chalcones of Type (VII) have been 
carried out by condensation of 4'-[(4'''-chlorophenyl)(phenyl) methyl amino] 
phenyl} ethanone with different aromatic aldehyde in presence of aqueous 
NaOH.  
Cl
NH
O
R
R = arylType -VII
 
 The structure elucidation of synthesized compounds has been done on 
the basis of elemental analysis, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by Mass spectrometry.   
 All the compounds have been evaluated for their in vitro biological 
assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards Aspergillus niger at a 
concentration of 50 µg/ml. The biological activities of synthesized compounds 
were compared with standard drugs. Some compounds have been found to 
have moderate activity as compared to known standard drugs recorded on 
Graphical Chart No. 7.        
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IR SPECTRAL STUDY OF N-{4'-[(4'''-CHLOROPHENYL)(PHENYL) 
METHYLAMINO]PHENYL-1'-YL}-3-(4""-METHOXYPHENYL)-2-
PROPENE-1-ONE. 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc).     
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
Aromatic 
 
α,β un. ketone 
 
Halide 
Ether 
Sec. Amine 
C-H Str. (asym.) 
C-H Str. (sym.) 
C-H def. (asym.) 
C-H Str. 
C=C Str. 
C=O Str. 
CH=CH Str. vinylic 
C-Cl Str. 
C-O-C Str. 
C-NH Str. 
2966 
2864 
1375 
3084 
1597 
1665 
1655 
782 
1168 
3421 
2975-2950 
2880-2860 
1385-1370 
3090-3030  
1600-1450 
1685-1665 
1655-1618 
800-600 
1200-1100 
3500-3100 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OFN-{4'-[(4'''-CHLOROPHENYL)(PHENYL) 
METHYLAMINO]PHENYL-1'-YL}-3-(4""-METHOXYPHNEYL)-2-
PROPENE-1-ONE. 
 
Internal Standard: TMS; Solvent: CDCl3; Instrument Bruker Spectometer (300 MHz) 
Signal 
No.  
Signal 
Position  
(δppm) 
Relative 
No. of 
protons  
 
Multiplicity Inference 
1  3.86 3H singlet  Ar-OCH3(a) 
2 4.16 1H singlet N-H(h)  
3 5.61-5.60 1H doublet C-H(i) 
4  6.69-6.71 2H doublet Ar-H(gg') 
5 6.98-6.99 2H doublet Ar-H(bb') 
6  7.02-7.05 1H doublet  C-H(e) 
7 7.31-7.39 9H multiplet  Ar-H(jj',kk',l) 
8 7.45-7.49 1H doublet C-H(d) 
9 8.18-8.19 2H doublet Ar-H(cc') 
10 8.45-8.47 2H doublet Ar-H(ff') 
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MASS SPECTRAL STUDY OF N-{4'-[(4'''-CHLOROPHENYL)(PHENYL) METHYLAMINO]PHENYL-1'-YL}-3-(4""-
METHOXYPHNEYL)-2-PROPENE-1-ONE. 
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EXPERIMENTAL 
SYTHESIS AND BIOLOGICAL SCREENING OF N-{4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYLAMINO] PHENYL-1'-YL}-3-ARYL-2-
PROPENE-1-ONES.        
(A)Synthesis of N-{4'-[(4'''-Chlorophenyl)(phenyl)-methyl-amino]             
phenyl-1yl} ethanone.         
A mixture of (4’-Chlorophenyl)(phenyl)-methyl) chloride in methanol (2.37 
gm, 0.01 M) and p-amino acetophenone (1.47 gm, 1.2 M) is heated in the 
presence of basic catalyst as pyridine (2 ml) for 8 hrs. The completion of the 
reaction is checked by TLC and poured the reaction in ice cold water filter it 
and wash with water till neutral pH and dry it at room temparature the yield is 
65 %, m.p.134 o C. 
(B) Synthesis of N-{4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] 
phenyl}-3-(4''''-methoxyphenyl) prop-2-en-1 ones.  
A mixture of 4’-[(4”’-Chlorophenyl)(phenyl)-methyl-amino] phenyl-1-yl}- 
ethanone (3.35 gm, 0.01 M) in a mixture of methanol. Add p-methoxy 
benzaldehyde (1.36 gm, 0.01 M) and methanol (25 ml). Stirr the content at 
room temperature for 24 hr. in presence of catalytically amount of 40% NaOH. 
The resulting solution was poured on to crush ice, thus the solid separated 
was filtrated and crystallized from ethanol, Yield 52 %, m. p. 102 o C. 
(C29H24ClNO2: required: C, 76.73; H, 5.33; N, 3.09 %; found: C: 76.71; H, 
5.31; N, 3.07 %). 
Similarly, other compounds were prepared. The physical data are 
recorded in Table no: 7.         
(C) Biological Screening of N-{4'-[(4"'-Chlorophenyl) (phenyl) methyl 
amino] phenyl-1'-yl}-3-aryl-2-propene-1-ones.     
Biological screening was carried out as described in Part-I Section-I (E). 
The zone of inhibition of test solutions are recorded in Graphical Chart No. 7. 
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     TABLE NO. 7: PHYSICAL CONSTANT OF N-{4'-[(4'''-CHLOROPHENYL)(PHENYL) METHYL AMINO] PHENYL-1'-YL}-
3-ARYL-2-PROPENE-1-ONES. 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield % 
 
Calcd.  Found.
JG-73       C6H5- C28H22ClNO 423.5 240 62 3.30 3.2
JG-74 4-Cl-C6H4- C28H21Cl2NO      458.0 114 60 3.05 3.04
JG-75 4-F-C6H4-  C28H21ClFNO      441.5 140 58 3.17 3.15
JG-76 4-Br-C6H4- C28H21BrClNO      502.5 138 52 2.79 2.75
JG-77 2-OH-C6H4- C28H22ClNO2 439.5     108 66 3.18 3.15
JG-78 3- OH-C6H4- C28H22ClNO2 439.5     248 60 3.18 3.16
JG-79 4-OH-C6H4-  C28H22ClNO2 439.5     248 58 3.18 3.17
JG-80 4-OCH3-C6H4- C29H24ClNO2 453.5     102 52 3.09 3.07
JG-81 3-OCH3-4-OH-C6H4- C29H24ClNO3 469.5     101 62 2.98 2.95
JG-82 4-N-(CH3)2-C6H3- C30H27ClN2O      466.5 230 64 6.00 5.98
JG-83 C10H7-(Naphthayl) C32H24ClNO     473.5 111 58 2.95 2.94
JG-84 C14H9- (Anthranyl)
 C36H26ClNO     523.5 174 55 2.67 2.65
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GRAPHICAL CHART NO.7: BIOLOGICAL SCREENING OF N-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] 
                         PHENYL-1'-YL}-3-ARYL-2-PROPENE-1-ONES. 
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-IV 
 
Section –I: Biological screening of N-{4'-[(4'''-chlorophenyl) (phenyl) methyl amino] phenyl-1'-yl}-3-aryl-2 
       -propene-1-ones. 
 
                                                                     Antibacterial activity                                                 Antifungal activity 
                                                                              Zone of inhibition in m. m.                                      Zone of inhibition in m. m.  
                                                                  
                                     B. mega           S. aureus              E-coli             S. typhi            A. niger 
                                                                                                                                                                                        
                                            JG-75(18)                JG-74(15)                JG-78(17)            JG-78(17)              JG-78(18)                         
                                            JG-79(19)               JG-77(15)                 JG-80(20)            JG-79(15)              JG-80(21)                         
                                            JG-83(18)               JG-79(16)                 JG-81(17)            JG-81(18)              JG-83(18)                         
                                                                                                                                                                               
Ampicillin             (50 µg)        23                           22                           21                          15                           -- 
Chloromphenicol (50 µg)        22                           23                           21                          18                           -- 
Norfloxacin          (50 µg)         24                           17                           23                          17                           -- 
Greseofulvin        (50 µg)         --                             --                            --                             --                           25 
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STUDIES ON PYRAZOLINES 
INTRODUCTION 
The chemistry of pyrazoline was reviewed by Jarobe in 1967. Pyrazoline has 
three possible tautomeric structures, but the structure (I) shown is the most 
stable which can be prepared by the action of hydrazine hydrate with acrolein.
  
NH2
NH2
CH3
CHO
+ N
N
H
( I )  
 2-Pyrazoline consist a unique class of five member nitrogen heterocycle. 
During the past year considerable evidence has been accumulated to 
demonstrate the importance of 2-pyrazoline derivatives. There has been 
considerable interest in the pyrazoline ring system both with regard to 
heterocyclic chemistry and the pharmacological activities of several of its 
derivatives. 
SYNTHETIC ASPECT        
 Different methods for the preparation of 2-pyrazoline derivatives 
documented in literature are as follows. 
1.  2-Pyrazolines can be synthesized by the cycloaddition of diazomethane to 
substituted chalcones232.
2.  Epoxy ketone reacts with hydrazine and phenyl hydrazine to give 
pyrazolines233. Furthermore, B. Gyassi et al.234 investigated the one pot 
synthesis of some pyrazolines in dry media under microwave irradiation S. Paul 
et al.235 and A. Dandia et al.236 have also described the microwave assisted 
synthesis of 2-pyrazolines. 
3.  2-Pyrazolines can also be prepared by the condensation of chalcone 
dibromide with hydrazines237.
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4. 2-Pyrazolines (II) can be constructed by the cyclocondensation of 
chalcones with hydrazine hydrate238.      
  
R
O
R1 NH
N
R
R1
NH2NH2.HCl
( II )  
 
MECHANISM   
 The following mechanism seems to be operable for pyrazoline by the 
condensation of chalcones with hydrazine hydrate.239  
 
 Nucleophilic attack by hydrazine at the β-carbon of the α, β-unsaturated 
carbonyl system (I) forms species (II), in which the negative charge is mainly 
accommodated by the electronegative oxygen atom. 
Proton transfer from the nitrogen to negative oxygen produces an 
intermediate enol which simultaneously ketonises to ketoamine (III). Another 
intramolecular nucleophilic attack by the primary amino group of ketoamine on 
its carbonyl carbon followed by proton transfer from nitrogen to oxygen leads 
ultimately to carbonyl amine (IV). The later with a hydroxy group and amino 
group on the same carbon lose water molecule to yield the pyrazoline (V).  
THERAPEUTIC IMPORTANCE   
 From the literature survey, it was revealed that 2-pyrazolines are better 
therapeutic agents. They possess valuable bioactivities like 
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1. Antimicrobial240
2. Anticonvulsant and Antidepressant241
3. Antiallergic242
4. Fungicidal243, 244 
5. Antidiabetic245
6. Antiimplantation246
7. Antiinflammatory247, 248
8. Antitumor249
9. Antineoplastic250
10. Analgesic251, 252
11. Bactericidal253, 254
12. Herbicidal255
13. Cardiovascular256
14. Diuretic257
15. Antiamoebic258
16. Tranquilizer259
Moreover F. Manna et al.260 have described 1-acetyl-5-(2'-bromophenyl)-
4, 5- dihydro-3-(2'-hydroxyphenyl)-1H-pyrazoline and its derivatives act as potent 
anti-inflammatory, analgesic and antipyretic agents. R. H. Udupi et al261 have 
reported the synthesis and biological activity of Mannich bases of certain 1,2-
pyrazolines. N. Richard262 investigated pyrazolines bis phosphonate ester as 
novel anti-inflammatory and antiarthritic agent. F. Rainer et al.263 have prepared 
some new 1H-pyrazoline derivatives (III) and reported them as pesticides. 
Furthermore, Tsubai et al.264 have synthesized some new (phenylcarbamoyl) 
pyrazolines (IV) as an insecticides and at 40% concentration shows 100% 
mortality of spodopetra litura larve after seven drops.    
116 
 
"Studies on some heterocyclic compounds of medicinal interest” 
 
    
 
N N
H
N N
Cl
N
N
NH
CF3
O
( III ) ( IV )
R
 
M. M. Abdalla et al.265 have synthesized pyrazolines and tested their 
antiandrogenic activity. M. A. Berghot et al.266 have prepared pyrazolines as 
antibacterial agents. M. Fritz et al.267 have synthesized pyrazoles and screened 
for their pesticidal activity. E. Palska et al.268 have prepared 3,5-diphenyl-2-
pyrazolines (V) and cited their antidepressant activity. B. Shivrama et al.269, 270 
have synthesized pyrazolines as antibacterial agents. S. P. Hiremath et al.271 
have reported pyrazolines as analgesics, antiinflammatory and antimicrobial 
agents. J. R. Goodell et al.272 have synthesized some newer 1,3,5-trisubstituted 
pyrazoline derivatives (VI) which shows anti west nile virus activity.
 
N NH R2
OMe
OMe
R1
NN
S
R2
R1
( V )
( VI )
 
J. Almstead et al.273 have prepared pyrazolines as vascularization agents. 
Guniz Kuchkguzel et al.274 have synthesized pyrazolines as a antimicrobial and 
anticonvulsant agents. T. Z. Gulhan and co-workers275 have prepared 
pyrazolines as a hypotensive agent. 
Moreover, T. M. Stivensen et al.276have also investigated N-substituted 
pyrazoline type insecticides. T. Katsohori277 have patented pyrazoline derivatives 
as herbicides, K. Johannes et al.278 as insecticides. Z. Moritaz et al279 
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investigated a semi emperial molecular orbital study on the reaction of 
aminopyrazolinyl azodye with singlet molecular oxygen. M. K. Shivnanda and 
co-workers280 have prepared substituted pyrazolines and reported their 
antibacterial activity. 
S. S. Sonarc et al.281 have synthesized-3-(2-acetoxy-4-methoxyphenyl)-5- 
(substituted phenyl)-pyrazolines and tested their biological screening. H. H. 
Parekh et al282. have also synthesized some new pyrazolines as an antimicrobial 
agent.  
 
CONTRIBUTION FROM OUR LABORATORY: 
D. M. Purohit et al283, 284 (VII, VIII, IX) have synthesized 2-(4'-
Chlorophenyl)-6-methyl-3-(1"-H / 1"-acetyl / 1"-phenyl-4"-5"-dihydro pyrazol-5"-
yl)-imadozo [1,2-a] pyridines as a antimicrobial agents. 
(VII)
N
N
CH3
Cl
NH
N R
(VIII)
N
N
CH3
Cl
N
N R
O
CH3
(IX)
N
N
CH3
Cl
N
N R
 
The significant biological properties associated with pyrazolines 
derivatives have aroused considerable interest to design the compounds with 
better drug potential and to study their pharmacological profile, which have been 
described as under. 
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(H)-3-N- {4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYL AMINO] PHENYL}-5-ARYL-
PYRAZOLINES. 
 
SECTION-II: SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ACETYL-3-N- 
{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] PHENYL}-5-
ARYL-PYRAZOLINES. 
 
SECTION-III SYNTHESIS AND BIOLOGICAL SCREENING OF 1-PHENYL-3-
N-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] PHENYL}-
5-ARYL-PYRAZOLINES. 
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SECTION-I 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(H)-3-N-{4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYLAMINO] PHENYL}-5-ARYL-PYRAZOLINES. 
 Pyrazolines derivatives showed remarkable antimicrobial activities. 
Looking at their versatile therapeutic importance and with an aim to getting better 
drug, it was considered worthwhile to synthesise some new pyrazolines bearing 
4-[(4"-Chlorophenyl)(phenyl)methylamino]-phenyl nucleus. The preparation of 1-
(H)-3-N-{4'-[(4"'-Chlorophenyl) (phenyl) methylamino] phenyl}-5-aryl pyrazolines-(VIII) 
have been synthesized by the cyclocondensation of chalcones of Type (VII) with 
hydrazine hydratyte.  
   
Type - VIII
Cl
NH
N
NH
R
  R=  Aryl
 
 The structure elucidation of synthesized compounds has been done on 
the basis of elemental analysis, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by Mass spectrometry.    
 All the compounds have been evaluated for their in vitro biological assay 
like antibacterial activity towards Gram positive and Gram negative bacterial 
strains and antifungal activity towards Aspergillus niger at a concentration of 
50µg/ml. The biological activities of synthesized compounds were compared 
with standard drugs. Some compounds have been found to have moderate 
activity as compared to known standard drugs recorded on Graphical Chart 
No.8.         
 
 
 
 
 
119 
 
"Studies on some heterocyclic compounds of medicinal interest” 
 
   
IR SPECTRAL STUDY OF 1-(H)-3-N-{4'-[(4'''-CHLOROPHENYL) (PHENYL) 
METHYL AMINO] PHENYL}-5-(4''''-METHOXY PHENYL)-PYRAZOLINE. 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc) 
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Halide 
Ether 
pyrazoline 
 
Sec.amine 
C-H   str. (asym.) 
C-H   str. (sym.) 
C-H   def. (asym.) 
C-H   def. (sym.) 
C-H   str.  
C=C str. 
C-Cl str. 
C-O-C str. 
C-N str. 
C=N str. 
N-Hstr. 
2958 
2865 
1439 
1378 
3039 
1439 
690 
1279 
1058 
1605 
3397 
2975-2950 
2880-2860 
1470-1435 
1390-1370 
3090-3030 
1540-1480 
800-600 
1280-1200 
1220-1020 
1612-1593 
3500-3100 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF 1-(H)-3-N-{4'-[(4'''-CHLOROPHENYL) (PHENYL) 
METHYL AMINO] PHENYL}-5-(4''''-METHOXY PHENYL)-PYRAZOLINE. 
 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (400 MHz) 
Signal 
No.  
Signal 
Position  
(δppm) 
Relative No. of 
protons  
 
Multiplicity Inference 
1  2.23-2.32 1H dd  C-H(e) 
2 2.82-2.92 1H dd C-H(d)  
3 3.83 3H singlet Ar-OCH3(a) 
4  4.19 1H singlet N-H(i) 
5 5.19-5.27 1H triplet C-H(f) 
6  5.65 1H doublet  C-H(k) 
7 6.34-6.38 2H doublet Ar-H(ii') 
8 6.50-6.53 2H doublet Ar-H(bb') 
9 7.13 1H singlet N-H(g) 
10 7.15-7.17 2H doublet Ar-H(hh') 
11 
12 
13 
7.21-7.25 
7.26-7.35 
7.54-7.57 
5H 
4H 
2H 
multiplet 
doublet 
doublet 
Ar-H(n) 
Ar-H(ll',mm') 
Ar-H(cc') 
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MASS SPECTRAL STUDY OF 1-(H)-3-N-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] PHENYL}-5-(4''''-METHOXY 
PHENYL)-PYRAZOLINE. 
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m/z = 252 m/z = 203
m/z = 294 m/z = 362
m/z = 392
m/z = 357
m/z = 442
m/z = 422
m/z = 438
m/z = 281
m/z = 267
m/z = 176
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Cl
Cl
Type - VIII                    R = Aryl
NH2
O
CH3
R
H
O
REACTION SCHEME 
Cl
NH
O
CH3
Cl
NH
O
R
NH2NH2.H2O
Cl
NH
N
NH
R
+
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(H)-3-N-{4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYLAMINO] PHENYL}-5-ARYL-
PYRAZOLINES. 
(A)Synthesis of 1-{4-[(4'"-Chlorophenyl)(phenyl)-methyl-amino] phenyl} 
ethanone. 
See Part-IV, section-I, Chalcone page no:109     
(B) Synthesis of N- {4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] 
phenyl- 
1'-yl}-3-aryl-2-propene-1-ones.       
See Part-IV, section-I, Chalcone page no:109     
 (C)Synthesis of 1-(H)-3-N {4'-[(4'''-Chlorophenyl) (phenyl) methyl amino]  
phenyl}-5-(4""-methoxy phenyl) Pyrazolines. 
 A mixture of N- {4'-[(4'''-chlorophenyl) (phenyl) methyl amino] Phenyl-1'-
yl}-3-(4""-methoxy phenyl) -2-propene-1-ones (4.53 gm, 0.01 M), hydrazine 
hydrate (0.5 ml, 0.01 M) in 30 ml methanol was refluxed for 12 hrs. The 
product obtained was filtered, washed with methanol and crystallised from 
1,4-dioxane. Yield: 64%, m.p.1560C. (C29H26ClN3O; Requires: C, 74.43; H, 
5.56; N, 8.98%; found: C, 74.41; H, 5.55; N, 8.95%). 
 Similarly other pyrazolines have been synthesized. The physical data 
are recorded in Table No. 8. 
(D)Biological Screening of 1-(H)-3-N-{4'-[(4'''- chlorophenyl) (phenyl) 
methyl amino] - phenyl}-5-(arly) - pyrazolines.    
Biological screening was carried out described in Part - I, Section (I) 
(E). The zones of inhibition of test solutions are recorded in Graphical Chart 
No. 8. 
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TABLE NO. 8: PHYSICAL CONSTANT OF 1-(H)-3-N-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] 
PHENYL}-5 ARYL-PYRAZOLINES. 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield % 
 
Calcd.  Found.
JG-85 C6H5-   C28H24ClN3 437.5 112 55 9.60 9.55 
JG-86 
4-Cl-C6H4-     C28H23Cl2N3 472.0 208 53 8.89 8.87
JG-87 
4-F-C6H4-      C28H23ClFN3 455.5 125 57 9.22 9.20
JG-88 
4-Br-C6H4-     C28H23BrClN3 516.5 131 56 8.13 8.11
JG-89 
2-OH-C6H4-      C28H24ClN3O 453.5 188 61 9.26 9.25
JG-90 
3- OH-C6H4-      C28H24ClN3O 453.5 174 60 9.26 9.24
JG-91 
4-OH-C6H4-       C28H24ClN3O 453.5 233 63 9.26 9.23
JG-92 
4-OCH3-C6H4-      C29H26ClN3O 467.5 156 64 8.98 8.95
JG-93 
3-OCH3-4-OH-C6H4-     C29H26ClN3O2 483.5 202 67 8.68 9.66
JG-94 
4-N-(CH3)2-C6H3-     C30H29ClN4 480.5 178 68 11.65 11.63
JG-95 C10H7-(Naphthayl) C32H26ClN3 487.5    166 54 8.61 8.60
JG-96 
C14H9- (Anthranyl)
 C36H28ClN3 537.5    136 55 7.81 7.78
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GRAPHICAL CHART NO.8: BIOLOGICAL SCREENING OF 1-(H)-3-N-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL 
        AMINO] PHENYL}-5-ARYL-PYRAZOLINES. 
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-V 
 
Section – I: Biological screening of 1-(H)-3-N-{4'-[(4'''-chlorophenyl) (phenyl) methyl amino] phenyl}-5 aryl- 
                    pyrazolines 
 
                                                                           Antibacterial activity                                                    Antifungal activity 
                                                                           Zone of inhibition in m. m.                                         Zone of inhibition in m. m.   
                                                                   
                                   B. mega             S. aureus                E-coli              S. typhi             A. niger 
                                                                                                                                                                                        
                                          JG-88(18)                JG-88(18)                      JG-88(18)              JG-89(14)                JG-89(20)                 
                                          JG-92(18)                JG-94(17)                      JG-92(19)              JG-94(14)                JG-94(21)                 
                                          JG-94(19)                JG-96(16)                      JG-94(17)              JG-95(14)                JG-95(19)                 
                                                                                                                                                                               
Ampicillin             (50 µg)       23                           22                                   21                          15                             -- 
Chloromphenicol (50 µg)       22                           23                                   21                          18                            -- 
Norfloxacin          (50 µg)        24                           17                                   23                          17                            -- 
Greseofulvin        (50 µg)        --                             --                                     --                           --                             25 
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SECTION - II 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ACETYL-3-N- {4'-[(4"'-
CHLOROPHENYL)(PHENYL) METHYLAMINO] PHENYL-5-ARYL-
PYRAZOLINES. 
Pyrazolines play a vital role owing of their wide range of biological 
activity and with an aim to getting better drug, it was considered worthwhile to 
synthesize some new acetyl pyrazolines. The synthesis of 1-Acetyl-3-N-{4'-
[(4'''-chlorophenyl) (phenyl) methyl amino] phenyl}-5-aryl pyrazolines of 
Type (IX) have been synthesis by the cyclocondensation of chalcones of Type 
(VII) with hydrazine hydrate in glacial acetic acid.  
  
Type - IXCl
NH
N
N
R
CH3
O
  R=  Aryl
 
The structure elucidation of synthesized compounds has been done on 
the basis of elemental analysis, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by Mass spectrometry. 
All the compounds have been evaluated for their in vitro biological 
assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards Aspergillus niger at a 
concentration of 40µg/ml.The biological activities of synthesized compounds 
were compared with standard drugs. Some compounds have been found to 
have moderate activity as compared to known standard drugs recorded on 
Graphical Chart No. 9.        
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IR SPECTRAL STUDY OF 1-ACETYL-3-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL)METHYLAMINO]PHENYL}-5-(4''''-METHOXYPHENYL)PYRAZOLINE. 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc)    
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Halide 
Ether 
pyrazoline 
 
 
Sec. amine 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def.(asym.) 
C-H  def.(sym.) 
C-H str.  
C=C str. 
C-Cl str. 
C-O-C str. 
C=N str. 
C-N str. 
C=O str. 
N-H str. 
2964 
2869 
1459 
1346 
3050 
1525 
752 
1258 
1598 
1184 
1658 
3352           
2975-2950 
2880-2860 
1470-1435 
1390-1370 
3090-3030 
1600-1450 
800-600 
1280-1200 
1612-1593 
1220-1020 
1680-1590 
3500-3100 
516 
 " 
" 
" 
517 
" 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF 1-ACETYL-3-N-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL) METHYL AMINO] PHENYL}-5-(4-""METHOXY PHENYL)-
PYRAZOLINE. 
 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (400 MHz) 
Signal 
No. 
Signal 
Position 
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1  
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
2.40 
2.70-2.79 
3.22 
3.54-3.59 
3.93 
5.00-5.08 
5.62-5.63 
6.61-6.63 
6.77-6.78 
7.24-7.34 
7.67-7.69 
7.80-7.89 
3H 
1H 
1H 
1H 
3H 
1H 
1H 
2H 
2H 
9H 
2H 
2H 
singlet  
dd 
singlet 
dd 
singlet 
dd 
doublet 
doublet 
doublet 
multiplet 
doublet 
doublet           
CO-CH3(g) 
C-H(d) 
N-H(j) 
C-H(e) 
Ar- OCH3(a) 
C-H(f) 
C-H(k) 
Ar-H(ii) 
Ar-H(bb') 
Ar-H(ll',mm',n) 
Ar-H(hh') 
Ar-H(cc')         
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MASS SPECTRALSTUDY OF 1-ACETYL-3-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] PHENYL}-5-(4''''-
METHOXY PHENYL)-PYRAZOLINE. 
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Type - IX                    R = Aryl
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ACETYL-3-N-{4'-[(4'''-
CHLOROPHENYL)(PHENYL)METHYLAMINO]PHENYL-5-ARYL-PYRAZOLINES. 
 
(A) Synthesis of 1-{4'-[(4'''-Chlorophenyl)(phenyl)-methyl-amino] phenyl} 
 ethanone  
See Part-IV, section-I, Chalcone page no:109 
  
(B) Synthesis of N-1-{4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] 
phenyl}-3-(4''''-methoxyphenyl) prop-2-ene-one     
See Part-IV, section-I, Chalcone page no:109 
      
(C) Synthesis of 1-Acetyl-3- {4'-[(4'''- chlorophenyl) (phenyl) methyl 
amino] - phenyl}-5-(4””-methoxy phenyl) - pyrazolines. 
 A mixture of N-1-{4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] phenyl}-
3-(4''''-methoxyphenyl) prop-2-ene-one (4.53 gm, 0.01 M), hydrazine hydrate 
(0.5 ml, 0.04 M) in and 30 ml. glacial acetic acid was refluxed for 12 hrs. The 
solution was poured into crushed ice. Product was isolated and crystallized 
from DMF - Methanol. Yield 58%, m.p. 1150C (C31H28ClN3O2; Requires C, 
73.00; H, 5.53; N, 8.24%; found: C, 72.98; H, 5.51; N, 8.21%). 
Similarly, other pyrazolines were prepared. The physical data are 
recorded in Table No. 9. 
          
(D)Biological Screening of 1-Acetyl-3- {4'-[(4'''- chlorophenyl) (phenyl) 
methyl amino] - phenyl}-5-(aryl)-pyrazolines.    
Biological screening was carried out described in Part - I, Section (I) 
(E). The zones of inhibition of test solutions are recorded in Graphical Chart 
No. 9. 
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TABLE NO. 9: PHYSICAL CONSTANT OF 1-ACETYL-3-N-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] 
PHENYL}-5-ARYL-PYRAZOLINES. 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield %
 
Calcd.  Found.
JG-97 C6H5-   C30H26ClN3O 479.5 142 56 8.75 8.74 
JG-98 
4-Cl-C6H4-      C30H25Cl2N3O 514.0 144 51 8.17 8.15
JG-99 
4-F-C6H4-       C30H25ClFN3O 497.5 218 57 8.44 7.50
JG-100 
4-Br-C6H4-      C30H25BrClN3O 558.5 151 55 7.52 8.40
JG-101 
2-OH-C6H4-     C30H26ClN3O2 495.5 166 60 8.47 8.44
JG-102 
3- OH-C6H4-     C30H26ClN3O2 495.5 212 56 8.47 8.41
JG-103 
4-OH-C6H4-      C30H26ClN3O2 495.5 106 60 8.47 8.43
JG-104 
4-OCH3-C6H4-     C31H28ClN3O2 509.5 156 61 8.24 8.20
JG-105 
3-OCH3-4-OH-C6H4-     C31H28ClN3O3 525.5 206 58 7.99 7.97
JG-106 
4-N-(CH3)2-C6H3-     C32H31ClN4O 522.5 181 54 10.71 10.70
JG-107 C10H7-(Naphthayl) C34H28ClN3O    529.5 162 60 7.93 7.90
JG-108 
C14H9- (Anthranyl)
 C38H30ClN3O    579.5 186 63 7.24 7.22
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GRAPHICAL CHART NO.9: BIOLOGICAL SCREENING OF 1-ACETYL-3-N-{4'-[(4'''-CHLOROPHENYL) (PHENYL)  
           METHYL AMINO] PHENYL}-5-ARYL-PYRAZOLINES. 
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-V 
 
Section – II: Biological screening of 1-Acetyl-3-N-{4'-[(4'''-chlorophenyl) (phenyl) methyl amino] phenyl} 
-5-aryl-pyrazolines 
 
                                                           Antibacterial activity                                                                    Antifungal activity 
                                                           Zone of inhibition in m. m.                                                           Zone of inhibition in m.m.  
                                                                   
                                   B. mega             S. aureus                 E-coli              S. typhi               A. niger 
                                                                                                                                                                                        
                                           JG-99(19)                 JG-100(16)                 JG-100(14)             JG-102(15)              JG-100(19)               
                                           JG-100(17)               JG-107(17)                 JG-102(16)             JG-105(14)              JG-104(20)               
                                           JG-107(16)               JG-108(13)                 JG-98(13)               JG-107(17)              JG-107(20)               
                                                                                                                                                                               
Ampicillin             (50 µg)       23                             22                                21                            15                              -- 
Chloromphenicol (50 µg)      22                             23                                 21                            18                              -- 
Norfloxacin           (50 µg)      24                             17                                 23                            17                              -- 
Greseofulvin         (50 µg)      --                               --                                   --                             --                               25 
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SECTION-III 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-PHENYL-3- {4'-[(4''' 
-CHLOROPHENYL) (PHENYL) METHYL AMINO] - PHENYL}-5-ARYL- 
PYRAZOLINES. 
  1-phenyl pyrazolines play a vital role owing of their wide range to 
pharmacological activity. In view of these findings, it appeared of interest to 
preparing better therapeutic agents. The preparation and biological 
Screening of 1-Phenyl-3-{4'-[(4'''- chlorophenyl) (phenyl) methyl amino] - 
phenyl}-5-aryl pyrazolines of Type (X) have been undertaken by the synthesis 
of chalcones Type (VII) with phenyl hydrazine in ethanol. 
  Type - X
Cl
NH
N
N
R
  R=  Aryl
 
 The constitutions of the synthesised products have been characterized 
using elemental analyses, IR and 1H nuclear magnetic resonance 
spectroscopy and mass spectrometry also. 
All the compounds have been evaluated for their in vitro biological 
assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards Aspergillus niger at a 
concentration of 50 µg/ml. The biological activities of synthesized compounds 
were compared with standard drugs. Some compounds have been found to 
have moderate activity as compared to known standard drugs recorded on 
Graphical Chart No. 10.         
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IR SPECTRAL STUDY OF 1-PHENYL-3-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL)METHYLAMINO]PHENYL}-5-(4""-METHOXYPHENYL)-PYRAZOLINE.  
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Halide 
Ether 
Sec. amine 
Pyrazoline 
 
C-H   str. (asym.) 
C-H   str. (sym.) 
C-H   def. (asym.) 
C-H   def. (sym.) 
C-H str. 
C=C str. 
C-Cl Str. 
C-O-C str. 
R-NH 
C=N Str. 
C-N Str. 
2960 
2852 
1442 
1381 
3048 
1492 
706 
1250 
3318 
1638 
1108 
2975-2950 
2880-2860 
1470-1435 
1390-1370 
3090-3030 
1540-1480 
800-600 
1260-1200 
3500-3100 
1612-1593 
1220-1020 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF 1-PHENYL-3-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL)METHYLAMINO]PHENYL}-5-(4""-METHOXYPHENYL)-PYRAZOLINE. 
 
Internal Standard: TMS; Solvent: CDCl3; Instrument Bruker Spectometer (400 MHz) 
Signal 
No. 
Signal 
Position 
(δppm) 
Relative No. 
of protons 
 
Multiplicity Inference 
1 2.21-2.40 1H dd C-H(e) 
2 2.53-3.30 1H dd C-H(d) 
3 3.27-3.31 1H triplet C-H(f) 
4 3.34 3H singlet Ar-OCH3(a) 
5 5.68-5.70 1H doublet C-H(k) 
6 6.64-6.66 2H doublet Ar-H(bb') 
7 6.67-7.08 4H doublet Ar-H(ii',hh') 
8 7.11-7.12 2H doublet Ar-H(ll') 
9 7.14-7.43 10H multiplet Ar-H(n,g) 
10 7.54-7.57 2H doublet Ar-H(mm') 
11 
12 
7.58-7.59 
8.07 
2H 
1H 
doublet 
singlet 
Ar-H(cc') 
N-H(j) 
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MASS SPECTRAL STUDY OF 1-PHENYL-3-{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYLAMINO]PHENYL}-5-(4""-METHOXY 
PHENYL)-PYRAZOLINE. 
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Cl
Cl
Type - X                    R = Aryl
NH2
O
CH3
R
H
O
REACTION SCHEME 
Cl
NH
O
CH3
Cl
NH
O
R
Ph - NH - NH2
Cl
NH
N
N
R
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-PHENYL-3- {4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYL AMINO] -PHENYL}-5 -ARYL-
PYRAZOLINES. 
     
(A)Synthesis of 1-{4'-[(4'''-Chlorophenyl)(phenyl)-methyl-amino] phenyl} 
ethanone. 
See Part-IV, section-I, Chalcone page no:109  
 
(B)Synthesis of N-{4-[(4'''-Chlorophenyl) (phenyl) methyl amino] phenyl}-
3-(4''''-methoxyphenyl) prop-2-ene-1-one. 
See Part-IV, section-I, Chalcone page no:109      
 
(C)Synthesis of 1-Phenyl-3- {4'-[(4'''- chlorophenyl) (phenyl) methyl 
amino] - phenyl}-5-(4''''-methoxy phenyl) - pyrazolines. 
 A mixture of N-{4-[(4'''-Chlorophenyl) (phenyl) methyl amino] phenyl}-3-
(4''''-methoxyphenyl) prop-2-ene-1-one (4.53 gm, 0.01 M), Phenyl hydrazine 
hydrate (1.08 gm, 0.01 M) in and 30 ml. glacial acetic acid was refluxed for 12 
hrs. The reaction mixture was poured into crushed ice. Product was isolated 
and crystallized from DMF - Methanol. Yield 58%, m.p. 144ºC. (C35H30ClN3O; 
Requires C, 77.26; H, 5.56; N, 7.72%; found: C, 77.24; H, 5.54; N, 7.71%).  
Similarly, other pyrazolines were prepared. The physical data are 
recorded in Table No. 10.         
 
(D)  Biological Screening of 1-Phenyl-3- {4'-[(4'''-chlorophenyl) 
(phenyl) methyl amino] - phenyl}-5-aryl-pyrazolines.    
 Biological screening was carried out described in Part - I, Section (1) 
(E). The zones of inhibition of test solutions are recorded in Graphical Chart 
No. 10.          
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TABLE NO. 10: PHYSICAL CONSTANT OF 1-PHENYL3-N-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYLAMINO] PHENYL}-
5-ARYLPYRAZOLINES. 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield %
 
Calcd
. 
Found. 
JG-109 C6H5-     C34H28ClN3 513.5 140 52 8.17 8.16
JG-110 
4-Cl-C6H4-     C34H27Cl2N3 548.0 112 55 7.66 7.60
JG-111 
4-F-C6H4-      C34H27ClFN3 531.5 102 51 7.90 7.90
JG-112 
4-Br-C6H4-     C34H27BrClN3 592.5 130 60 7.09 7.08
JG-113 
2-OH-C6H4-      C34H28ClN3O 529.5 190 61 7.93 7.91
JG-114 
3- OH-C6H4-      C34H28ClN3O 529.5 148 56 7.93 7.92
JG-115 
4-OH-C6H4-       C34H28ClN3O 529.5 96 54 7.93 7.90
JG-116 
4-OCH3-C6H4-      C35H30ClN3O 543.5 144 58 7.72 7.71
JG-117 
3-OCH3-4-OH-C6H4-     C35H30ClN3O2 559.5 188 52 7.50 7.49
JG-118 
4-N-(CH3)2-C6H3-     C36H33ClN4 556.5 98 50 10.06 10.04
JG-119 C10H7-(Naphthayl) C38H30ClN3 563.5    126 52 7.45 7.44
JG-120 
C14H9- (Anthranyl)
 C42H32ClN3 613.5    150 50 6.84 6.80
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GRAPHICAL CHART NO.10: ANTIMICROBIAL ACTIVITY OF 1-PHENYL-3-N-{4'-[(4'''-CHLOROPHENYL) (PHENYL) 
                                      METHYLAMINO] PHENYL}-5-ARYL-PYRAZOLINES. 
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-V 
 
Section – III: Biological screening of 1-Phenyl-3-{4'-[(4'''-chlorophenyl) (phenyl) methylamino] -phenyl} 
- 5-arylpyrazolines. 
 
                                                                           Antibacterial activity                                                    Antifungal activity 
                                                                           Zone of inhibition in m. m.                                         Zone of inhibition in m. m.   
                                                                   
                                    B. mega             S. aureus                 E-coli              S. typhi             A. niger 
                                                                                                                                                                                         
                                           JG-109(17)               JG-113(16)                    JG-110(17)           JG-109(14)            JG-109(17)                
                                           JG-116(17)               JG-116(15)                    JG-114(17)           JG-115(15)            JG-115(20)                
                                           JG-119(17)               JG-119(15)                     JG-119(16)          JG-118(14)            JG-116(19)                
                                                                                                                                                                               
Ampicillin             (50 µg)       23                              22                                  21                         15                            -- 
Chloromphenicol (50 µg)       22                              23                                  21                         18                            -- 
Norfloxacin          (50 µg)        24                              17                                  23                         17                            -- 
Greseofulvin        (50 µg)         --                               --                                    --                           --                            25                   
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STUDIES ON CYANOPYRANS 
INTRODUCTION         
 The chemistry of pyran with different functional group exhibit wide range 
of applications in the field of pharmaceuticals, dyes, insecticides and sweet 
smelling substances. Pyran ring system is also present in large number of 
natural colored compounds in Vitamin E, hemorrhagic compound in cloves, in 
fishpoisions, in certain alkaloids and other substances.   
 Pyran is a doubly unsaturated six membered ring system with single 
oxygen as hetero atom. The two double bonds may be conjugated as α or 1, 2-
pyran or isolated as in ץ or 1, 4-pyran.      
    
O O
1, 4- Pyran 1, 2- Pyran
( I )    
     
A degree of stabilization of the pyran nucleus is achieved by substituting 
phenyl group in the 2 or 4 and preferably also in the 6 position.  
SYNTHETIC ASPECT       
 Various methods for the preparation of pyran derivatives have been cited 
in the literature285-294.         
1. Reaction between (A) with CH2 (CN) 2 led to corresponding 2-amino-3- cyano-
4H-pyrans (B) 295.         
  
O
N
NC
NH2
R O
R1
O
NR1
O
R
OO
CH2(CN)2
( A ) ( B )( II )
 
MECHANISM:         
 The reaction of malononitrile with α, β-unsaturated system leads to the 
formation of cyano 4H-pyran via Michael addition.    
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THERAPEUTIC IMPORTANCE       
 Literature survey revealed that various pyrans have resulted in many 
potential drugs and are known to possess a broad biological spectrum such as,
   
1. Anti-HIV296-297. 
2. Antifungal298-300
3. Antiallergic301 
4. Analgesic302
5. Antagonist 303-304
6. Antitumor305
7. CNS active agent306
8. Cytotoxic307
9. Inhibitors of cell proliferation308
10. Gastric acid secretion inhibitor309
11. Antimicrobial310
12. Hypolipidemic311
13. Antipyretic312
14. Antiinvasive313         
 Moreover, F. F. Abdel-Latif et. al.314 have reported the synthesis of 2-
amino-3-cyanopyran derivatives and studied their biological activity. P. M. Zhu 
et. al.315 have prepared biologically active 2-amino pyran derivatives. 
 Y. U. A. Sharanin et. al.316 have suggested new 2-amino-3-cyano-4-H-
pyran derivatives (III).        
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O
OCH3
O R
CN
NH2
( III )     
 M. E. Zwaagstra 317 have newly synthesized pyran derivatives and tested 
for antiashamatic activity. E. B. Frederick et. al.318 have prepared some new- 2-
amino-3-cyano-4-H-pyran and reported anti HIV agent and antiviral activity.
 Some of the pyran derivatives have been patented for their use as 
antihypertensive319, antiestogens320, antagonist321, 322, antitumor323 and 
antiviral324 activities. Synthesis and biological activity of pyran ring system have 
been reported by O'Brien et. al.325
           
    
O
CNNC
CN
NH2
( IV )
  
Synthesis and anticancer activity of pyran (V) containing fluorine have been 
reported by M. S. El. Gaby et. al.326 4H-pyran of type (VI) were prepared to   
enhance the anticancer and anti HIV activity.     
  
 
O NH2
CN
X
N
N
S
O
F
HOOC
CH3
NH2
CN
Cl
( V ) ( VI )
R
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 El-Subbagh and co-worker327 have synthesized cyanopyran derivatives 
and showed their antiviral activity. C. Romuld et. al.328 have synthesised 
cyanopyran derivatives (VII) which have significant pharmacological activity.
           
  
O
N
N NH2
CN
OCH3
OCH3
( VII )
 
CONTRIBUTION FROM OUR LABORATORY      
A. R. Parikh et.al.329 have synthesized cyanopyrans bearing 2-chloro-6- 
bromoquinoline nucleus as a potential antimicrobial and anticancer agents. With 
a view to get better therapeutic agent, it was contemplated to synthesize pyran 
derivatives to enhance the overall activity of resulting compounds which have 
been described as under 
SECTION-I: SYNTHESIS AND BIOLOGICAL EVOLUTION OF 2-AMINO-6-{4'-
[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO]-PHENYL}-
4-ARYL-4H- PYRAN -3-CARBONITRILES.   
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SECTION -I 
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-6--{4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYL AMINO] - PHENYL}-4-ARYL-4H- 
PYRAN -3-CARBONITRILES.       
 3-Cyano-4, 6-disubstituted 4H-pyrans are endowed with a variety of 
pharmacodynamic activities such as anticonvulsant, antiinflammatory, 
antihypertensive, antitumor etc. Looking to the interesting properties of 
cyanopyrans, it was considered worthwhile to synthesis some new 2-Amino-6-
{4'-[(4"'-chlorophenyl) (phenyl) methyl amino]-phenyl}-4-aryl-4-H-pyran-3-
carbonitriles of Type (XI). The cyanopyranes of type (XI) have been synthesized 
by the condensation of the chalcones of Type (VII) with malanonitrile in pyridine.
   
   
Cl
NH
O
NH2
N
R
Type - XI   R=  Aryl
 
 The constitutions of the synthesized products have been characterized by 
using elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy 
and mass spectrometry also.       
 All the compounds have been also evaluated for their antibacterial activity 
towards Gram positive and Gram negative bacterial strains and antifungal 
activity towards Aspergillus niger at a concentration of 50 µg/ml. The biological 
activities of the synthesised compounds have been compared with standard 
drugs. Some compounds have been found to have good and equivalent activity 
as compared to the known standard drugs recorded on Table no.11. 
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IR SPECTRAL STUDY OF 2-AMINO-6-{4'-[(4'''-CHLOROPHENYL) (PHENYL) 
METHYL AMINO]-PHENYL}-[4-(4""-METHOXY PHENYL)-(4H)-PYRAN -3-
CARBONITRILE. 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc).   
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
Aromatic 
 
Halide 
Ether 
Sec. amine  
Pyrane 
 
C-H Str. (asym.) 
C-H Str. (sym.) 
C-H def. (asym.) 
C-H Str. 
C=C Str. 
C-Cl Str 
C-O-C Str. 
N-H Str. 
C=N Str. 
CΞN Str. 
N-H Str.(NH2) 
2969 
2821 
1455 
3075 
1600 
754 
1101 
3375 
1600 
2221 
3425&3459 
2975-2950 
2880-2860 
1470-1435 
3090-303  
1600-1450 
800-600 
1200-1100 
3500-3100 
1650-1600 
2240-2120 
3400-3500 
516 
" 
" 
517 
" 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF 2-AMINO-6-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL) METHYL AMINO]-PHENYL}-[4-(4""-METHOXY PHENYL)-(4H)-
PYRAN -3-CARBONITRILE. 
 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (400 MHz) 
Signal No.  
Signal Position  
(δppm) 
Relative 
No. of 
protons  
 
Multiplicity Inference 
1  3.85 3H singlet Ar-OCH3(a) 
2 4.60 1H Singlet N-H(i) 
3 5.89-5.90 1H doublet C-H(j) 
4  6.65-6.69 4H doublet Ar-H(hh',bb') 
5 6.95-7.01 10H multilet Ar-H(hh') 
6  7.09-7.13 4H doublet  Ar-H(bb') 
7 7.24 2H singlet  NH2(f) 
8 7.35-7.37 2H doublet Ar-H(mm') 
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MASS SPECTRAL STUDY OF 2-AMINO-6-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO]-PHENYL}-[4-(4""-
METHOXY PHENYL)-(4H)-PYRAN -3-CARBONITRILE. 
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Cl
Cl
Type - XI                    R = Aryl
NH2
O
CH3
R
H
O
REACTION SCHEME 
Cl
NH
O
CH3
Cl
NH
O
R
CH2(CN)2
Cl
NH
O NH2
N
R
Pyridine
+
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-6-{4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYL AMINO]- PHENYL}-4-ARYL-4H- 
PYRAN -3-CARBONITRILES.  
(A) Synthesis of 1-{4-[(4"'-Chlorophenyl)(phenyl)-methyl-amino] 
phenyl}ethanone.  
See Part-IV, section-I, Chalcone page no:109      
(B) Synthesis of N-{4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] 
phenyl-1'-yl}-3-(4""-methoxy phenyl)-2-propene-1-ones  
See Part-IV, section-I, Chalcone page no:109     
(C) Synthesis of 2-Amino-6-{4'-[(4"'-chlorophenyl)(phenyl)methylamino] 
phenyl}-4-(4””-methoxyphenyl)-4H-pyran-3-carbonitrile.  
A mixture of N-{4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] 
phenyl-1'-yl}-3-(4""-methoxy phenyl)-2-propene-1-ones (4.53 gm, 0.01 
M), malononitrile (0.66 g, 0.01 M) dissolved in pyridine (20 ml) was heated 
under reflux for 12 hrs. The product was isolated and crystallized from 
absolute ethanol. Yield, 58%, m.p. 192OC. (C32H26ClN3O2); requires C, 73.91; 
H, 5.04; N, 8.08; found: C, 73.91; H, 5.02; N, 8.07 %). 
Similarly other cyanopyrans have been prepared. The physical constants 
are recorded in Table No11.         
(D) Biological Screening of 2-Amino-6-{4'-[(4'''-chlorophenyl) (phenyl) 
methyl amino]- phenyl}-4-aryl-4H- pyran -3-carbonitriles. 
Antimicrobial activity was carried out as described in Part-I, Section-I (E). The 
zone of inhibitions of the test solutions are recorded in Graphical Chart No. 
11.           
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TABLE NO. 11: PHYSICAL CONSTANT OF 2-AMINO-6-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO]-
PHENYL}-4-ARYL- (4H)-PYRAN -3-CARBONITRILES. 
 
% of Nitrogen 
 
Sr.No.  
  
R
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield %
 
Calcd. Found.
JG-121       C6H5- C31H24ClN3O 489.5 292 57 8.58 8.55
JG-122 4-Cl-C6H4-      C31H23Cl2N3O 524.0 184 55 8.01 8.00
JG-123 4-F-C6H4-       C31H23ClFN3O 507.5 180 60 8.27 8.25
JG-124 4-Br-C6H4-       C31H23BrClN3O 568.5 130 58 7.39 7.36
JG-125 2-OH-C6H4-     C31H24ClN3O2 505.5 178 59 8.30 8.29
JG-126 3- OH-C6H4-     C31H24ClN3O2 505.5 136 53 8.30 8.28
JG-127 4-OH-C6H4-      C31H24ClN3O2 505.5 144 55 8.30 8.27
JG-128 4-OCH3-C6H4-     C32H26ClN3O2 519.5 192 58 8.08 8.07
JG-129 3-OCH3-4-OH-C6H4-     C32H26ClN3O3 535.5 170 60 7.84 7.82
JG-130 4-N-(CH3)2-C6H3-      C33H29ClN4O 532.5 120 51 10.51 10.50
JG-131 C10H7-(Naphthayl)      C35H26ClN3O 539.5 146 52 7.78 7.75
JG-132 C14H9- (Anthranyl)
 C39H28ClN3O     589.5 192 53 7.12 7.10
 
 
 
 
 
161 
 
"Studies on some heterocyclic compounds of medicinal interest" 
 
 
 
GRAPHICAL CHART NO.11: BIOLOGICAL SCREENING OF 2-AMINO-6-{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYL 
            AMINO]-PHENYL}-4-ARYL- (4H)-PYRAN -3-CARBONITRILES. 
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B.mega 11 14 11 13 17 11 14 15 12 11 14 11 23 22 24 0
S.aureus 14 15 19 12 15 14 10 13 11 14 15 19 22 23 17 0
E.coli 11 16 11 15 13 10 16 14 15 10 16 17 21 21 23 0
S. typhi 13 11 10 14 13 11 11 12 15 13 11 10 15 18 17 0
A.niger 17 12 20 11 12 16 19 13 19 17 12 20 0 0 0 25
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-VI 
 
Section – I: Biological screening of 2-Amino-6-{4'-[(4'''-chlorophenyl) (phenyl) methyl amino]-phenyl} 
-4-aryl- (4H)-pyran-3-carbonitriles  
 
                                                                            Antibacterial activity                                                   Antifungal activity 
                                                                            Zone of inhibition in m. m.                                         Zone of inhibition in m. m.  
                                                                   
                                     B. mega            S. aureus              E-coli                S. typhi             A. niger 
                                                                                                                                                                                        
                                            JG-125(17)              JG-123(19)               JG-127(16)              JG-124(14)             JG-123(20)                 
                                            JG-128(15)              JG-125(15)               JG-131(16)              JG-129(15)             JG-132(20)                 
                                            JG-131(14)              JG-132(19)               JG-132(17)              JG-130(13)                   ----                         
                                                                                                                                                                               
Ampicillin             (50 µg)        23                            22                              21                            15                             -- 
Chloromphenicol (50 µg)        22                           23                              21                             18                             -- 
Norfloxacin          (50 µg)         24                           17                              23                             17                             -- 
Greseofulvin        (50 µg)         --                             --                                --                              --                              25 
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STUDIES ON CYANOPYRIDINES 
INTRODUCTION 
Pyridine with different functional groups, exhibit wide range of applications 
in the field of medicine, agriculture and dyes. Although many substituted pyridine 
compounds like other heterocyclic compounds are synthesized with their 
functional group present from cyclic compounds. The simple pyridine compounds 
are prepared by the cyclization of aliphatic raw material. The availability of 3-
cyanopyridines, nicotinamide and nicotinic acid make possible their use as 
synthetic intermediates. 
Most of pyridine derivatives are synthesized by manipulation of pyridine 
and its simple homologues in a manner similar to chemistry of the benzenoid 
chemistry. However the simple pyridine compounds are prepared by the 
cyclization of aliphatic raw materials. 
SYNTHETIC ASPECT: 
Different methods for the preparation of 3-cyanopyridines are available in 
literature330-336 .The well-known methods are: 
1.  Substituted cyanopyridine derivatives were prepared from 3-substituted 
phenyl pyrazolone derivatives with malononitrile.337  
2.  A. Samour and co-workers338 have prepared substituted cyanopyridines 
by the condensation of chalcones with malononitrile in presence of 
ammonium acetate. 
3.  A. Sakurai and Midorikaw339, 340 have reported that malononitrile reacts 
with α,β-unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted 
pyridines. 
4.  M. D. Bowman et al.341 have synthesized fluorescent cyanopyridine and 
deazalumazine dyes using small molecule macroarrays. 
MECHANISM          
 The reaction proceeds through conjugate addition of active methylene 
compound to the αβ-unsaturated system as shown below.    
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THERAPEUTIC IMPORTANCE 
Cyanopyridines have attracted considerable attention as they appeared of 
interest to possess antibacterial, anticholestemic, antifungal, antihypertensive 
and antidiabetic activities. E. G. Hammana Abou and co-workers342 have studied 
anticancer and anti HIV activity of 3-cyanopyridines. N. A. Abdallah et al.343 have 
prepared cyanopyridine derivatives which showed analgesic and anti-
inflammatory activity. M. Fedele and co-workers344 have reported the anti-
inflammatory activity of 3-cyanopyridines. H. Yoshida et al.345 have studied the 
antihistaminic and antiallergic activity of 3-cyanopyridine derivatives. Abd El-Galil 
and co-workers346 have prepared 3-cyanopyridines (I) and studied their 
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pharmacological activity. G. S. Gadaginamath et al.347 have synthesized various 
cyanopyridyl derivatives (II) and documented their variety of biological activities.  
 
N
N
N
CN
NH2
NC
NH2
Ar Ar
N NNH2
NC
H3CO
COCH3
CH3
R
( I ) ( II )
 
 Many naturally occurring and synthetic compounds containing the pyridine 
scaffold possess interesting pharmacological properties348. Among them, 2-
amino-3 cyanopyridines have been identified as IKK-2 inhibitors349.  
 J. J. Baldwin350-352 has prepared cyanopyridines exhibiting 
antihypertensive activity. A. Streightoff353 and J. Seydal354 have studied the 
bacteriostatic effect of some substituted 3- cyanopyridines. E. Francis and co-
workers355 have studied the effect of some substituted pyridines on the growth of 
the walker carcinosarcome-256 in tissue culture. Barton et al.356 have reported 
fungicidal and insecticidal properties. J. A. Tucker et al.357 have synthesized 
novel piperazinyl oxazolidinone containing cyanopyridine (III) as an antibacterial 
agents.           
            
  
N
N N N
O
NC
F
NHAc
O
( III )
  
 W. V. Behenburg et al.358 have synthesized 2-amino-3, 6-disubstituted 
pyridines as antiepileptic agents. V. Scott and E. Joseph359, 360 have prepared 2-
amino-3- cyanopyridine derivatives which were found to be useful as 
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antipsoriasis pharmaceuticals. J. A. Vann Allan et al.361 have prepared fused 
heterocyclic 3-cyanopyridine (IV). B. Abu Shana and co-workers362 have 
prepared novel fused cyanopyridines (V) for the treatment and preparation of 
systemic fungal infection. 
S N
N
Ph
CN
NH2
S
N
NH2
CN
CH3
NC
NH2
( IV ) ( V )
 
 
 Abdel Galil E. Amr et al.363 have synthesized heterocyclic pyridine 
derivatives (VI) fused with steroidal structure. Initially the acute toxicity of the 
compounds was assayed via the determination of their LD50. Heterocyclic 
pyridines fused with steroid structure are active as anti-inflammatory agents. H. 
foks et al.364 investigated new 3- cyanopyridine derivatives show an antibacterial 
activity. 
 
N
CH3
CH3
CH3
NC OC2H5
Ar
( VI )
  
  
J. L. Marco et al.365 have synthesized acetyl cholinesterase inhibitors. M. 
A. Moustafa et al.366 have prepared antibacterial agents. E. H. S. Sousa et al.367 
documented thionicotinamide coordinated to the a model system for the in vitro 
activation of thioamides antituberculosis drugs. R. Ulrich et al.368 have 
synthesized a new cyanopyridine as receptor agonists in the treatment of cardiac 
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or urogenital disease cancer, inflammation, neurodegenerative disease (VII). G. 
T. Wang and co-workers369 have synthesized of o-trifluoromethylbiphenyl 
substituted 2-amino-nicotinonitriles (VIII) as inhibitors of farnesyl transferase. 
            
 
NNH2 SCH2R2
NC CN
O(CH2)nOR1
O
N
N
CH3
N
NC
N
R1
R2
CN
F3C
( VII )
( VIII )
 
 
 Dipeptidyl peptidase (DPP-IV) inhibition has the potential to become a 
valuable therapy for diabetes. E. B. Villhauer and co-workers370 have reported 
the first use of solid-phase synthesis in the discovery of a new DPP-IV inhibitor 
class and a solution phase synthesis that is practical up to the multikilogram 
scale. One compound, NVPDPP728 (IX), is profiled as a potent, selective and 
short acting DPP-IV inhibitor that has excellent oral bioavailability and potent 
antihyperglycemic activity. 
   
N NH
NH
N
O
NC
NC
( IX )
   
  In view of therapeutic activities shown by cyanopyridines, it was 
ontemplated to synthesize some new cyanopyridines in search of agents 
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possessing higher biological activities with least side effect have been described 
as under. 
SECTION - I: SYNTHESIS AND BIOLOGICAL SCREENING OF 2-METHOXY-6- 
{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYLAMINO] PHENYL} -
4-ARYL NICOTINONITRILES. 
 
SECTION - II: SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-6-
{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYLAMINO] PHENYL} -
4-ARYL NICOTINONITRILES. 
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SECTION - I 
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-METHOXY-6-{4'-[(4'''-
CHLOROPHENYL)(PHENYL)METHYLAMINO]PHENYL}-4-ARYL 
NICOTINONITRILES. 
Cyanopyridines play a vital role owing to their range of biological and 
physiological activities. In the light of these biological activities and variety of 
industrial applications, some new 2-methoxy-6- {4'-[(4'''- chlorophenyl) (phenyl) 
methyl amino] phenyl} -4-aryl nicotinonitriles derivatives of Type (XII) have been 
prepared, by the cyclocondensation of chalcones of Type (VII) with malononitrile 
in presence of sodium methoxide. 
Cl
NH
N
O
N
R
CH3
Type - XII R = aryl
 
The structure elucidation of synthesized compounds has been done on 
the basis of elemental analysis, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by Mass spectrometry.    
 All the compounds have been evaluated for their in vitro biological assay 
like antibacterial activity towards Gram positive and Gram negative bacterial 
strains and antifungal activity towards Aspergillus niger at a concentration of 
50 µg/ml. The biological activities of synthesized compounds were compared 
with standard drugs. Some compounds have been found to have moderate 
activity as compared to known standard drugs recorded on Graphical Chart No. 
12.            
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IR SPECTRAL STUDY OF 2-METHOXY-6-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL)METHYLAMINO]PHENYL}-4-(4""-METHOXYPHENYL)  
NICOTINONITRILE. 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc).     
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Halide 
Ether 
Sec. amine 
Pyridine 
 
C-H str. (asym.) 
C-H str. (sym.) 
C-H. def.(asym) 
C-H str.(sym) 
C-H str. 
C=C str. 
C-Cl str 
C-O-C str. 
N-H str. 
C=N str. 
C≡N str. 
2928 
2872 
1440 
1390 
3055 
1492 
819 
1176 
3287 
1618 
2166 
2975-2950 
2880-2860 
1470-1435 
1395-1370 
3090-303  
1600-1480 
800-600 
1200-1100 
3500-3100 
1650-1600 
2240-2120 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF 2-METHOXY-6-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL)METHYLAMINO]PHENYL}-4-(4""-METHOXYPHENYL)  
NICOTINONITRILE. 
 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (400 MHz) 
 
Signal 
No.  
Signal Position  
(δppm) 
Relative No. 
of protons  
 
Multiplicity
Inference 
1  3.60 6H singlet Ar-OCH3(a,e) 
2 5.02-5.07 1H doublet C-H(i) 
3 7.03 1H singlet C-H(d) 
4  7.26-7.60 11H multiplet Ar-H(l,jj',gg',bb') 
5 7.60-7.68 2H doublet Ar-H(kk') 
6  7.87-7.95 4H doublet  Ar-H(ff',cc') 
7 8.20 1H singlet N-H(h) 
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MASS SPECTRAL STUDY OF 2-METHOXY-6-{4'-[(4'''-CHLOROPHENYL) (PHENYL)METHYLAMINO]PHENYL}-4-
(4""-METHOXYPHENYL)  NICOTINONITRILE. 
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Cl
Cl
Type - XII                     R = Aryl
NH2
O
CH3
R
H
O
REACTION SCHEME 
Cl
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O
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O
R
CH2(CN)2
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N O
N
R
CH3
CH3ONa
+
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-METHOXY-6-{4'-[(4'''-
CHLOROPHENYL)(PHENYL)METHYLAMINO]PHENYL}-4-ARYL 
NICOTINONITRILES. 
 (A) Synthesis of 1-{4-[(4"'-Chlorophenyl)(phenyl)-methyl-amino] phenyl} 
ethanone.          
See Part-IV, section-I, Chalcone page no:109    
(B) Synthesis of N-4'-{[4"'-(Chlorophenyl) (phenyl) methyl amino] 
-phenyl-1’-yl}-3-aryl-prop-2-en-1-ones.  
 See Part-IV, section-I, Chalcone page no:109   
(C) Synthesis of 2-Methoxy-6- {4'-[(4'''-chlorophenyl) (phenyl) methyl amino] 
phenyl} 4-(4””-methoxy phenyl) nicotinonitriles. 
A mixture of 4-{[4’-(Chlorophenyl) (phenyl) methyl] amino-phenyl}-3-(4”-
methoxyphenyl)-prop-2-en-1-one (4.53 gm, 0.01 M), malononitrile (0.67 gm, 
0.01 M) in methanol (10 ml) and sodium methoxide. The content was heated 
under reflux with stirring for 12 hr. The reaction mixture was cooled and poured 
on to crushed ice; the separated solid was filtered out and crystallized from 
ethanol. Yield 55%, m .p. 136oC, Anal. Calcd. For C33H26ClN3O2; Requires: C, 
74.50; H, 4.93; N, 7.90; Found: C, 74.45, H, 4.92; N, 7.88%. 
Similarly, other 2-Methoxy-6-{4'-[(4'''-chlorophenyl)(phenyl)methylamino] 
phenyl}-4-aryl nicotinonitriles were prepared. The physical data are recorded in 
Table No.12. 
(D) Biological Screening of 2-methoxy-6- {4'-[(4'''-chlorophenyl) (phenyl) 
methyl amino] phenyl} -4-aryl nicotinonitriles. 
Biological screening was carried out as described in Part-I Section-1(E). 
The zones of inhibition of test solution are recorded in Graphical Chart No 12. 
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TABLE NO. 12: PHYSICAL CONSTANT OF 2-METHOXY-6-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL 
AMINO] PHENYL} -4-ARYL-NICOTINONITRILES. 
 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield %
 
Calcd.  Found.
JG-133       C6H5- C32H24ClN3O 502.0 136 64 8.37 8.34
JG-134 4-Cl-C6H4-      C32H23Cl2N3O 536.4 136 60 7.83 7.80
JG-135 4-F-C6H4-        C32H23ClFN3O 519.9 136 61 8.08 8.04
JG-136 4-Br-C6H4-       C32H23BrClN3O 580.9 136 58 7.23 7.20
JG-137 2-OH-C6H4-      C32H24ClN3O2 518.0 136 57 8.11 8.08
JG-138 3- OH-C6H4-      C32H24ClN3O2 518.0 136 52 8.11 8.10
JG-139 4-OH-C6H4-       C32H24ClN3O2 518.0 136 54 8.11 8.07
JG-140 4-OCH3-C6H4-      C33H26ClN3O2 532.0 136 55 7.90 7.88
JG-141 3-OCH3-4-OH-C6H4-      C33H26ClN3O3 548.0 136 56 7.67 7.64
JG-142 4-N-(CH3)2-C6H3-      C34H29ClN4O 545.0 136 58 10.28 10.25
JG-143 C10H7-(Naphthayl)      C36H26ClN3O 552.0 136 60 7.61 7.60
JG-144 C14H9- (Anthranyl)
 C40H28ClN3O     602.1 136 57 6.98 6.95
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GRAPHICAL CHART NO.12: BIOLOGICAL SCREENING OF 2-METHOXY-6-{4'-[(4'''CHLOROPHENYL)  (PHENYL)  
                                  METHYLAMINO] PHENYL} -4-(ARYL)NICOTINONITRILES. 
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
 
PART-VII 
 
Section - I: Biological screening of 2-Methoxy-6-{4'-[(4'''-chlorophenyl) (phenyl) methyl amino] phenyl}  
       -4-(aryl) nicotinonitriles 
 
                                                                           Antibacterial activity                                                    Antifungal activity 
                                                                           Zone of inhibition in m. m.                                         Zone of inhibition in m. m.   
                                                                   
                                   B. mega             S. aureus                 E-coli              S. typhi             A. niger 
                                                                                                                                                                                        
                                           JG-137(17)               JG-133(16)                JG-134(17)             JG-136(14)              JG-135(19)                
                                           JG-141(21)               JG-138(16)                JG-141(17)             JG-137(16)              JG-138(20)                
                                           JG-143(18)               JG-142(16)                JG-143(17)             JG-141(16)              JG-144(19)                
                                                                                                                                                                               
Ampicillin             (50 µg)       23                             22                              21                             15                             -- 
Chloromphenicol (50 µg)       22                             23                              21                             18                             -- 
Norfloxacin          (50 µg)        24                             17                              23                             17                             -- 
Greseofulvin        (50 µg)        --                              --                                 --                               --                             25                   
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SECTION - II 
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-6-{4'-[(4'''-
CHLOROPHENYL)(PHENYL)METHYLAMINO]PHENYL}-4-(ARYL) 
NICOTINONITRILES. 
Cyanopyridines play a vital role owing to their range of biological and 
therapeutic activities. In view of getting to synthensized some new 2-amino-6- 
{4'-[(4'''- chlorophenyl) (phenyl) methyl amino] phenyl} -4-aryl nicotinonitriles 
derivatives of Type (XIII) have been synthesized, by the cyclocondensation of 
chalcones of Type (VII) with malononitrile in presence of ammonium acetate. 
Cl
NH
N
NH2
N
R
Type - XIII R = Aryl
 
The structure elucidation of synthesized compounds has been done on 
the basis of elemental analysis, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by Mass spectrometry.   
  All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram 
negative bacterial strains and antifungal activity towards Aspergillus niger at 
a concentration of 50 µg/ml. The biological activities of synthesized 
compounds were compared with standard drugs. Some compounds have 
been found to have moderate activity as compared to known standard drugs 
recorded on Graphical Chart No. 13.      
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IRSPECTRALSTUDY OF 2-AMINO-6-{4'-[(4'''-CHLOROPHENYL)(PHENYL) 
METHYLAMINO]PHENYL}-4-(4''"-METHOXYPHENYL) NICOTINONITRILE. 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc).     
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Halide 
Ether 
Sec .amine  
Pyridine 
 
 
C-H str. (asym.) 
C-H def. (sym.) 
C-H def.(asym) 
C-H str.(sym.) 
C-H str. 
C=C str. 
C-Cl str.  
C-O-C str. 
N-H str. 
N-H str.(-NH2) 
C=N str. 
C≡N str. 
2984 
2840 
1445 
1382 
3084 
1615 
689 
1125 
3157 
3299 
1651 
2166 
2975-2950 
2880-2860 
1470-1435 
1395-1370 
3090-3030  
1600-1480 
800-600 
1200-1100 
3500-3100 
3300-3200 
1650-1600 
2240-2120 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF 2-AMINO-6-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL)METHYLAMINO]PHENYL}-4-(4''"-METHOXYPHENYL) 
NICOTINONITRILE.  
 
Internal Standard: TMS; Solvent :CDCl3; Instrument Bruker Spectometer (400 MHz). 
Signal No.  
Signal Position  
(δppm) 
Relative 
No. of 
protons  
 
Multiplicity Inference 
1  3.74 3H singlet Ar-OCH3(a) 
2 5.44 1H doublet C-H(i) 
3 7.02-7.05 2H doublet Ar-H(gg') 
4  7.31-7.33 2H doublet Ar-H(bb') 
5 7.38-7.40 2H doublet  Ar-H(jj') 
6  7.50-7.52 2H doublet  Ar-H(kk') 
7 
8 
9 
10 
7.62-7.71 
7.78-7.98 
8.25-8.26 
8.87 
5H 
2 H 
2 H 
1 H 
muliplet 
doublet 
doublet 
singlet 
Ar-H(l) 
Ar-H(cc') 
Ar-H(ff') 
Ar-H(d) 
11 
12 
10.07 
10.73 
1 H 
2 H 
singlet 
singlet 
N-H(h) 
NH2(e) 
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MASS SPECTRAL STUDY OF 2-AMINO-6-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] PHENYL} -4-(4""-
METHOXYPHENYL)NICOTINONITRILE. 
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m/z = 216 m/z = 294
m/z = 414
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Cl
Cl
Type - XIII                     R = Aryl
NH2
O
CH3
R
H
O
REACTION SCHEME 
Cl
NH
O
CH3
Cl
NH
O
R
CH2(CN)2
Cl
NH
N NH2
N
RCH3COONH4
+
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-6- {4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYL AMINO] PHENYL} -4-(ARYL) 
NICOTINONITRILES. 
(A) Synthesis of 1-{4'-[(4"'-Chlorophenyl)(phenyl)-methyl-amino] phenyl} 
ethanone.          
See Part-IV, section-I, Chalcone page no:109    
(B) Synthesis of N-4'-{[4"'-(Chlorophenyl) (phenyl) methyl] amino 
phenyl}-3-(4""-methoxyphenyl) prop-2-en-1-one.     
See Part-IV, section-I, Chalcone page no:109    
 (C) Synthesis of 2-amino-6- {4'-[(4'''-chlorophenyl) (phenyl) methyl 
amino] phenyl} - 4-(4""-methoxy phenyl) nicotinonitriles. 
 A mixture of 4'-{[4"'-(Chlorophenyl) (phenyl) methyl] amino phenyl}-3-
(4””-methoxyphenyl) prop-2-en-1-one (4.53 gm, 0.01 M), malononitrile (0.67 
gm, 0.01 M) in methanol (10 ml) and ammonium acetate were added. The 
contents were heated under reflux with stirring for 12 hr. The reaction mixture 
was cooled and poured on to crushed ice; the separated solid was filtered out 
and crystallized from ethanol. Yield 60%, m .p. 177oC, Anal. Calcd. for 
C32H25ClN4O; Requires: C,74.34; H, 4.87; N, 10.84; Found: C, 74.30, ; H, 
4.82; N,10.80%.  
 Similarly, other 2-Amino-6- {4'-[(4'''-chlorophenyl) (phenyl) methyl 
amino] phenyl} -4-(aryl)nicotinonitriles were prepared. The physical data are 
recorded in Table No.13. 
(D)  Biological Screening of 2-amino-6- {4'-[(4'''-chlorophenyl) (phenyl) 
methyl amino] phenyl} -4-(aryl)nicotinonitriles. 
Biological screening was carried out as described in Part-I Section-1. 
The zones of inhibition of test solution are recorded in Graphical Chart No 13
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TABLE NO. 13: PHYSICAL CONSTANT OF 2-AMINO-6-{4'-[(4'''-CHLOROPHENYL)(PHENYL) METHYL AMINO] 
PHENYL}-4-ARYL-NICOTINONITRILES. 
 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield %
 
Calcd.  Found.
JG-145       C6H5- C31H23ClN4 486.9 210 54 11.50 11.48
JG-146 4-Cl-C6H4-      C31H22Cl2N4 521.4 206 52 10.74 10.71
JG-147 4-F-C6H4-       C31H22ClFN4 504.9 194 58 11.09 11.05
JG-148 4-Br-C6H4-      C31H22BrClN4 565.9 156 59 9.90 9.88
JG-149 2-OH-C6H4-      C31H23ClN4O 502.9 188 54 11.14 11.11
JG-150 3- OH-C6H4-      C31H23ClN4O 502.9 201 56 11.14 11.13
JG-151 4-OH-C6H4-       C31H23ClN4O 502.9 198 57 11.14 11.10
JG-152 4-OCH3-C6H4-      C32H25ClN4O 517.0 177 60 10.84 10.80
JG-153 3-OCH3-4-OH-C6H4-      C32H25ClN4O2 533.0 151 61 10.51 10.50
JG-154 4-N-(CH3)2-C6H3-      C33H28ClN5 530.0 167 65 13.21 12.81
JG-155 C10H7-(Naphthayl)      C35H25ClN4 537.0 234 60 10.43 10.40
JG-156 C14H9- (Anthranyl)
 C39H27ClN4 587.1     256 58 9.54 9.51
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GRAPHICAL CHART NO.13: BIOLOGICAL SCREENING OF 2-AMINO-6-{4'-[(4'''-CHLOROPHENYL)(PHENYL) 
          METHYLAMINO]PHENYL}-4-(ARYL) NICOTINONITRILES. 
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B.mega 17 12 13 15 10 15 12 16 17 14 13 17 23 22 24 0
S.aureus 14 16 11 16 17 13 11 15 16 15 16 11 22 23 17 0
E.coli 15 14 12 15 12 17 13 13 11 16 14 15 21 21 23 0
S. typhi 11 12 10 12 14 13 15 13 10 13 11 16 15 18 17 0
A.niger 13 16 15 14 17 16 16 12 21 13 16 19 0 0 0 25
JG-145 JG-146 JG-147 JG-148 JG-149 JG-150 JG-151 JG-152 JG-153 JG-154 JG-155 JG-156
Ampicilli
n
Chloram
phenicol
Norfloxa
cin
Greseof
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
 
PART-VII 
 
Section – II: Biological screening of 2-Amino-6-{4'-[(4'''-chlorophenyl)(phenyl) methylamino]phenyl} 
-4-(aryl)nicotinonitriles 
 
                                                                      Antibacterial activity                                                  Antifungal activity 
                                                                             Zone of inhibition in m. m.                                        Zone of inhibition in m. m.  
                                                                   
                                    B. mega             S. aureus               E-coli               S. typhi               A. niger 
                                                                                                                                                                                        
                                           JG-145(17)              JG-146(16)                  JG-148(15)             JG-149(14)              JG-149(17)               
                                           JG-153(17)              JG-149(17)                  JG-150(17)             JG-151(15)              JG-153(21)               
                                           JG-156(17)              JG-153(16)                  JG-154(16)             JG-156(16)              JG-156(19)               
                                                                                                                                                                               
Ampicillin             (50 µg)        23                           22                                 21                           15                               -- 
Chloromphenicol (50 µg)        22                          23                                  21                           18                               -- 
Norfloxacin           (50 µg)        24                          17                                  23                           17                               -- 
Greseofulvin         (50 µg)        --                            --                                    --                             --                               25 
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STUDIES ON PYRIMIDINES 
INTRODUCTION 
Pyrimidine is the most important member of all the diazines as this ring 
system occurs widely in living organisms. The naturally occuring pyrimidine 
derivatives was first isolated by Garbial and Colman in 1870, and its structure 
was confirmed in 1953 as 5-β-D-gluco-pyranoside of divicine. Pyrimidine 
derivatives which occurs in natural products371 like nucleic acid, vitamin-B and 
having remarkable pharmaceutical importance because of their broad 
spectrum of biological activities. Several analogs of nucleic acids like 
fluorouracil which has been used in cancer treatment. Pyrimidines are among 
those molecules that make life possible as being some of the building blocks 
of DNA and RNA.         
 Some pyrimidines of physiologically as well as pharmacologically 
importance are as under: e.g., cytosine, bedmethrin (I) and trimethoprim 
(II).   
N
N
CH3OH
O
CH3
N
N
NH2
NH2
CH3
Cl
( I ) ( II )
 
Pyrimidine is considered to be a resonance hybrid of the charged and 
uncharged cannonical structures, its resonance energy has been found to be 
less than benzene or pyridine.        
SYNTHETIC ASPECT        
 A very important general method for preparing pyrimidines is the 
condensation between a three carbon compounds of the type YCH2Z, where 
Y and Z = -COR, -COOR, -CN, and compounds having the amidine structure 
R(C=NH)-NH2, where R = R (an amidine), SH or SR (thiourea or its s-
derivative), -NH2 (guanidine); the condensation is carried out in the presence 
of sodium hydroxide or sodium ethoxide. This general reaction may be 
illustrate by the condensation of acetamidine with ethylacetoacetate to form 4-
hydroxy-2, 6-dimethylpyrimidine.  
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NH
NH2
NH2
CH3
O
O
O
CH3+
N
NH
NH2
O
CH3 N
N
NH2
OH
CH3
NaOEt
 
The reaction of chalcone with guanidine hydrochloride in presence of 
potass
yl iety was investigated in order to 
ium t-butoxide in t-butanol yielded corresponding 2-amino pyrimidine 
derivatives372. P. Sharma and co-workers373 have investigated the insertion of 
dimethylvin idene carbene into azo mo
synthesize 4,6-dimethyl-5-[2-(2-methylprop-1-enyl)-1H-benzimidazol-1-yl] 
pyrimidine-2(5H) thiones under kinetically controlled phase transfer catalysis 
conditions.  
N
N
N
N
CH3
CH3
S
CH3
CH3
R
 
R. A. Osisanya374 synthesized 2-amino-pyrimidine by the reaction of 
chalco  g
of
ne epoxides with uanidine carbonate in xylene. S. M. Sondhi et al.375 
have synthesized pyrimidine derivatives by an efficient, one-pot reaction  
functionalized amines with either 4-isothiocyanato-4-methyl-2-pentanone or 3-
isothiocyanatobutanal. 
N
N
H S
CH3
CH3
CH3
S N
N
HS
CH3
CH3
CH3
O
O
 
There are many other methods of pyrimidine ring synthesis which are 
of more limited scope. The reaction of 1,3-dicarbonyl compound or an 
equivalent reagent with formamide provides a route of several pyrimidine 
which are unsubstituted at the 2-position. 
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HCONH2
CHO
NHO
HCONH2
N
NNH
CH3
CHO
 
REACTION MECHANISM       
 The reaction mechanism for the formation of pyrimidine derivatives 
described as under.         
   
THERAPEUTIC IMPORTANCE 
 Large number of drugs possesses pyrimidine ring system. Well-known 
antimalarial agents like hypotensive agent like minoxidil (III), pyrimethamine 
(V), antibacterial agent like ormetraprim (V) possess pyrimidine ring system.
     
NN
NH2
CH3
CH3
N
CH3
N
O CH3O
CH3
NH2
NH2
N
H
NN
NH2
NH2
( III ) ( IV ) ( V ) 
 
Pyrimidine derivatives exhibit a wide spectrum of pharmacological 
activities, few of them are as under. 
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1. Antitubercular376
2. Antidiabetic377
3. Anticonvulsan378
4. Fungicidal379
5. Insecticidal380
6. Analgesic381
7. Tranquilizing382
8. Antibacterial383 
9. Diuretic384
10. Antihypertensive385
M. Gompel and co-workers386 have showed that meridianins inhibit 
various protein kinases such as cyclin-dependent kinases, glycogen synthase 
kinase-3, cyclic nucleotide-dependent kinases and casein kinase (VI). A. H. 
Bingham et al.387 have synthesized a novel series of aminopyrimidine IKK-2 
inhibitors which show excellent in vitro inhibition of this enzyme and good 
selectivity over the IKK1 isoform. The relative potency and selectivity of these 
compounds has been rationalized using QSAR and structure based modeling 
(VII). 
N
H
N
N
NH2
R
R
R
R
N
N
NH
N
NH
S
O
O
R
( VI ) ( VII ) 
 
S. S. Sangopure388 have tested the antimicrobial activity of 
benzofuro[3,2-d]pyrimidine derivatives (VIII). El Sayed389 have synthesized 
alkylated substituted mercapto pyrimidine derivatives (IX) and studied their 
anticancer and antineoplastic activity. H. Y. Moustafa390 have reported some 
pyrimidine derivatives and studied their biological activities. 
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N
N
H
O
S
NH2
N
N
Cl
CH3S
CH3
( VIII ) ( IX ) 
 
L. R. Patil et al.391 have synthesized some new pyrimidines bearing 
paracetamol and imidazolyl moieties. B. J. Ghiya et al.392 synthesized some 
mercapto pyrimidine derivatives (X) and screened for their anticancer, 
antitubercular and anti HIV activities. N. V. Kaplina and co-workers393 shows 
herpes inhibiting activity of some mercapto pyrimidine derivatives (XI). 
N
NH
N
R1
R2
CH3
R3
NH2
NN
R1
R2
R3
R4
R5
SH( X ) ( XI )  
M. D. Varney394 have synthesized and evaluated biological activity of 5 
thia- 2,6-diamino-4(3H)-oxopyrimidines (XII) as potent inhibitors of 
Glycinamide Ribonucleotide Transformylase with potent cell growth inhibition. 
N
NH (CH2)n
S
NH2
NH
C6H4
O
NH2
O
COOH
COOH
( XII )  
V. Lather and co-workers395 have been proposed to predict the anti-
HIV activity of dihydro(alkylthio)(naphthylmethyl)oxopyrimidines. These 
models are capable of providing lead structures for development of potent but 
safe anti-HIV agents (XIII). 
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( XIII )
 
A. Mai et al.396 have synthesized 5-alkyl-2-alkylamino-6-(2,6 
difluorophenylalkyl)- 3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, 
broad-spectrum nonnucleoside reverse transcriptase inhibitors belonging to 
the DABO family. I. Yamamoto et al.397 have reported some oxopyrimidines 
searching for the novel antagonist or agonist of barbiturates to the sleep 
mechanism based on the uridine receptor. Y. L. Huang et al.398 have 
synthesized non-classical antifolates, 5-(N phenylpyrrolidin-3-yl)-2,4,6-
triaminopyrimidines and 2,4-diamino-6(5H) oxopyrimidines as antitumor 
activity.            
T. Shimizu et al.399 have described N3 substituted uridine and related 
pyrimidine nucleosides as antinociceptive effects in mice. C. Sanmartin et 
al.400 have prepared new symmetrical derivatives as cytotoxic agents and 
apoptosis inducers. A. Agarwal et al.401 have synthesized 2,4,6-trisubstituted 
pyrimidine derivatives as pregnancy interceptive agents. S. Shigeta et al402 
have been synthesized 5-alkyl-2-thiopyrimidine nucleoside analogues and 
examined for antiviral activities against Herps Simplex virus (HSV), Varicella-
Zoster virus (SZV) and Human Cytomegalo virus (HCMV). 
H. S. Joshi et al.403 have synthesized some new pyrimidines (XIV) and 
reported as antitubercular and antimicrobial agents. 
NH
N
Br
R SH
( XIV )
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Looking to the diversified activities exhibited and in continuation of our 
work on the synthesis of biologically active heterocycles, the synthesis and 
biological screening of pyrimidine derivatives have been described as under. 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING 2-AMINO-{4'-
[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] - 
PHENYL}-6-ARYL PYRIMIDINES.  
   
SECTION-II: SYNTHESIS AND BIOLOGICAL SCREENING 6-{4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYL AMINO]-PHENYL}-
4-ARYL PYRIMIDINE-2(1H)-ONES. 
 
SECTION-III: SYNTHESIS AND BIOLOGICAL SCREENING 6-{4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYL AMINO]-PHENYL}-
4-ARYL PYRIMIDINE-2(1H)-THIONES. 
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SECTION-I 
SYNTHESIS AND BIOLOGICAL SCREENING 2-AMINO-{4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYL AMINO] - PHENYL}-6-ARYL 
PYRIMIDINES.    
  Aminopyrimidines represent one of the most active classes of 
compounds possessing a wide spectrum of biological activities, such as 
significant in vitro activity against DNA and RNA viruses including polio 
viruses, diuretic, antitubercular spermicidal etc. These valid observation led us 
to 2-amino-{4'-[(4'''-chlorophenyl)(phenyl)methylamino]-phenyl}-6-aryl pyrimidines 
of Type (XIV) have been synthesized by cyclocondensation of chalcones of 
Type (VII) and guanidine hydrochloride in presence of KOH as catalyst. 
    
Cl
NH
N N
NH2
R
Type - XIV R = Aryl
 
 The structure elucidation of synthesized compounds has been done on 
the basis of elemental analysis, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by Mass spectrometry.    
 All the compounds have been evaluated for their in vitro biological 
assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards Aspergillus niger at a 
concentration of 50 µg/ml. The biological activities of synthesized compounds 
were compared with standard drugs. Some compounds have been found to 
have moderate activity as compared to known antibiotics recorded on 
Graphical Chart No. 14.      
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IR SPECTRAL STUDY OF 2-AMINO-{4'-[(4'''-CHLOROPHENYL) (PHENYL) 
METHYL AMINO] - PHENYL}-6-(4""-METHOXYPHENYL) PYRIMIDINE.  
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr DISC).  
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Halide 
Ether 
Pyrimidine 
 
Sec. amine 
Prim. amine 
C-H str. (sym.) 
C-H str. (asym) 
C-H def. (asym.) 
C-H  def. (sym.) 
C-H str.  
C=C str. 
C-Cl str. 
C-O-C str. 
C=N str. 
C-N str. 
N-H str. 
NH2str. 
2969 
2909 
1448 
1372 
3052 
1485 
760 
1275 
1648 
1186 
3244               
3250&3335 
2975-2950 
2962-2853 
1470-1435 
1390-1370 
3090-3030 
1540-1480 
800-600 
1200-1100 
1650-1600 
1220-1020 
3500-3100 
3350-3250 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF 2-AMINO-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL)METHYLAMINO]-PHENYL}-6-(4""-METHOXYPHENYL) 
PYRIMIDINE 
Internal Standard:TMS;Solvent:CDCl3;Instument Bruker Spectometer(300 MHz) 
Signal 
No.  
Signal 
Position  
(δppm) 
Relative 
No. of 
protons  
 
Multiplicity Inference 
1  2.95 1H singlet  N-H(i) 
2 3.37 2H singlet Ar-NH2(f)  
3 3.85 3H singlet Ar-OCH3(a) 
4  5.60-5.61 1H doublet C-H(j) 
5 7.16-7.17 2H doublet Ar-H(hh') 
6  7.27-7.28 2H doublet  Ar-H(bb') 
7 7.36-7.37 2H doublet  Ar-H(kk') 
8 7.37-7.43 2H doublet Ar-H(gg') 
9 7.71 1H singlet N-H(e) 
10 7.73-7.79 10H multilet Ar-H(cc',ll',m) 
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MASS SPECTRAL STUDY OF 2AMINO-{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYLAMINO]-PHENYL}-6-(4""-
METHOXYPHENYL)-PYRIMIDINE. 
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Cl
Cl
Type - XIV                   R = Aryl
NH2
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CH3
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REACTION SCHEME
+
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING 2-AMINO-{4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYL AMINO] - PHENYL}-6-ARYL 
PYRIMIDINES.  
(A) Synthesis of 1-{4'-[(4"'-Chlorophenyl)(phenyl)-methyl-amino] 
phenyl} ethanone.         
  See Part-IV, section-I, Chalcone page no:109     
(B)  Synthesis of N-{4'-[(4'''-Chlorophenyl) (phenyl)methylamino] 
phenyl-1'-yl}-3-(4""-methoxy phenyl)-2-propene-1-one.  
  See Part-IV, section-I, Chalcone page no:109   
(C)  Synthesis of 2-Amino-{4'-[(4'''-chlorophenyl) (phenyl) methyl amino] - 
phenyl}-6-(4""-methoxy phenyl) pyrimidines.     
  A mixture of N-{4'-[(4'''-Chlorophenyl)(phenyl)methylamino]phenyl-
1'-yl}-3-(4"-methoxy phenyl)-2-propene-1-ones (4.53 gm, 0.01 M) and 
guanidine hydrochloride (1.10gm, 0.01 M) in methanol (20 ml) was refluxed 
on water bath in presence of alcoholic KOH for 8 hr. The excess solvent was 
distilled off and the residue was neutralized with 20 % HCl, the separated 
solid was filtered out and crystallized from ethanol. Yield 62 %, m.p. 134oC 
Anal. Calcd. for C30H25ClN4O Requires: C,73.09; H, 5.11; N,11.37% Found: 
C,73.07; H, 5.10; N,11.32 %. 
Similarly, other 2-Amino-{4'-[(4'''-chlorophenyl) (phenyl) methyl amino] - 
phenyl}-6-aryl pyrimidines were prepared. The physical data are recorded in 
Table No. 14. 
(D)  Biological Screening of 2-amino-{4'-[(4'''-chlorophenyl) (phenyl) 
methyl amino] - phenyl}-6-aryl pyrimidines.    
Antimicrobial testing were carried out as described in Part-I Section-I 
(E). The zones of inhibition of test solution are reported in Graphical Chart 
No.14. 
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TABLE NO. 14: PHYSICAL CONSTANT OF 2-AMINO-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] - 
PHENYL}-6-ARYL- PYRIMIDINES.  
 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield % 
 
Calcd.  Found.
JG-157      C6H5- C29H23ClN4 462.5 189 62 12.10 12.08 
JG-158 4-Cl-C6H4-      C29H22Cl2N4 497.0 106 55 11.26 11.24
JG-159 4-F-C6H4-       C29H22ClFN4 480.5 205 60 11.65 11.61
JG-160 4-Br-C6H4-      C29H22BrClN4 541.5 171 54 10.34 10.32
JG-161 2-OH-C6H4-     C29H23ClN4O 478.5 109 55 11.70 11.67
JG-162 3- OH-C6H4-     C29H23ClN4O 478.5 211 68 11.70 11.66
JG-163 4-OH-C6H4-      C29H23ClN4O 478.5 162 66 11.70 11.67
JG-164 4-OCH3-C6H4-     C30H25ClN4O 492.5 134 62 11.37 11.32
JG-165 3-OCH3-4-OH-C6H4-      C30H25ClN4O2 508.5 142 63 11.01 11.00
JG-166 4-N-(CH3)2-C6H3-      C31H28ClN5 505.5 269 57 13.84 13.80
JG-167 C10H7-(Naphthayl)      C33H25ClN4 512.5 232 55 10.92 10.90
JG-168 C14H9- (Anthranyl)
 C37H27ClN4 562.5     183 58 9.95 9.91
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GRAPHICAL CHART NO.14: BIOLOGICAL SCREENING OF 2-AMINO-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL  
                                  AMINO]– PHENYL}-6-ARYL- PYRIMIDINES. 
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COMPARATIVE BIOLOGICAL SCREENING STUDY KNOWN STANDARD DRUGS 
 
 
PART-VIII 
 
Section – I: Biological screening of 2-Amino-{4'-[(4'''-chlorophenyl) (phenyl) methyl amino] - phenyl}-6-aryl- 
         pyrimidines. 
  
                                                                     Antibacterial activity                                             Antifungal activity 
                                                                                  Zone of inhibition in m. m.                                  Zone of inhibition in m. m.  
                                                                   
                                   B. mega              S. aureus                 E-coli             S. typhi                A. niger 
                                                                                                                                                                                        
                                   JG-157(17)                JG-157(15)                 JG-164(17)             JG-157(14)              JG-158(17) JG-159(17)   
                                   JG-160(21)                JG-160(16)                 JG-166(17)             JG-165(16)              JG-160(17) JG-163(17)   
                                   JG-163(16)                JG-163(16)                 JG-168(17)             JG-166(14)              JG-166(21)                      
                                                                                                                                                                               
Ampicillin            (50 µg)    23                           22                             21                          15                                 -- 
Chloromphenicol(50 µg)    22                          23                              21                          18                                 -- 
Norfloxacin          (50 µg)    24                          17                              23                          17                                 -- 
Greseofulvin        (50 µg)    --                            --                                --                           --                                  25 
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SECTION-II 
SYNTHESIS AND BIOLOGICAL SCREENING 6-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL) METHYL AMINO] - PHENYL}-6-ARYL PYRIMIDIN-2(1H)-ONES.
  Oxo pyrimidine derivatives are reported to possess different 
therapeutic activities. In view of these findings, it was considered worthwhile 
to synthesize some new 6-{4'-[(4'''-chlorophenyl) (phenyl) methyl amino] - 
phenyl}-6-aryl pyrimidines -2(1H)-ones of Type (XV) to study their therapeutic 
activities. Oxo pyrimidine derivatives of Type (XV) have been prepared by the 
reaction of the chalcones of Type (VII) with urea in presence of basic catalyst 
KOH in ethanol shown as under. 
    
Cl
NH
NH N
O
R
Type - XV R = Aryl
 
 The structure elucidation of synthesized compounds has been done on 
the basis of elemental analysis, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by Mass spectrometry.    
 All the compounds have been evaluated for their in vitro biological 
assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards Aspergillus niger at a 
concentration of 50 µg/ml. The biological activities of synthesized compounds 
were compared with standard drugs. Some compounds have been found to 
have moderate activity as compared to known antibiotics recorded on 
Graphical Chart No. 15.   
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IR SPECTRAL STUDY OF 6-{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYL 
AMINO]-PHENYL}-4-(4""-METHOXY PHENYL)-PYRIMIDIN-2(1H)-ONE. 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Halide 
Ether 
Pyrimidine 
 
Sec.amine 
 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.) 
C-H   str.  
C=C str. 
C-Cl str. 
C-O-C str. 
C=O str. 
C-N str. 
C=N str. 
N-H str. 
2958 
2875 
1472 
1366 
3079 
1512 
758 
1239 
1651 
1205 
1575 
3398    
2975-2950 
2880-2860 
1470-1435 
1390-1370 
3090-3030 
1540-1480 
800-600 
1260-1200 
1672-1640 
1220-1020 
1612-1593 
3500-3100 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF 6-{4'-[(4'''-CHLOROPHENYL)(PHENYL) 
METHYLAMINO]-PHENYL}-4-(4""-METHOXYPHENYL)-PYRIMIDIN-2(1H)-  
ONE.
 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (300 MHz) 
Signal 
No.  
Signal 
Position  
(δppm) 
Relative No. 
of protons  
 
Multiplicity Inference 
1  3.25 1H singlet  N-H(h) 
2 3.83 3H singlet Ar-OCH3(a)  
3 5.60-5.61 1H doublet C-H(i) 
4  6.62-6.64 2H doublet Ar-H(gg') 
5 6.83-6.86 2H doublet Ar-H(bb') 
6  6.94-6.99 2H doublet  Ar-H(jj') 
7 7.22-7.43 5H multiplet  Ar-H(l) 
8 7.61 1H singlet Ar-H(d) 
9 7.63-7.78 5H multiplet Ar-H(ff',kk') 
10 7.99-8.35 2H doublet Ar-H(cc') 
11 8.57 1H singlet N-H(e) 
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MASS SPECTRAL STUDY OF 6-{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYLAMINO]-PHENYL}-4-(4""-
METHOXYPHENYL-PYRIMIDIN-2(1H)-ONE.. 
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Cl
Cl
Type - XV                  R = Aryl
NH2
O
CH3
R
H
O
REACTION SCHEME 
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING 6-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL) METHYL AMINO] - PHENYL}-6-(ARYL) PYRIMIDINE -2(1H)-
ONES.     
(A) Synthesis of 1-{4’-[(4”’-Chlorophenyl)(phenyl)-methyl-amino] 
phenyl} ethanone. 
  See Part-IV, section-I, Chalcone page no:109    
(B)  Synthesis of N-{4'-[(4'''-Chlorophenyl) (phenyl)methylamino] 
phenyl-1'-yl}-3-(4””-methoxy phenyl)-2-prop-2-ene-1-one. 
  See Part-IV, section-I, Chalcone page no:109   
(C)  Synthesis of 6-{4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] - 
phenyl}-6-(4””-methoxy phenyl) pyrimidines-2(1H)-ones.   
A mixture of N-{4'-[(4'''-Chlorophenyl)(phenyl)methylamino]phenyl-
1'-yl}-3-(4””-methoxy phenyl)-2-prop-2-ene-1-one (4.53 gm, 0.01 M) and 
urea (1.0gm, 0.01 M) in methanol (20 ml) was refluxed on waterbath in 
presence of alcoholic KOH for 10 hr. The excess solvent was distilled out and 
the residue was neutralized with 20 % HCl, the separated solid was filtered 
out and crystallized from ethanol. Yield 54%, m.p. 189°C Anal. Calcd. for 
C30H24ClN3O2, Requires: C, 72.94; H, 4.90; N,8.51 % Found: C, 72.94; H, 
4.90; N,8.50 %. 
Similarly, other 6-{4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] - phenyl}-
6-aryl pyrimidines -2(1H)-ones were prepared. The physical data are recorded 
in Table No. 15. 
 
(D) Biological Screening of 6-{4'-[(4'''-Chlorophenyl) (phenyl) methyl 
amino] - phenyl}-6-aryl pyrimidines -2(1H)-ones.   
Antimicrobial testing were carried out as described in Part-I Section-I 
(E). The zones of inhibition of test solution are reported in Graphical Chart No. 
15. 
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TABLE NO. 15: PHYSICAL CONSTANT OF 6-{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYL AMINO]-PHENYL}-4-ARYL-
PYRIMIDINE 2(1H)-ONES. 
 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield % 
 
Calcd.  Found.
JG-169       C6H5- C29H22ClN3O 463.5 101 52 9.06 9.04
JG-170 4-Cl-C6H4-      C29H21Cl2N3O 498.0 202 60 8.43 8.40
JG-171 4-F-C6H4-       C29H21ClFN3O 481.5 167 53 8.72 8.70
JG-172 4-Br-C6H4-      C29H21BrClN3O 542.5 145 61 7.74 7.72
JG-173 2-OH-C6H4-     C29H22ClN3O2 479.5 165 58 8.76 8.74
JG-174 3- OH-C6H4-     C29H22ClN3O2 479.5 148 53 8.76 8.75
JG-175 4-OH-C6H4-      C29H22ClN3O2 479.5 210 58 8.76 8.73
JG-176 4-OCH3-C6H4-     C30H24ClN3O2 493.5 189 54 8.51 8.50
JG-177 3-OCH3-4-OH-C6H4-     C30H24ClN3O3 509.5 194 60 8.24 8.23
JG-178 4-N-(CH3)2-C6H3-      C31H27ClN4O 507.5 155 57 11.03 11.00
JG-179 C10H7-(Naphthayl)      C33H24ClN3O 513.5 134 52 8.17 8.14
JG-180 C14H9- (Anthranyl)
 C37H26ClN3O     563.5 225 59 7.45 7.41
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GRAPHICAL CHART NO.15: BIOLOGICAL SCREENING OF 6-{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYL AMINO]- 
                                    PHENYL}-4-ARYL-PYRIMIDIN-2(1H)-ONES.  
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-VIII 
 
Section – II: Biological screening of 6-{4'-[(4'''-chlorophenyl)(phenyl)methyl amino]-phenyl}-4-aryl- 
pyrimidin-2(1H)-ones. 
 
                                                                   Antibacterial activity                                              Antifungal activity 
                                                                                Zone of inhibition in m. m.                                     Zone of inhibition in m. m.  
                                                                   
                                     B. mega           S. aureus                E-coli               S. typhi                A. niger 
                                                                                                                                                                                        
                                            JG-174(15)            JG-171(16)                  JG-169(16)             JG-171(14)               JG-171(18)               
                                            JG-176(16)            JG-179(15)                  JG-172(17)             JG-173(16)               JG-177(20)               
                                            JG-180(14)            JG-180(17)                  JG-179(15)             JG-180(14)               JG-180(19)               
                                                                                                                                                                               
Ampicillin              (50 µg)       23                          22                                 21                          15                                -- 
Chloromphenicol  (50 µg)       22                          23                                 21                          18                                -- 
Norfloxacin           (50 µg)        24                          17                                 23                          17                                -- 
Greseofulvin         (50 µg)        --                            --                                   --                           --                                 25 
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SECTION-III 
SYNTHESIS AND BIOLOGICAL SCREENING 6-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL) METHYL AMINO] - PHENYL}-6-ARYL PYRIMIDINES -2(1H)-
THIONES  
  Thiopyrimidine derivatives are reported to possess different therapeutic 
activities. In view of these findings, it was considered worthwhile to synthesize 
some new 6-{4'-[(4'''-chlorophenyl) (phenyl) methyl amino] - phenyl}-6-aryl 
pyrimidines -2(1H)-thiones of Type (XVI). Thiopyrimidine derivatives of Type 
(XVI) have been prepared by the reaction of the chalcones of Type (VII) with 
thiourea in presence of basic catalyst KOH. 
    
Cl
NH
NH N
S
R
Type - XVI R = Aryl
 
 The structure elucidation of synthesized compounds has been done on 
the basis of elemental analysis, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by Mass spectrometry.    
 All the compounds have been evaluated for their in vitro biological 
assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards Aspergillus niger at a 
concentration of 50 µg/ml. The biological activities of synthesized compounds 
were compared with standard drugs. Some compounds have been found to 
have moderate activity as compared to known antibiotics recorded on 
Graphical Chart No. 16.  
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IR SPECTRAL STUDY OF 6-{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYL 
AMINO]-PHENYL}-4-(4""-METHOXYPHENYL)-PYRIMIDIN-2(1H)-THIONE. 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Halide  
Ether 
Thio. Pyrimidine 
 
Sec. amine 
C-H  str. (asym.) 
C-H  str. (sym.) 
C-H def. (asym.) 
C-H   def. (sym.) 
C-H   str.  
C=C str. 
C-Cl str. 
C-O-C str. 
C=S str. 
C=N str. 
N-H str. 
2922 
2854 
1455 
1380 
3060 
1509 
760 
1246 
1574 
1168 
3244            
2975-2950 
2880-2860 
1470-1435 
1390-1370 
3090-3030 
1540-1480 
800-600 
1260-1200 
1590-1550 
1220-1020 
3500-3100 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF 6-{4'-[(4'''-CHLOROPHENYL)(PHENYL) 
METHYLAMINO]-PHENYL}-4-(4""-METHOXYPHENYL)-PYRIMIDIN-2(1H)-
THIONE. 
 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (300 MHz) 
Signal 
No.  
Signal 
Position  
(δppm) 
Relative 
No. of 
protons  
 
Multiplicity Inference 
1  3.85 3H singlet  Ar-OCH3(a) 
2 4.01 1H Singlet N-H(a)  
3 5.68-5.69 1H doublet C-H(i) 
4  7.00-7.03 2H doublet Ar-H(gg') 
5 7.12 1H Singlet N-H(e) 
6  7.12-7.25 10H multiplet Ar-H(bb',jj',l) 
7 7.25-7.25 2H doublet  Ar-H(ff') 
8 7.35 1H Singlet Ar-H(d) 
9 7.52-7.53 2H doublet Ar-H(kk') 
10 8.35-8.38 2H doublet Ar-H(cc') 
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MASS SPECTRAL STUDY OF 6-{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYL AMINO]-PHENYL}-4-(4""-
METHOXYPHENYL) -PYRIMIDIN-2(1H)-THIONE. 
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EXPERIMENTAL 
SYNTHESIS AND BIOLOGICAL SCREENING 6-{4'-[(4'''-CHLOROPHENYL) 
(PHENYL) METHYL AMINO] - PHENYL}-6-(4""-METHOXY PHENYL) 
PYRIMIDIN-2(1H)-THIONES.     
(A) Synthesis of 1-{4'-[(4"'-Chlorophenyl)(phenyl)-methyl-amino] 
phenyl} ethanone. 
  See Part-IV, section-I, Chalcone page no:109     
(B)  Synthesis of N-{4'-[(4'''-Chlorophenyl) (phenyl)methylamino] 
phenyl-1'-yl}-3-(4"" -methoxy phenyl)-2-propene-1-ones. 
  See Part-IV, section-I, Chalcone page no:109  
 (C)  Synthesis of 6-{4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] - 
phenyl}-6-(4""-methoxy phenyl) pyrimidin-2(1H)-thiones.   
  A mixture of N-{4'-[(4'''-Chlorophenyl)(phenyl)methylamino]phenyl-
1'-yl}-3-(4””-methoxy phenyl)-2-propene-1-ones (4.53 gm, 0.01 M) and 
thiourea (0.78 gm, 0.01 M) in methanol (20 ml) was refluxed on water bath in 
presence of alcoholic KOH for 10 hr. The excess solvent was distilled out and 
the residue was neutralized with 20 % HCl, the separated solid was filtered 
out and crystallized from ethanol. Yield 57 %, m.p. 193°C Anal. Calcd. for 
C30H24ClN3OS Requires: C, 70.64; H, 4.74; N, 8.24 % Found: C, 70.62; H, 
4.72; N, 8.23 %.  
Similarly, other 6-{4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] - phenyl}-
4-aryl pyrimidine -2(1H)-thiones were prepared. The physical data are 
recorded in Table No. 16. 
(D)  Biological Screening of 6-{4'-[(4'''-Chlorophenyl) (phenyl) methyl 
amino] - phenyl}-4-aryl pyrimidin -2(1H)-thiones.    
Antimicrobial testing were carried out as described in Part-I Section-I 
(E). The zones of inhibition of test solution are reported in Graphical Chart No. 
16. 
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TABLE NO. 16: PHYSICAL CONSTANT OF 6-{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYL AMINO]-PHENYL}-4-
ARYL-PYRIMIDIN-2(1H)-THIONES. 
 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield %
 
Calcd.  Found.
JG-181       C6H5- C29H22ClN3S 479.5 204 61 8.76 8.74
JG-182 4-Cl-C6H4-      C29H21Cl2N3S 514.0 212 60 8.17 8.15
JG-183 4-F-C6H4-       C29H21ClFN3S 497.5 106 58 8.44 8.41
JG-184 4-Br-C6H4-       C29H21BrClN3S 558.5 126 57 7.52 7.50
JG-185 2-OH-C6H4-      C29H22ClN3OS 495.5 166 55 8.47 8.44
JG-186 3- OH-C6H4-      C29H22ClN3OS 495.5 152 52 8.47 8.43
JG-187 4-OH-C6H4-       C29H22ClN3OS 495.5 184 58 8.47 8.45
JG-188 4-OCH3-C6H4-      C30H24ClN3OS 509.5 193 57 8.24 8.23
JG-189 3-OCH3-4-OH-C6H4-       C30H24ClN3O2S 525.5 228 59 7.99 7.95
JG-190 4-N-(CH3)2-C6H3-      C31H27ClN4S 522.5 216 52 10.71 10.67
JG-191 C10H7-(Naphthayl)      C33H24ClN3S 529.5 201 53 7.93 7.90
JG-192 C14H9- (Anthranyl)
 C37H26ClN3S     579.5 209 51 7.24 7.20
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GRAPHICAL CHART NO.16: ANTIMICROBIAL ACTIVITY OF 6-{4'-[(4'''-CHLOROPHENYL)(PHENYL)METHYL AMINO] 
                                           PHENYL}-4-ARYL-PYRIMIDIN-2(1H)-THIONES. 
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-VIII 
 
Section – III: Biological screening of 6-{4'-[(4'''-Chlorophenyl) (phenyl)methyl amino]-phenyl}-4-arylpyrimidine- 
2(1H)-  thiones 
 
                                                                           Antibacterial activity                                                    Antifungal activity 
                                                                           Zone of inhibition in m. m.                                         Zone of inhibition in m. m.   
                                                                   
                                    B. mega             S. aureus             E-coli                S. typhi            A. niger 
                                                                                                                                                                                         
                                           JG-186(15)               JG-184(16)               JG-182(16)            JG-186(14)              JG-181(20)                  
                                          JG-189(16)                JG-190(15)               JG-187(17)            JG-188(16)              JG-183(23)                 
                                          JG-192(14)                JG-191(17)               JG-189(15)            JG-191(14)              JG-192(21)                  
                                                                                                                                                                               
Ampicillin             (50 µg)       23                              22                              21                          15                             -- 
Chloromphenicol (50 µg)       22                              23                              21                          18                             -- 
Norfloxacin          (50 µg)        24                              17                              23                          17                             -- 
Greseofulvin        (50 µg)        --                                --                                --                           --                              25                     
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STUDIES ON ISOXAZOLES 
INTRODUCTION          
 Isoxazole is a five membered heterocyclic compound having two hetero 
atoms: oxygen at position 1 and nitrogen at position 2. In 1888, L. Claisen404 
reported an isoxazole (I) for a product from the reaction of 1,3 diketone with 
hydroxylamine. Subsequently a solid foundation for the chemistry of isoxazole 
was laid down by Claisen and his students. It was shown to possess typical 
properties of an aromatic system but under certain reaction conditions. 
Particularly in reducing or basic media, it becomes very highly labile. 
O
N
( I )  
The next important contribution to the chemistry of isoxazoles was made by A. 
Quelico405 in 1945, when he begin to study the formation of isoxazoles from 
nitrile N- oxide and unsaturated compounds. 
SYNTHETIC ASPECT 
 Isoxazoles can be prepared by various methods, which are described as 
under. 
1. K. M. Dawood et al.406 have prepared isoxazole derivatives from enamino 
nitriles. 
2. V. B. Tayade et al.407 synthesized some new 3,5-diarylisoxazoles from the 
reaction of 2-aryl acetophenones with hydroxyl amine hydrochloride in 
presence of alkali. 
3. L. S. Crawley and W. J. Fanshawe408 were prepared isoxazole (II) from αβ-
unsaturated carbonyl compounds, hydroxylamine hydrochloride and KOH in 
methanol. 
R
R'
O
+ NH2OH.HCl
KOH
O
N
R
R'
(II)
 
230 
 
“Studies on some heterocyclic compounds of medicinal interest” 
 
 
4. K. Suzuki et al.409 have synthesized functionalized isoxazole (III)       
derivatives by cyclocondensation of C-chlorooximes with cyclic 1,3-diketones. 
O
CH3
Cl
N
OH
+
O
O
PrOH
NaO/Pr
O
CH3
N O
O
(III)  
5. M. Lautens and A. Roy410 have constructed isoxazoles (IV) were achieved in 
good yields in a rapid and simple way by using N-acetoacetyl derivatives. 
  
CH3
O
CH3
O
N CH3
CH3
NH2OH.HCl
NaOAC MeOH
N
O
CH3
CH3 N CH3
CH3
(IV)
  
6. Solid phase synthesis of isoxazole derivatives based on aminoacids was 
reported by L. De Luca and co-workers411 in the presence of basic catalyst 
and dichloromethane used as a solvent. N. Nishiwaki412 reported One-Pot 
synthesis of polyfunctionalized isoxazoles have been prepared by the reaction 
of dipyrrolidinium 3,3-dimethylpentanedinitrile  -2,4-dinitronate and acetyl 
chloride in benzene. 
7.  A variety of 3,5-disubstituted 4-bromoisoxazoles (IV) 413 were prepared in 
good    to excellent yields under mild reaction conditions as under. 
O
CH3
NH2OMe.HCl
N
O
CH3
CH3
Br2
N
O CH3
Br
(V)
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REACTION MECHANISM   
  
THERAPEUTIC IMPORTANCE 
 Isoxazole derivatives exhibit various biological activities such as, 
1. Anticonvulsant414, 415
2. Anticholestermic416
3. Antibacterial417-419
4. Anthelmintic420
5. Anticancer421
6. Adenosine antagonist422
7. Fungicidal423-425
8. Herbicidal426, 427
9. Hypoglycemic428
10. Muscle relaxan429, 430
11. Nematocidal431
12. Insecticidal432
13. Antiinflammatory433-436
14. Antimicrobial437
15. Antiviral438          
 S. Chimichi and co-workers439 have investigated cytotoxic activity of 3-
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quinolinoyl isoxazoles (VI) against leukemia and adenocarcinoma derived cell 
lines in comparison to the normal human keratinocytes. Novel cyclohexyl drug 
resistance modulators440 (VII) were synthesized and evaluated for in vitro 
inhibition of the drug resistance transporter, MRP1.     
 
N
OH
CH3
O
O N
O
NH
N
O
Cl
N
O
CH3(VI) (VII)
 
 J. Kaffy et al.441 have been synthesized various five membered 
heterocycles with oxygen and nitrogen atoms. The 4,5 diarylisoxazole (VIII) 
exhibited greater antitubulin activity, but modest antiproliferative activity. K. F.  
Cheng et al442 have reported isoxazole derivatives (IX) have found 20-Fold more 
potent than 3-(4-hydroxyphenyl)-4,5-dihydro-5-acetic acid methyl ester isoxazole 
inhibits MIF tautomerase with an IC50 of 550 nM.  
 
CH3
O
O
CH3
O
CH3
O
N OH
O
CH3
OH
F
N
O
O
O
CH3
CH3
CH3
(VIII)
(IX)
 T. D. Aicher et al.443 reported isoxazoles (X) as hypoglycemic agents. H. 
H. Parekh et al.444 have synthesized 3-(p-methoxyphenyl)-5-(2'-chloro-7'-
methylquinolin-3'-yl)-isoxazole (XI) and studied their biological activity.  
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N
O
Cl Cl
O
Cl
N
O
N
CH3 Cl
R
(X) (XI)
 
 Moreover, S. Rung and D. Dus445 have synthesized some new isoxazoles 
as remedy for leukemia. M. Scobie and co-workers446 have prepared isoxazole 
derivatives and studied their antitumor activity. G. Daidone et al.447 synthesized 
novel 3-(isoxazol-3- yl)-quinazolin-4-(3H)-one derivatives and tested for their 
analgesic and anti-inflammatory activities as well as for their acute toxicity and 
ulcerogenic effect. M. W. Salter et al.448 have prepared some novel isoxazoles as 
cellular neuroplasticity mechanisms mediating pain persistence. M. Matringe et 
al.449 have reported some new p-hydroxyphenylpyruvates dioxygenase inhibitor-
resistant plants. D. R. Mehlisch et al.450 have synthesized isoxazole derivatives 
as analgesic efficacy of intramuscular parecoxib sodium in postoperative dental 
pain. M. A. Ray et al.451 have reported isoxazole derivatives as cardiovascular 
toxicity of valdecoxib. 
H. S. Joshi et al.452 have synthesized isoxazole derivatives (XII) and 
reported their antitubercular and antimicrobial activity.     
   
Br
O
N
R
(XII)
   
 P. M. Welsing et al.453 have documented the isoxazoles as tumornecrosis 
factor blocking agents and leflunomide for treating rheumatoid arthritis in the 
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Netherlands. S. J. Bingham et al.454 have synthesized isoxazole derivatives as an 
antiulcer agents. M. R. Barbachyn et al.455 have described the 
phenylisoxazolines as novel and viable antibacterial agents active against Gram-
positive pathogens. 
M. Masui et al.456 have prepared isoxazoles having pesticidal activity. 
Some excellent herbicidal results obtained by K. V. Reddy et al.457
With an intension of preparing the compounds possessing better 
therapeutic activity, we have under taken the preparation of isoxazoles bearing 
derivatives which have been described as follows. 
 
CONTRIBUTION IN OUR LABORATORY: 
D. M. Purohit et. al.458 have been synthesized (XIII) 2-(4'-Chlorophenyl)-6-
methyl-3-[(3"-aryl isoxazole-5'-yl)-imidazo [1,2-a] pyridine as a antimicrobial 
agents. 
    
N
N
CH3
Cl
O
N
CH3
( XIII )  
SECTION: I SYNTHESIS SND BIOLOGICAL SCREENING OF 3-{4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYL AMINO] - PHENYL} -5-
ARYL ISOXAZOLES.   
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SECTION: I  
SYNTHESIS SND BIOLOGICAL SCREENING OF 3-{4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYL AMINO] - PHENYL} -5-ARYL 
ISOXAZOLES.           
 Isoxazoles have been reported to have various pharmacological activities 
like antibacterial, antifungal, insecticidal etc. In order to achieving better drug 
potency, we have prepared isoxazole derivatives of Type (XVII) by the 
cyclocondensation of chalcones of Type-(VII) with hydroxylamine hydrochloride 
in presence of sodium acetate in glacial acetic acid. 
Type - XVII
Cl
NH
N
O
R
 R = Aryl
 
The structure elucidation of synthesized compounds has been done on 
the basis of elemental analysis, IR and 1H nuclear magnetic resonance 
spectroscopy and further supported by Mass spectrometry. 
All the compounds have been evaluated for their in vitro biological assay 
like antibacterial activity towards Gram positive and Gram negative bacterial 
strains and antifungal activity towards Aspergillus niger at a concentration of 
50 µg/ml. The biological activities of synthesized compounds were compared 
with standard drugs. Some compounds have been found to have moderate 
activity as compared to known standard drugs recorded on Graphical Chart No. 
17.         
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IR SPECTRAL STUDY OF 3-{4'-[(4'''-CHLOROPHENYL)(PHENYL) METHYL 
AMINO] - PHENYL} -5-(4""-METHOXYPHENYL)ISOXAZOLE.  
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Halide 
Ether 
Sec. amine 
 
C-H Str. (asym.) 
C-H Str.(sym.) 
C-H def. (asym.) 
C-H def.(sym.) 
C-H Str. 
C=C str. 
C-Cl Str 
C-O-C Str. 
N-H Str. 
C=N str. 
2955 
2877 
1460 
1379 
3039 
1554 
750 
1176 
3417 
1658 
2975-2950 
2880-2860 
1470-1435 
1385-1370 
3090-3030  
1600-1450 
800-600 
1200-1100 
3500-3100 
1660-1630 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF 3-{4'-[(4'''-CHLOROPHENYL) (PHENYL) 
METHYL AMINO] - PHENYL} -5-(4""-METHOXYPHENYL)ISOXAZOLE.   
 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (300 MHz) 
Signal 
No.  
Signal 
Position  
(δppm) 
Relative 
No. of 
protons  
 
Multiplicity Inference 
1  3.66 3H singlet Ar-OCH3(a) 
2 4.16 1H singlet N-H(g)  
3 5.59-5.61 1H doublet C-H(h) 
4  6.58-6.60 2H doublet Ar-H(bb') 
5 7.27-7.36 9H multilet Ar-H(ii',ff',k) 
6  7.52 1H doublet  Ar-H(d) 
7 7.71-7.73 2H doublet  Ar-H(jj') 
8 7.78-7.86 2H doublet Ar-H(ee') 
9 8.11-8.13 2H singlet N-H(cc') 
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MASS SPECTRAL STUDY OF 3-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] - PHENYL} -5-(4""-
METHOXYPHENYL) ISOXAZOLE.  
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O
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+
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+
o
+
o
+
o
+
o
+
o
+
o
m/z = 467
m/z = 266 m/z = 203
m/z = 251 m/z = 216 m/z = 294
m/z = 361
m/z = 391
m/z = 433
m/z = 356
m/z = 175
m/z = 440
m/z = 280
m/z = 224
m/z = 402
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Cl
Cl
Type - XVII                    R = Aryl
NH2
O
CH3
R
H
O
REACTION SCHEME 
Cl
NH
O
CH3
Cl
NH
O
R
H2NOH-HCl
Cl
NH
N
O
R
+
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EXPERIMENTAL    
SYNTHESIS AND BIOLOGICAL SCREENING OF 3-{4'-[(4'''-
CHLOROPHENYL) (PHENYL) METHYL AMINO] PHENYL} -5-ARYL 
ISOXAZOLES. 
(A) Synthesis of 1-{4'-[(4"'-Chlorophenyl)(phenyl)-methyl-amino] phenyl} 
ethanone. 
See Part-IV, section-I, Chalcone page no:109  
(B) Synthesis of 4’-{[(4”’-Chlorophenyl)(phenyl) methyl amino] phenyl-1-
yl}-3-(4””-methoxyphenyl)-2-propene-1-ones. 
See Part-IV, section-I, Chalcone page no:109 
(C)  Synthesis of 3-{4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] phenyl} -
5-(4””-methoxyphenyl) isoxazoles. 
 A mixture 4’-{[(4’’’-Chlorophenyl)(phenyl) methyl amino] phenyl-1-yl}-3-
aryl-2-propene-1-ones. (3.56 gm, 0.01 M) in ethanol (25 ml), anhydrous sodium 
acetate (0.739gm, 0.01 M) and hydroxylamine hydrochloride (0.59 gm, 0.01 mol) 
in acetic acid were added. The reaction mixture was refluxed on oil bath for 7-8 
hr. The product was isolated and crystallized from ethanol. Yield 59%, m.p. 
130 °C Anal. Calcd. For C29H23ClN2O2 Requires; C, 74.59; H, 4.96; N, 6.00%; 
Found: C, 74.58, H, 4.95; N, 5.97%.  
Similarly, other 3-{4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] - phenyl} -
5-aryl isoxazoles were prepared. The physical data are recorded in Table No.17. 
(D) Biological Screening of 3-{4'-[(4'''-Chlorophenyl) (phenyl) methyl 
amino] - phenyl} -5-aryl isoxazoles.     
Biological screening was carried out as described in Part-I Section-1(E). 
The zones of inhibition of test solution are reported in Graphical Chart No 17. 
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TABLE NO. 17: PHYSICAL CONSTANT OF 3-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] - PHENYL} -5-ARYL 
ISOXAZOLES. 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield % 
 
Calcd.  Found.
JG-193       C6H5- C28H21ClN2O 436.5 138 55 6.41 6.40
JG-194 4-Cl-C6H4- C28H20Cl2N2O     471.0 155 59 5.94 5.93
JG-195 4-F-C6H4-  C28H20ClFN2O     454.5 196 58 6.16 6.14
JG-196 4-Br-C6H4- C28H20BrClN2O      515.5 190 56 5.43 5.41
JG-197 2-OH-C6H4- C28H21ClN2O2 452.5     152 58 6.18 6.15
JG-198 3- OH-C6H4- C28H21ClN2O2 452.5     114 55 6.18 6.14
JG-199 4-OH-C6H4-  C28H21ClN2O2 452.5     118 60 6.18 6.16
JG-200 4-OCH3-C6H4- C29H23ClN2O2 466.5     130 59 6.00 5.97
JG-201 3-OCH3-4-OH-C6H4- C29H23ClN2O3 482.5     170 58 5.80 5.77
JG-202 4-N-(CH3)2-C6H3- C30H26ClN3O     479.5 205 57 8.75 8.74
JG-203 C10H7-(Naphthayl) C32H23ClN2O     486.5 212 55 5.75 5.70
JG-204 C14H9- (Anthranyl)
 C36H25ClN2O     536.5 189 57 5.21 5.20
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GRAPHICAL CHART NO.17: BIOLOGICAL SCREENING OF 3-{4'-[(4'''-CHLOROPHENYL) (PHENYL) METHYL AMINO] 
                                      PHENYL} -5-ARYL ISOXAZOLES. 
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S. typhi 10 11 17 10 9 11 10 16 13 15 14 13 15 18 17 0
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-IX 
 
Section – I: Biological screening of 3-{4'-[(4'''-Chlorophenyl) (phenyl) methyl amino] - phenyl} -5-aryl isoxazoles. 
 
                                                                   Antibacterial activity                                              Antifungal activity 
                                                                                Zone of inhibition in m. m.                                     Zone of inhibition in m. m.  
                                                                   
                                    B. mega              S. aureus              E-coli                S. typhi             A. niger 
                                                                                                                                                                                        
                                           JG-196(18)               JG-196(16)                 JG-194(16)            JG-195(17)              JG-193(20)                
                                           JG-199(19)               JG-199(21)                 JG-198(15)            JG-200(16)              JG-195(23)                
                                           JG-203(16)               JG-202(15)                 JG-203(15)            JG-202(15)              JG-204(21)                
                                                                                                                                                                               
Ampicillin             (50 µg)       23                              22                                21                          15                              -- 
Chloromphenicol (50 µg)      22                              23                                 21                          18                              -- 
Norfloxacin          (50 µg)       24                              17                                 23                          17                              -- 
Greseofulvin        (50 µg)        --                               --                                   --                            --                              25 
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STUDIES ON BENZODIAZEPINES 
INTRODUCTION  
 Benzodiazepines are characterized by their possession of fused 
benzene ring with seven membered heterocyclic ring containing amino group 
at five position and nitrogen, sulphur or oxygen at one position with double 
bond in between forth carbon and fifth nitrogen atom.  
x
N
( I ) X = NH,S,O
  
 1,5-Benzodiazepines  viz. benzodiazepine, benzothiazepines and 
benzoxazepines are very important compounds because of their 
pharmacological properties. Some of the popular drugs based on these 
compounds are Thiazesim, Diltiazem459 and Clentienzem460etc.  
 Many pharmacological compositions of benzodiazepines have been 
patented.461-464  
SYNTHETIC ASPECT  
 The literature survey revealed that the most explored route for the 
synthesis of 1,5-benzodiazepines is the reaction either of o-phenylene 
diamine with 1,3-disubstituted-2-propen-1-ones (chalcone). 1,5-
Benzodiazepines  are also synthesized by cyclocondensation of the 
corresponding 2-substitutted anilines with suitable enones or 1,3 or (α, β-
dicarbonyl compounds. 
 Different methods for preparation of 1, 5-benzodiazepines  are reportd 
in literature as under.  
 Methods for the preparation of 1,5-benzodiazepines are as under. 
1. By the condensation of o-phenylenediamine with α, β-unsaturated 
carbonyl compounds.465-467
2. By the condensation of o-phenylenediamine with α-haloketones.468  
3. By the condensation of o-phenylenediamine with ketones in the 
presence of polyphosphoric acid, silica gel469, MgO and POCl3.470
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MECHANISM  
 
R'
OR
R'
O
+
R H
XH
NH2
..
..
+H
+
H
+
..
R'
R
HX
NH
OH
-H2O
R'
NR
HX
..
N
X
R'
R
H
+
(b)
(c)
(d)
(a)
(e)
(f)
N
H
X
R'
R
X= NH, S, O
 The mechanism includes the attack of lone pair of electron of nitrogen 
atom of 2-substituted aniline (b) on keto-enol form of 1,3-disubstituted-2-
propen-1-ones (a) affords hydrated product (c) which on dehydration yields 
intermediate product (d). Intermediate (d), on intramolecular cyclization yield 
dihydro intermediate (e) in the presence of acid. (e) On tautomerises to the 
final product (f). 
MEDICINAL  INTEREST        
 Considerable research has been undertaken to extend the activity and 
reduce toxicity of benzodiazepines . The specific biological activities to 
Benzoheterozepines have been summarized as under. 
1. Central nervous stimulating agent 471, 472
2. Tranquilizer473
3. Antidepressant474
4. Antitumor activity475, 476
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5. Antimicrobial activity477, 478
6. Platelet aggregation inhibitors479
7. Antipyretic480
8. Ca-channel antagonist481
9. Antifeedant482
10. Analgesic483
11. Anticonvulsant activity484
   A. Bauer et. al.485 have synthesized 4-amino-1,5-benzodiazepines 
having psychotropic activity.  R. G. Smith et. al.486 have synthesized pyrazino 
benzodiazepines possessing anxiolytic activity.  G.B. De Sarro et. al.,487 have 
synthesized 1,5-benzodiazepines (I) derivatives possessing anticonvulsant 
activity.  H.F. Miranda et.al.488 has reported antinociceptive action 
benzodiazepines. H. Yamaji et.al.489 have prepared benzodiazepines 
derivatives (II) as gastrin receptor antagonists.  
R1= CO2H
N
N
NH
CO
NH
O
Ph
R1
CH3
                 
X
N
R
R1
R2
R1=O; R2=Ph, X=NH
( I ) ( II )
 
 A. Farese et. al. 490 have synthesized benzodiazepines and evaluated 
their biological activities by luciferase transactivation and anti-viral assay. De 
S. Giovambattista et. al.491 have synthesized 1,4-benzodiazepine derivatives 
as anticonvulsant agents. S. E. Ellen 492 has prepared 1,5-benzodiazepines 
(III) having cholecystokininantagonistic or agonistic activity. 
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N
N
O
O
NHCOR2
CH2COR1
R3
X2
R1R2=heterocycle; R3=H,alkyl,Ph; 
X=H,trifluoromethl
( III )
  
  K.A. Rao et. al.493 have synthesized 1,4-benzodiazepines as DNA-
interactive antitumor antibiotics.  L. Wang et. al.494 have synthesized 
benzodiazepine derivatives as CDK5 inhibitors. R. Kumar et. al.495 have 
synthesized 3H-1,5-benzodiazepine derivatives and screened for anthelmintic 
activities.  S. Joseph et. al.496 have reported benzodiazepines that activates 
cardiac slow delayed rectifier K+ currents. 
  T. Nagao et.al.497 have synthesized 1,5-benzothiazepine derivatives 
and tested their coronary vasodilating effect.  K.S. Atwal et. al.498 have 
synthesized 1,5-benzothiazepines (IV) ,which are calcium channel blockers. 
V. Ambrogi et. al.499 have synthesized 1,5-benzothiazepines and screened for 
their CNS activity.  
N
X
CO2R1
CH3R
R
X=S, R1=H, R=Substituted phenyl
( IV )
 
  C. Saturnino et. al. 500 have synthesized 1,5-benzothiazepines and 
examined in vitro for their calcium antagonist activity compared to the 
diltiazem. S. Koichi et. al.501 have prepared  benzodiazepines, 
benzothiazepines and benzoxazepines compounds (V),(VI) of potentiating 
retinoid.   
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N
X
Y+
CO2R1R4
R2
R3
N
X
O
R6
R5
Y+
CO2R1
R2
R3
R1-R3R5R6=H; R4=H, OH,NO2, X=NH,S
     Y = O( V ) ( VI )
 
 C. Sanchez-Mateo et. al. 502have studied neuropharmacological activity 
of hetero[2,1] benzothiazepines. F. L. Ansari et. al.503 have synthesized 1,5-
benzothiazepine derivatives and studied their urease and  α-glucosidase 
inhibitors properties. N. Rastkari et. al.504 have synthesized benzothiazepine 
derivatives (VII) and reported their antidiabetic activities. . 
 
   
N
S
O
N
R
R= Substituted Phenyl
( VII )
    
 L.R.Swettt et. al. 505 have reported anti-inflammatory activity of 4,5-
dihydro benzoxazepine derivatives.  D. M. Zisterer et al506 have reported 
pyrrolo-1,5-benzoxazepines as a new class of apoptotic agents.  
 
 P. B. Bharucha and H. B. Naik507 have prepared 1,4-oxazipine 
derivatives and studied their antimicrobial activity.  M. Takashi et. al. 508 have 
synthesized 4,1-benzoxazepine (VII) derivatives with potent squalene 
synthase inhibitory activities. 
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O
N
OMe
OMe
Cl
O
But
CO2H
( VIII )  
          
 Shalaby and Alyaa A.509 has synthesized pyrrolo-1,5-benzoxazepine-6 
derivatives (IX) and reported as microtubule-targeting agent, in both STl-5H-
sensitive and resistant Bcr-Abl-positive human chronic myeloid leukemia cells. 
 
O
N
N
N
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Ph
( IX )
 
  Younes Laras et. al.510 have prepared various substituted 4,5-dihydro-
3H-spiro [1,5]-benzoxazepine-2,4’-piperidine and assayed as the possible 
aspartyl protease inhibitors HIV Protease (HIV-1) and B-Secretase (BACF-1). 
 B. Basavaraju et al511 have synthesized methylquinolono[3,2-b][1,5] 
benzodiazepine (X) and methylquinolono[3,2-b][1,5] benzoxazepine (XI) and 
its various metal complexes and screened for antimicrobial activity.   
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In light of wide varieties of biological activities exhibited by 1,5-
benzoheterozepines it appeared of interest to synthesize 1,5-
benzoheterozepines derivatives, in order to achieving compounds having 
better therapeutic activity described as under. 
SECTION:-I  SYNTHESIS AND BIOLOGICAL SCREENING OF 2-ARYL-
4-YL-[4'-(4'''-CHLOROPHENYL)(PHENYL)METHYLAMINO 
PHENYL]-1H-1,5-BENZODIAZEPINES. 
     
 
 
 
 
 
 
 
 
 
 
 
 
           
           
           
           
           
           
        
253 
 
“Studies on some heterocyclic compounds of medicinal interest’’ 
 
SECTION:-I 
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-ARYL-4-YL-[4'-(4'''-
CHLOROPHENYL)(PHENYL)METHYLAMINOPHENYL]-1H-1,5-
BENZODIAZEPINES. 
 Benzodiazepines and its derivatives showed remarkable biological 
activity and potent therapeutic agents, with a view of to synthesis of 2-Aryl-4-
yl-[4'-(4'''-chlorophenyl)(phenyl)methylaminophenyl]-1H-1,5-benzodiazepines 
have been synthesized by the condensation of chalcones of Type (VII) with o-
phenylene diamine in acidic medium.       
Cl
NH
N
N
H
R
 R = ArylType -XVIII
 
 The structure elucidation of synthesized compounds has been done on 
the basis of elemental analysis, IR and 1HNMR and further supported by Mass 
spectrometry.         
 All the compounds have been evaluated for their in vitro biological 
assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards Aspergillus niger at a 
concentration of 50 µg/ml. The biological activities of synthesized compounds 
were compared with standard drugs. Some compounds have been found to 
have moderate activity as compared to known standard drugs recorded on 
Graphical Chart No. 18.        
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IR SPECTRAL STUDY OF 2-(4""-METHOXYPHENYL)-4-YL-[4'-(4'''-
CHLORO-PHENYL)(PHENYL)-METHYLAMINOPHENYL]-1H-1,5 
BENZODIAZEPINE.   
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1(KBr disc). 
Type Vibration Mode Frequency in cm-1 Ref. 
  Observed Reported  
Alkane 
 
 
 
Aromatic 
 
Halide 
Ether 
Benzodiazepine 
 
 
C-H   str. (asym.) 
C-H   str. (sym.) 
C-H   def. (asym.) 
C-H   def. (sym.) 
C-H   str. 
C=C   str. 
C-Cl  str. 
C-O-C str. 
C-N str. 
C=N str. 
N-H str. 
2952 
2878 
1471 
1400 
3087 
1586 
787 
1173 
1037 
1706 
3119 
2975-2950 
2880-2860 
1470-1435 
1390-1370 
3090-3030 
1540-1480 
800-600 
1200-1100 
1220-1020 
1710-1650 
3500-3100 
516 
" 
" 
" 
517 
" 
" 
" 
" 
" 
" 
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NMR SPECTRAL STUDY OF 2-(4""-METHOXYPHENYL)-4-YL-[4'-(4'''-
CHLORO-PHENYL)(PHENYL)-METHYLAMINOPHENYL]-1H-1,5 
BENZODIAZEPINE.   
 
Internal Standard: TMS;Solvent :CDCl3; Instument Bruker Spectometer (400 MHz) 
Signal 
No.  
Signal 
Position  
(δppm) 
Relative No. 
of protons  
 
Multiplicity Inference 
1  3.89 3H singlet Ar-OCH3(a) 
2 6.04 1H singlet C-H(k)  
3 6.93-6.97 2H doublet Ar-H(hh') 
4  7.15-7.18 4H doublet Ar-H(bb',ii') 
5 7.19-7.27 4H doublet Ar-H(ii',ff',k) 
6  7.27-7.31 5H multilet Ar-H(n) 
7 7.34-7.39 2H doublet  Ar-H(jj') 
8 7.41-7.433 2H doublet Ar-H(ee') 
9 
10 
11 
7.438-7.46 
8.00-8.02 
9.33 
2H 
2 H 
1 H 
doublet 
doublet 
singlet 
N-H(cc') 
Ar-H(d) 
N-H(j) 
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MASS SPECTRAL STUDY OF 2-(4""-METHOXYPHENYL)-4-YL-[4'-(4'''-CHLORO-PHENYL)(PHENYL)-
METHYLAMINOPHENYL]-1H-1,5 BENZODIAZEPINE.   
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EXPERIMENTAL     
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-ARYL-4-YL-[4'-(4'''-
CHLOROPHENYL)(PHENYL)METHYLAMINOPHENYL]-1H-1,5-BENZO-  
DIAZEPINES.     
(A) Synthesis of 1-{4'-[(4"'-Chlorophenyl)(phenyl)-methyl-amino] 
phenyl} ethanone. 
See Part-IV, section-I, Chalcone page no:109   
(B)  Synthesis of 4’-{[(4'"-Chlorophenyl)(phenyl) methyl amino] phenyl-
1-yl}-3-(4""-methoxyphenyl)-2-propene-1-one. 
See Part-IV, section-I, Chalcone page no:109    
(C) Synthesis of(4""-Methoxyphenyl)-4-yl-[4'-(4'''-chlorophenyl) (phenyl) 
methylaminophenyl]-1H-1, 5-benzodiazepine. 
To a solution of 4-{[(4′-Chlorophenyl) (phenyl) methyl amino] phenyl-1-
yl}-3-aryl-2-propene-1-ones (4.53 gm, 0.01 M), and o-phenylenediamine (1.32 
gm, 0.01 M) in ethanol (20ml) and sulphuric acid was refluxed for 8 to 10 hrs. 
The resulting mixture was poured on to crush ice. The product obtained was 
filtered and crystallized from methanol. Yield: 55%, M.P.:192oC, C35H28ClN3O 
Requires; C, 77.55; H, 5.21; N, 7.75; Found 77.51; H, 5.20; N, 7.73%.  
Similarly, other 2-Aryl-4-yl-[4'-(4'''- chlorophenyl) (phenyl) methyl amino 
phenyl]-1H-1, 5-benzodiazepines were prepared. The physical data are 
recorded in Table No.18. 
(D) Biological screening of 2-Aryl-4-yl-[4'-(4'''-chloro phenyl)(phenyl) 
methylaminophenyl]-1H-1,5-benzodiazepines. 
Antimicrobial testing were carried out as described in Part-I Section-
1(E). The zones of inhibition of test solution are reported in Graphical Chart 
No 18. 
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TABLE NO. 18: PHYSICAL CONSTANT OF 2-ARYL-4-YL-[4'-(4'''-CHLOROPHENYL)(PHENYL)-METHYLAMINO 
PHENYL]-1H-1,5-BENZODIAZEPINES. 
 
 
% of Nitrogen 
 
Sr. 
No. 
R 
 
Molecular 
Formula 
M. W. 
 
M.P.  º C 
 
Yield %
 
Calcd.  Found.
JG-205       C6H5- C34H26ClN3 511.5 292 60 8.21 8.20
JG-206 4-Cl-C6H4-      C34H25Cl2N3 546.0 184 62 7.69 7.66
JG-207 4-F-C6H4-       C34H25ClFN3 529.5 180 64 7.93 7.90
JG-208 4-Br-C6H4-      C34H25BrClN3 590.9 130 65 7.11 7.10
JG-209 2-OH-C6H4-       C34H26ClN3O 527.5 178 58 7.96 7.95
JG-210 3- OH-C6H4-       C34H26ClN3O 527.5 136 57 7.96 7.94
JG-211 4-OH-C6H4-        C34H26ClN3O 527.5 144 59 7.96 7.93
JG-212 4-OCH3-C6H4-       C35H28ClN3O 541.5 192 55 7.75 7.73
JG-213 3-OCH3-4-OH-C6H4-      C35H28ClN3O2 557.5 170 54 7.53 7.50
JG-214 4-N-(CH3)2-C6H3-     C36H31ClN4 554.5 120 53 10.09 10.05
JG-215 C10H7-(Naphthayl)      C38H28ClN3 561.5 146 52 7.48 7.45
JG-216 C14H9- (Anthranyl)
 C42H30ClN3 611.5     192 54 6.86 6.84
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GRAPHICAL CHART NO.18: BIOLOGICAL SCREENING OF 2-ARYL-4-YL-[4'-(4'''-CHLOROPHENYL)(PHENYL) 
METHYLAMINOPHENYL]-1H-1,5-BENZODIAZEPINES. 
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B.mega 11 9 11 18 12 15 11 13 16 10 13 14 23 22 24 0
S.aureus 10 12 11 16 14 14 13 12 11 15 11 14 22 23 17 0
E.coli 20 16 11 10 14 15 11 12 11 13 15 19 21 21 23 0
S. typhi 8 11 10 10 11 14 13 16 13 15 14 13 15 18 17 0
A.niger 20 11 23 12 13 18 14 15 19 17 16 21 0 0 0 25
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS 
 
PART-X 
 
Section – I: Biological screening of 2-Aryl-4-yl-[4'-(4'''-chlorophenyl)(phenyl)-methylaminophenyl] 
         -1H-1, 5-benzodiazepines 
 
                                                           Antibacterial activity                                                        Antifungal activity 
                                                           Zone of inhibition in m. m.                                                         Zone of inhibition in m. m.  
                                                                   
                                   B. mega              S. aureus                E-coli               S. typhi            A. niger 
                                                                                                                                                                                        
                                          JG-208(18)                JG-208(16)                 JG-205(20)              JG-210(14)            JG-205(20)                
                                          JG-210(15)                JG-210(14)                 JG-206(16)              JG-212(16)            JG-207(23)                
                                          JG-213(16)                JG-214(15)                 JG-216(19)              JG-214(15)            JG-216(21)                
                                                                                                                                                                               
Ampicillin             (50 µg)       23                               22                              21                          15                              -- 
Chloromphenicol (50 µg)       22                              23                              21                          18                               -- 
Norfloxacin          (50 µg)        24                              17                              23                          17                               -- 
Greseofulvin        (50 µg)        --                                --                                --                           --                                25 
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